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Abstract 
Adoptive immunotherapy for cancer is a rapidly expanding field. Along with 
new techniques and technologies for cell engineering comes a pressing clinical 
need to discover the location of these cells after injection and to quantify the 
number of cells in a particular location. The use of agents to enhance tissue 
contrast is crucial to improve the ability of imaging techniques to distinguish 
cells from background signal, in order to track cells in vivo. 
Human donor T cells were transduced to express a tumour antigen specific T cell 
receptor. Transduced T cells were labeled with novel and conventional 
radiolabels for in vivo tracking using a combined single photon emission 
computed tomography and computed tomography (SPECT/CT) scanner.  
Transduced T cells were used in combination with TRAIL-expressing MSCs to 
produce a novel dual cell anti-cancer therapy in an in vivo lung metastases cancer 
model.  
The data in this thesis demonstrates that a novel tri-functional probe designed for 
long-term cell tracking, whilst resulting in superior cell labeling and retained 
activity over time compared with conventional methods, causes significant cell 
toxicity.  
It also demonstrates, for the first time, that a tumour antigen specific T cell 
therapy can be effective against lung metastases, leading to a significant 
reduction in tumour burden. These engineered T cells combined with MSC 
TRAIL also significantly reduce metastatic tumour burden, although there was 
no significant benefit to using the dual cell therapy. 
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1. Introduction 
1.1. Background 
Cell therapies for cancer are an attractive form of personalised medicine that can 
avoid the systemic side effects of conventional radiotherapy and chemotherapy. 
Adoptive immunotherapy has shown promise as a cancer therapy, as it harnesses 
the specificity of lymphocytes to kill cancer cells. In addition, TNF-related 
apoptosis-inducing ligand (TRAIL) expressing mesenchymal stem cells (MSCs), 
have previously been shown to home to and incorporate within lung metastases, 
leading to reduction or in some cases, elimination of lung metastases. A 
combination of these two cell therapy approaches may result in far superior 
cancer cell death than that observed using a single therapy alone. 
1.2. Lung Cancer 
Lung cancer is the second commonest form of cancer in the United Kingdom, 
representing 13.7% of all cancer diagnoses in men and 11.2% in women. [1] The 
majority of cases can be attributed to tobacco smoking, although other risk 
factors such as passive smoking, exposure to indoor radon gas, exposure to 
industrial or chemical carcinogens and air pollution are also recognized. Whilst 
the incidence of lung cancer in developed countries is declining in males and 
reaching a plateau in females due to a decline in smoking rates, the incidence is 
increasing in developing countries, reflecting increased smoking prevalence. [2] 
The incidence of lung cancer due to non-smoking causes is also increasing in 
females in developing countries, due to household air pollution from heating and 
cooking fires. 
The histological subtype of lung cancer is normally used to determine treatment, 
and distinguishes small cell lung cancer from non-small cell lung cancer. Small 
cell lung cancer accounts for a minority of lung cancers and is more aggressive, 
producing early metastasis. Non-small cell carcinoma has several subtypes, of 
which adenocarcinoma and squamous cell carcinoma are the most prevalent. 
Histological diagnosis is usually made using a tissue specimen collected during a 
bronchoscopic procedure or with percutaneous needle biopsy.  
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Tumour staging is assessed using CT imaging, using the tumour, nodes, 
metastases (TNM) classification. Along with an assessment of the patient’s 
fitness, the TNM stage is used to determine operability of the tumour. Generally, 
patients with stage I or II tumours, with N0 or N1 (no regional lymph node 
involvement or involvement of ipsilateral peribronchial, hilar or pulmonary 
nodes) are considered to be operable and have a reasonable chance of cure by 
surgery alone. Unfortunately, since the majority of patients present late, in the 
advanced stages of disease, survival rates remain extremely low, because early 
stage surgical resection offers the only hope of complete cure. 
Combination chemotherapy containing one platinum-based agent, for example 
cisplatin, with third-generation cytotoxic agents such as gemcitabine, has 
traditionally been the first-line treatment for both small cell and non-small cell 
lung cancer and provides a modest survival benefit. Unfortunately, the majority 
of patients treated with platinum-based agents will relapse as resistance to these 
develops over time. The use of platinum-based chemotherapy is also associated 
with severe side effects, particularly nephrotoxicity, nausea and vomiting, 
neurotoxicity and ototoxicity. 
An important breakthrough in the last 10 years was the approval of targeted 
chemotherapy agents for specific histological subtypes of lung cancer, for 
example, the antifolate agent pemetrexed for adenocarcinoma and large-cell 
carcinoma. [3] In a phase III trial following patients with advanced non-small 
cell carcinoma (stage IIIB or IV disease), pemetrexed treatment resulted in 
significantly improved overall survival of 13.4 months versus 10.6 months with 
placebo and best supportive care. [4] However, even with these new treatment 
options, the 5-year survival rate is less than 10% of patients with stage III or IV 
disease. [1] 
Recently, research into genomic subsets of adenocarcinoma has identified 
specific driver mutations that can provide differential sensitivities to 
chemotherapy agents, leading to a more personalized approach to treatment. 
Mutations of the tyrosine kinase domain of the epidermal growth factor receptor 
can be treated with tyrosine kinase inhibitors, such as gefitinib and erlotinib, 
leading to a clinical response in approximately 20% of patients. [5] Significantly, 
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these agents also produced much less toxicity than conventional chemotherapy 
regimens. 
Mutations involving fusion between the echinoderm microtubule-associated 
protein-like 4 gene and the anaplastic lymphoma kinase (ALK) gene, have also 
been identified in non-small cell lung cancer. [6] These mutations can be targeted 
with anaplastic lymphoma kinase inhibitors, such as crizotinib. However, this 
fusion gene was only detected in 6.7% of non-small cell lung cancers, 
representing a small minority of lung cancer cases. [7] The small percentage of 
patients whose cancer is positive for ALK experience a dramatic increase in 
survival with crizotinib therapy (12 month survival of 70% versus 44% in 
crizotininb naïve patients). [8] 
Unfortunately these advances have not yet resulted in a significant survival 
benefit to patients because the response to these chemotherapy agents remains 
transient. Median five-year survival rates for UK patients are currently 7.8% for 
men and 9.3% for women, and survival rates have not changed significantly 
since the 1970s. [1] 
In an attempt to diagnose more lung cancers at an early stage, several trials have 
explored screening programmes for current or ex-smokers using chest 
radiographs or low dose spiral computed tomography (CT). The largest of these, 
the National Lung Screening Trial, enrolled 53,454 subjects randomized to three 
annual screenings using chest radiographs or low dose spiral CT, and found a 
mortality reduction of 20% with low dose CT. [9] However, there is currently no 
lung cancer screening programme in place in the UK. [10] 
In the future, cancer genotyping and personalized chemotherapy with targeted 
agents may increase survival rates, and genotyping could be used to identify 
biomarkers of resistance or response, and adapt chemotherapy regimens. [11] 
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1.3. Immunotherapy for cancers 
Immune cells are known to play an important role in the control and 
development of malignancy, as evidenced by the increased incidence of 
malignancy in immunocompromised individuals, and an accumulation of 
immune cells at sites of malignancy. The immune system can be harnessed to 
treat cancer via four different methods: cytokine therapies, antibody therapies, 
vaccines and cell-based therapies. 
Cytokine-based therapies aim to stimulate the immune system to mount a 
response against tumour cells. The cytokine interleukin-2 (IL-2) activates 
adaptive immune cells and has been used as an intravenous bolus to treat 
malignant melanoma and renal cell carcinoma, with complete regression of 
disease in 7% of patients. [12] However, these are the only solid tumours known 
to respond to cytokine therapy, and despite over 20 years of experience in these 
agents, there is currently no cytokine therapy approved to treat lung cancer. 
Monoclonal antibodies are also used to stimulate a host immune response, and in 
addition have been developed to block certain cancer cell signaling pathways, or 
to act as a vehicle to deliver other therapies. In the past 10 years, many 
monoclonal antibodies targeting known tumour ligands or receptors have been 
approved for clinical use. An example is rituximab, a monoclonal antibody 
against CD20, which is used to treat non-Hodgkin’s lymphoma. Ipilimumab, a 
monocloncal antibody against CTLA-4, a receptor expressed on the surface of 
helper T cells that inhibits T cell function, has recently been combined with 
conventional first-line chemotherapy agents to treat non-small cell lung cancer 
with a small increase in progression-free survival (5.7 months compared with 4.6 
months with the control regimen). [13] However, monoclonal antibody therapy 
for lung cancers has not yet delivered the dramatic increase in survival rates that 
can be seen in other cancers. 
For the treatment of non-small cell lung cancer, there have been several recent 
trials evaluating allogeneic cancer vaccines, with the aim of stimulating a 
humoral immune response against a tumour antigen. Target antigens include 
mucin-1, [14] epidermal growth factor [15] and the melanoma antigen encoding 
gene A3, [16] and patients treated with these vaccines in phase II/III trails have 
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experienced a modest survival benefit (for example, 6 months progression free 
survival of 43.2% with the vaccine TG4010 targeting mucin 1, compared with 
35.1% for chemotherapy alone). [17] 
Lastly, cell-based immunotherapy consists of administering immune cells to the 
patient that have anti-tumour effects. The most potent tumour killing immune 
cells are cytotoxic T cells, which have the ability to specifically lyse tumour 
cells. 
1.4. T cells 
T cells are lymphocytes that play a crucial role in adaptive cell-mediated 
immunity. They are known as T cells since they mature in the thymus, although 
they originate from lymphoid progenitors derived from bone marrow 
haemopoietic stem cells (HSCs). Chemoattractive molecules secreted by the 
thymus during fetal development attract the circulating T cell precursors, which 
then populate the thymus. [18] In the cortex of the thymus, developing T cells 
(thymocytes) proliferate and interact with cortical epithelial cells. Each T cell 
undergoes random gene rearrangement to form a unique T cell receptor, so that 
within the millions of T cells generated, there are some cells with T cell receptors 
specific for potential microbial antigens. This process is known as the generation 
of diversity. [19] 
In the cortex, positive selection occurs, where thymocytes are presented with 
self-antigens; major histocompatibility complex (MHC) class I or II molecules. 
Those that can weakly bind self-MHC molecules are selected, whilst those that 
cannot recognize MHC undergo apoptosis. [20, 21] (Figure 1.1) 
The thymocytes then migrate into the medulla where they undergo negative 
selection. [22] Here dendritic cells or macrophages express self-antigens on 
MHC molecules. If a T cell binds to self-antigen it undergoes apoptosis, so that 
the remaining T cells have central tolerance and will not react to self-antigen and 
cause autoimmune disease.  
Less than 5% of thymocytes survive the process of selection. [23] Those that 
survive can recognize foreign, non-self antigen displayed by self-MHC 
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molecules only. These migrate to peripheral lymphoid tissues, such as the spleen 
and lymph nodes, where they complete their maturation. 
 
Figure 1.1: T cell development in the thymus. HSC migrate to the thymus and begin development in 
the cortex. Thymocytes begin as double negative (DN) for CD4 and CD8 molecules. After successful 
TCR gene rearrangement they become double positive, expressing both CD4 and CD8, and move into 
the cortico-medullary junction.  Positive selection occurs when double positive T cells bind to cortical 
epithelial cells expressing MHC class I or II, and self-antigen, with enough affinity to get a survival 
signal. Surviving T cells move into the medulla, where they undergo negative selection. T cells that 
bind to dendritic cells expressing MHC class I or II, and self-antigen, undergo apoptosis. Surviving T 
cells express either CD4 or CD8 and recognize foreign antigen only if they are displayed on MHC 
class I or II molecules. 
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1.4.1. The T cell receptor (TCR) 
The TCR is located within the cell membrane and consists of two different 
protein chains, an alpha and a beta chain, each of which contain a constant region 
and a variable region. The TCR forms a complex with CD3, so that the variable 
regions face outwards and the constant regions are closer to the cell membrane 
(Figure 1.2). [24] 
Assembly of the TCR occurs in the endoplasmic reticulum, where the α and β 
chains bind to CD3 molecules. [25] This complex then passes through the Golgi 
apparatus, before joining the cell membrane. 
Cell mediated, or adaptive immunity, is a result of the action of T cells 
interacting with antigen associated with MHC class I or II molecules, through 
their TCR. This is in contrast to innate immunity, which is a non-specific 
response involving complement, acute phase proteins and cytokines, as well as 
cells such as phagocytes, natural killer cells, mast cells and basophils. 
 
Figure 1.2: Diagram showing the structure of the T cell receptor, which is made up of α and β chains, 
each with a variable and constant region. CD3 anchors the TCR to the cell membrane. 
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1.4.2. Helper T cells/ CD4+ T cells 
Helper T cells play an important role in the activation of other T cells by 
releasing cytokines, such as interleukin-2 (IL-2). They can be differentiated from 
other T cells by their expression of cluster of differentiation 4 (CD4) molecules. 
Helper T cells display a specific TCR that recognizes and binds a particular 
antigen, displayed by major histocompatibility complex (MHC) class II 
molecules on the surface of antigen presenting cells (APCs). CD4 also binds to 
MHC class II molecules to create this link.  
In order to activate naïve T helper cells, another interaction must also occur 
between CD28 on the T cell and co-stimulatory molecules CD80 and CD86, 
expressed by APCs. This helps the T cell distinguish between foreign antigens 
and host antigens, as CD80 and CD86 are only displayed by APCs, thus reducing 
the risk of auto-immunity. To date, four distinct populations of helper T cells 
have been identified, and the fate of a naïve helper T cell is determined by the 
pattern of signals it receives during activation with antigen. [26] T helper 1 (Th1) 
cells mediate immune responses against intracellular pathogens, especially 
mycobacterium, and secrete interferon-γ (IFNγ), lymphotoxin α and IL-2, 
leading to activation of macrophages and CD4/CD8 cell memory formation. [27] 
T helper 2 (Th2) cells secrete many different interleukins, including interleukin-4 
(IL-4) and destroy extracellular parasites, such as helminths. [28] T helper 17 
(Th17) cells also produce various interleukins and mediate immune responses 
against extracellular bacteria and fungi. [29] Regulatory T cells (Treg) control 
the immune response and have an important role in immune self-tolerance. [30] 
1.4.3. Cytotoxic T cells/ CD8+ T cells 
Cytotoxic T cells are capable of killing infected or damaged cells, for example 
virally infected cells. Similar to helper T cells they also express a specific TCR, 
however, this recognizes antigen presented by MHC class I molecules. [31] 
Cytotoxic T cells also display cluster of differentiation 8 (CD8), that binds to 
MHC class I during T cell activation, to stabilize the interaction between the 
TCR and antigen.  
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The function of MHC class I molecules is to display short peptide sequences 
formed by the breakdown of cellular proteins by the proteosome system. [32] In 
order for this to occur, these peptides must be translocated across the 
endoplasmic reticulum, and combined with MHC class I and β2 microglobulin. 
After assembly, this complex passes through the Golgi apparatus for secretion to 
the cell surface. [33] 
This antigen display allows cytotoxic T cells to recognize foreign cells, or those 
with cellular changes caused by viral infection, since MHC class I molecules are 
present on all nucleated cells in the body, as well as on specialized antigen 
presenting cells (APCs). The function of APCs, such as dendritic cells, is to 
internalize exogenous antigen by endocytosis or phagocytosis, then present the 
antigen, with co-stimulatory molecules CD80 or CD86, to activate both helper 
and cytotoxic T cells. 
Cytotoxic T cells are also thought to provide some protection against 
malignancy, by recognizing antigenic differences caused by altered proteins in 
mutated cells. [33, 34]  
1.4.4. Cytotoxic T cell killing 
Cytotoxic T cells can kill target cells by several different pathways. Once TCR-
antigen recognition occurs, the cytotoxic T cell can release perforin, which 
punches holes through the cell membrane of the target cell, and granzymes, 
enzymes that cleave peptide bonds in proteins (Figure 1.3). This activates the 
caspase cascade and initiates apoptosis. Alternatively, activated cytotoxic T cells 
express Fas ligand that can bind to Fas expressed on the target cell. This recruits 
Fas-associated death domain (FADD) and procaspases 8 and 10 to form a death-
inducing signaling complex (DISC). This also activates the caspase cascade, 
leading to apoptosis. [35] 
Finally, cytotoxic T cells can kill target cells indirectly, by the secretion of 
cytokines such as tumour necrosis factor α (TNFα) and IFNγ, during interaction 
of the TCR with the MHC class I/antigen complex. Secreted TNFα causes 
apoptosis in surrounding target cells through the caspase cascade by binding to 
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its receptor on the target cell. IFNγ increases target cell death through the Fas 
pathway, by increasing transcription of MHC class I and Fas. [33] 
 
Figure 1.3: Mechanisms of apoptosis induced by cytotoxic T cells. Cytotoxic T cells can trigger 
apoptosis by secreting perforin and granzymes, activating the caspase cascades, or via the binding of 
Fas ligand to Fas, which also activates the caspase cascades. 
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1.5. Adoptive Immunotherapy for Cancer 
1.5.1. Tumour Antigens 
Malignant cells can express fragments of new or mutated intracellular proteins 
on their cell membrane, that can act as antigens to the immune system (Figure 
1.5). TCRs can specifically recognize these peptide sequences, resulting in T cell 
activation and cell-mediated killing.  Therefore, if tumour antigens bind to TCRs 
on cytotoxic T cells, the tumour cell is destroyed specifically. [36] 
Unfortunately, most cancers fail to trigger a response from cytotoxic T cells. 
This may be due to several different reasons; for example, the mutation will be 
immunologically silent if the antigen fails to bind with high affinity to MHC 
class I or II molecules on the tumour cell, and hence cannot be presented to T 
cells. [37] Another possibility is that tumour cells express antigens that are 
poorly immunogenic and fail to trigger a T cell response, so the tumour is 
allowed to evolve unchecked. Evidence suggests that tumour growth could be 
linked to selection of these cells, which fail to initiate an immune response. [38] 
Finally, many of the known tumour antigens are also expressed in normal tissues 
(tumour associated antigens or TAA), such as the Wilm’s tumour 1 antigen 
(WT1), expressed in leukaemias and some solid tumours. [39] T cells with high 
avidity for these antigens are removed by central or peripheral tolerance to 
reduce the risk of autoimmunity. As a result, T cells fail to provide protection 
against a tumour displaying these antigens. In these cases, using engineered T 
cells with high avidity for the TAA could result in damage to normal tissues. 
Therefore, T cell immunotherapy must provide high affinity T cell receptors 
recognising the correct MHC-peptide complex for adequate tumour control.  
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Figure 1.5: Tumour antigens targets for adoptive immunotherapy. 1. Viral mutations can cause the 
expression of new antigens (Dawson 2012 [40]). 2. Other mutations can confer a new antigenic 
determinant that can also be recognized (Sharkey 2004 [41], Robbins 1996 [42]). 3. Lastly, 
amplification or overexpression of genes can produce a target antigen for immunotherapy (Sierra 
2011 [43]). 
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1.5.2. Adoptive T Cell Therapy 
Adoptive T cell therapy is a form of personalised medicine, involving the 
transfusion of lymphocytes into a patient for the treatment of cancer or chronic 
infection. For tumour therapy, the aim is to generate tumour antigen specific 
cytotoxic T cells. [44] Early attempts of adoptive immunotherapy using tumour-
infiltrating lymphocytes from tumour biopsies in melanoma patients resulted in a 
clinical benefit in 8 out of 10 patients treated. [45] In this study, lymphocytes 
from melanoma tumour biopsies were cultured ex vivo, with selection of tumour 
specific cells using antigen stimulation, followed by clonal expansion of 
cytotoxic T cell subsets that could cause lysis of target cancer cells, and 
transfusion of these cells in divided doses. Following this study, it was quickly 
discovered that lymphoablative chemotherapy before the transfer of lymphocytes 
could improve the clinical response. [46-48] However, this approach was very 
labour and time intensive, requiring the testing and expansion of multiple T cell 
populations, and a significant number of patients failed to respond to the therapy. 
To solve this problem, high affinity tumour antigen-specific TCRs were 
identified by measuring in vitro activity and the genes for these TCR were 
isolated and transduced into peripheral blood lymphocytes, resulting in efficient 
lysis of target cells in vitro. [49, 50] This approach allowed quicker generation of 
a large number of lymphocytes with specific anti-tumour activity, without the 
need to clonally expand and test a large number of tumour-infiltrating 
lymphocytes. However, data from clinical studies was less favourable, with just 
2 patients out of 13 showing complete regression of their metastatic melanoma, 
and the rest having no response. [51] This was thought to be a result of the level 
of expression of the TCR transgene, which decreased over time, possibly due to 
the mispairing of the introduced α-chains and β-chains with endogenous chains. 
It has been shown that expression levels of the introduced TCR α–chains and β-
chains modulate antigen recognition, with higher expression leading to better T 
cell response against antigen. [52] 
An advantage to this cell engineering approach is that both CD8+ and CD4+ T 
cells can be transduced, resulting in antigen-specific cytotoxic T cells as well as 
helper T cells. This may be important for the complete elimination of tumour and 
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the establishment of memory for long-term maintenance. [53] Recently, efforts 
have focused on engineering T cells expressing a TCR with stable high 
expression and high affinity for tumour antigens. [54]  
T cell receptor gene transfer methods have also been used to insert TCRs with 
high affinity for tumour-associated antigens. For example, Xue et al. have shown 
that Wilm’s Tumour 1 (WT1) engineered TCRs in human T cells can eliminate 
human leukaemia cells expressing WT1, in NOD/SCID mice. [55] The TCR 
gene was later modified using codon optimization to improve synthesis, and a 
cysteine bond in the constant domains to prevent mispairing between 
endogenous and introduced chains. The resulting WT1-TCR had improved 
expression and was 5-fold more active against leukaemia cells in a Chromium-51 
cytotoxicity assay. Further testing using the optimized WT1-TCR to engineer a 
patient’s T cells to target autologous leukaemia cells in a NOD/SCID model 
resulted in a significant improvement of survival rates. [56] This study provided 
the rationale to proceed into phase I/II clinical trials at the Royal Free Hospital 
for adult patients with acute myeloid leukaemia and chronic myeloid leukaemia. 
1.5.3. The Epstein-Barr Virus 
The Epstein-Barr virus (EBV) is a gamma herpesvirus, which commonly causes 
a mild viral illness in childhood. If an individual is infected as an adolescent or 
young adult it causes infectious mononucleosis, commonly known as glandular 
fever. The virus primarily infects nasopharyngeal stratified squamous epithelial 
cells and B cells, where it establishes latency. In fact, more than 90% of adults 
have latent EBV infection and this is linked to certain cancers, such as Burkitt’s 
lymphoma, Hodgkin’s lymphoma and nasopharyngeal carcinoma. [57] 
EBV-positive cells can express latency in different patterns, corresponding to the 
expression of certain viral proteins. In immunocompetent hosts, the latency III 
proteins EBV nuclear antigen (EBNA) 3A, 3B and 3C are immunodominant and 
EBV specific T cells control the latency. [58] In contrast, EBV-positive 
Hodgkin’s lymphoma and nasopharyngeal carcinomas express the latency II 
antigens EBNA 1 and the latent membrane proteins (LMP) 1 and 2. [59, 60] 
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Latent membrane protein 2 (LMP2) is a transmembrane protein that can be 
utilized as a tumour antigen for adoptive immunotherapy. However, producing 
effective latency II antigen-specific T cells is difficult due to the weak 
immunogenicity of these antigens. Therefore, a cell engineering approach is 
needed to overcome this problem. 
Allogeneic donor cytotoxic T cells specific for EBV latency proteins have been 
used to combat lymphoproliferative disease resulting from reactivation of EBV, 
following bone marrow transplantation, for over 10 years. [59] Following the 
success of this treatment, donor EBV-specific cytotoxic T cells were used 
clinically in pilot studies for patients with EBV positive Hodgkin’s lymphoma. 
[60] In this study, cytotoxic T cells were not specific to the LMP2 antigen, and 
most patients (5/6) had disease progression after treatment.  
In another pilot study, patients with EBV-related nasopharyngeal carcinoma 
were transfused with autologous EBV-specific cytotoxic T cells that had been 
isolated and expanded ex vivo. [61] Out of the ten patients in the study, 2 had a 
partial response and 4 had stable disease, while 4 patients experienced disease 
progression. There were 4 patients who had LMP2 specific T cell responses, 3 of 
which had a clinical benefit; leading the authors to hypothesise that increasing 
the number of T cells specific for LMP1 and LMP2 could enhance antitumour 
response. Therefore, adoptive immunotherapy without selection of LMP2-
specific EBV-TCR T cells has failed to deliver significant clinical benefit. 
In an attempt to overcome this problem, dendritic cells and EBV-lymphoblastoid 
cell lines have been transduced to express the LMP2 antigen using an 
adenovirus. These were then used to stimulate and expand LMP2 specific T cells 
from patients ex vivo, which were transfused into the patient to provide a 
treatment for relapsed Hodgkin’s lymphoma. This resulted in 4 complete clinical 
responses and 1 partial response out of 6 patients with relapsed disease refractory 
to standard chemotherapy treatment. [62, 63]  
To further improve LMP2 targeting, a modified EBV-TCR has been developed 
that can be inserted using a retrovirus into peripheral blood lymphocytes. [64] 
This approach allows genetic transfer of TCRs with a high specificity to LMP2 
into a large proportion of proliferating T cells, rather than relying on the 
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expansion of a small subset of the population with TCRs that express reactivity 
to LMP2. The engineered TCR contains murine constant regions to enhance 
TCR association with CD3 molecules on the cell membrane, a self-cleaving 2A 
sequence for equimolar expression of both alpha and beta chains, and has been 
codon optimized to improve gene translation. The resulting human leukocyte 
antigen-A2 (HLA-A2) restricted EBV-TCR is dominant and suppresses the 
surface expression of endogenous TCR.  
In this thesis, I have used the direct retroviral gene transfer technique to 
transduce human donor peripheral blood lymphocytes to express the HLA-A2 
restricted LMP2 specific EBV-TCR described above. Instead of targeting 
leukaemia cells, these engineered T cells will be used to target lung metastases. 
The lung cancer cell line will be transduced to express the LMP2 antigen, to 
provide an antigen target for the EBV-TCR T cells. 
1.5.4. Adoptive T cell immunotherapy for lung cancer 
Adoptive immunotherapy for lung cancer was first described in 1987 by Kradin 
et al., who used tumour-infiltrating lymphocytes that were expanded ex vivo with 
IL-2 to target adenocarcinoma of the lung. [65] The next studies to look at 
adoptive immunotherapy to treat lung cancer were not published until 1995. In a 
randomized controlled clinical study spanning 7 years, Kimura et al. used 
injections of lymphokine-activated killer cells and recombinant IL-2 to target 
lung cancer as an adjuvant treatment to chemotherapy, radiotherapy or surgery, 
showing a significant improvement in survival rates in patients with 
adenocarcinoma but no difference in survival in those with squamous cell 
carcinoma. [66]  
Simultaneously, Ratto et al. were investigating the use of infusions of tumour-
infiltrating lymphocytes and recombinant IL-2 for non-small cell lung cancer 
(NSCLC), first in a pilot study, [67] then in a larger randomized controlled trial 
showing a significant difference in survival rates. [68] Unfortunately, a further 
phase II clinical trial looking at survival rates using this therapy in patients with 
advanced (stage III) NSCLC showed no benefit to patients with adoptive 
immunotherapy. [69] Most recently, the authors have published another phase 
I/II clinical trial using transfused autologous PBMC and recombinant IL-2, 
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combined with chemotherapy, as a neo-adjuvant treatment for patients with 
surgically resectable stage III NSCLC. [70] This study showed no immediate 
survival benefit to the neo-adjuvant therapy, but an increased 5-year survival 
rate.  
However, apart from these studies there has been little development in the field 
of adoptive immunotherapy for lung cancer, and no attempts of adoptive 
immunotherapy with T cells targeting tumour associated antigens. [71] In fact, 
most recently, Babiak et al. have started searching for tumour associated antigen 
candidates for an adoptive T cell therapy. [72] Therefore, adoptive 
immunotherapy with T cells having a high expression of high affinity tumour 
antigen specific TCRs is an important impending development in the field of 
lung cancer research. 
1.5.5. Disadvantages of adoptive T cell immunotherapy  
Despite the potential of adoptive immunotherapy to treat cancer without the 
systemic effects of radiotherapy and chemotherapy, there can be adverse effects 
associated with T cell transfusion. For example, adoptive immunotherapy against 
melanoma has resulted in cases of vitiligo, where transferred cytotoxic T cells 
have also attacked melanocytes. This side effect has occurred using both tumour-
infiltrating lymphocytes [73] and genetically engineered T cells specific for the 
melanoma antigen recognized by T cells 1 (MART-1) TCR. [74] Similar ‘on-
target’ side effects have also been noted using a TCR specific for 
carcinoembryonic antigen, expressed by colorectal carcinomas, where 
physiological expression of this antigen in the colon lead to inflammatory colitis 
after T cell transfer. [75] Therefore, careful selection of the tumour antigen target 
is needed.  
Viral antigens caused by malignant transformation, or mutated proteins caused 
by the genomic instability of cancer cells provide good targets to avoid damage 
to normal tissues. [76] The inclusion of a suicide gene into engineered T cells, 
such as inducible caspase-9, so that they can be destroyed in the event of serious 
side effects, provides extra safety and control over the therapy. [77] 
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More concerning is the possibility of tumour escape variants arising during 
adoptive immunotherapy, which would cause failure of the treatment. Genomic 
instability and a heterogeneous cancer cell population within tumours might 
favour the natural selection of tumour cells that do not express the antigen of 
interest during adoptive immunotherapy. [78] It is well known that antigen 
expression in tumours can change over time. For example, melanoma tumours 
have been shown to lose the tumour antigen MART-1, and become more 
heterogeneous, as the disease progresses. [79] This antigen loss could lead to 
failure of adoptive immunotherapy in advanced disease. 
Work by Restifo et al. has also shown that tumours can lose MHC class I 
molecules. In their study 4 out of 13 patients who had undergone adoptive 
immunotherapy for melanoma had lost MHC class I molecules from tumour cells 
after their treatment. [80] This was found to be due to a loss of β2-microglobulin 
expression, meaning that tumour antigens could not be processed in the 
endoplasmic reticulum for display on the cell surface membrane, giving the 
resulting tumour an immunoresistant phenotype.  
These studies may explain the resistance of some tumours to adoptive 
immunotherapy, although much further work is required in this area. At the 
moment the reasons why some patients respond to immunotherapy while others 
do not are poorly understood. It is possible that other complementary cell 
therapies may be required to optimize the anti-tumour response. 
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1.6. Stem Cells 
A stem cell has an unlimited capacity for self-renewal, and as well as dividing to 
renew itself it can also give rise to more differentiated progenitor cells. Stem 
cells are broadly divided into adult and embryonic stem cells. Adult stem cells 
are thought to be more cell lineage restricted than pluripotent embryonic stem 
cells. Adult stem cells can be found in stem cell niches present in many different 
tissues within the body, and are thought to play a role in tissue regeneration and 
repair after injury. Of these niches, bone marrow derived stem cells are the 
easiest to access, and can be aspirated with a simple bone marrow biopsy. These 
stem cells are a mixture of mesenchymal stem cells and haematopoietic stem 
cells. Mesenchymal stem cells can be isolated from other cell types due to their 
ability to adhere to tissue culture plastic. This thesis is concerned with adult 
mesenchymal stem cells only. 
1.7. Mesenchymal Stem Cell (MSC) Therapy 
1.7.1. MSCs 
Mesenchymal stem cells (MSCs) are present in adult human bone marrow and 
are described as stem cells due to their ability to proliferate over many 
generations and their potential to differentiate into multiple cell lineages, such as 
bone, cartilage, tendon and fat. [81] They can be readily removed from the body, 
isolated, and expanded. 
Whilst MSCs are predominantly present in the bone marrow, they are also found 
in large amounts in fat. They can be activated in response to specific chemical 
signals such as interleukins or growth factors from damaged areas, which can 
also cause recruitment of MSCs from the bone marrow. [82] 
This property of MSCs means they are able to home to, and incorporate 
themselves into areas of inflammation within the body that have increased 
expression of immunogenic markers. [83] Similarly, injected mesenchymal stem 
cells are also able to home to and incorporate into tumours. [84] In fact, MSCs 
labelled with superparamagnetic iron oxide nanoparticles (SPIOs) have been 
shown to migrate to and incorporate into lung metastases in a murine model 
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within 1 hour of i.v. administration, with a further increase at 24 hours, using 
magnetic resonance imaging (MRI). [85] However, in this paper immunostaining 
of the lungs for DiI labelled MSCs within the lung metastases was not 
convincing, with only 2 DiI labelled cells observed in a single lung metastasis 
and this DiI signal did not match the iron containing cells located with Prussian 
blue staining. Macrophage staining on these sections suggests that a number of 
the iron containing cells in the lung metastases are in fact macrophages, so this 
differentiation is crucial to the interpretation of their data. To further characterise 
the iron-containing cells, it would have been useful to use anti-TRAIL 
immunostaining to demonstrate definitively that the iron containing cells were 
not macrophages but were instead MSC TRAIL that had lost their DiI label over 
time. Anti-TRAIL staining would have been a convincing argument that these 
iron-containing cells were MSC that had homed to the metastases. 
The tumour homing potential of MSCs has been demonstrated with intra-
peritoneal, intra-venous and subcutaneous injection, although in these cases a 
proportion of the injected cells will also end up in the liver, lungs, kidneys and 
spleen. [86] Stem cells have been imaged trafficking to tumours using 
bioluminescence imaging [87], magnetic resonance imaging (MRI) [88], and 
positron emission tomography (PET) [89]. This tumour homing mechanism 
means that MSCs can be used as vectors for the delivery of anti-tumour 
treatments. In addition, MSCs are immunoprivileged, lacking MHC II and co-
stimulatory molecules CD80, CD86 and CD40. [90] This property means that 
allogenic cells could be used without the risk of immune rejection, and without 
the need for an HLA matched donor. 
1.7.2. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) 
The aim of cancer therapies is to cause apoptosis (programmed cell death) within 
a population of tumour cells, whilst limiting or avoiding apoptosis in surrounding 
healthy cells. Chemotherapy and radiotherapy cause DNA damage that results in 
apoptosis via the intrinsic apoptotic pathway (Figure 1.4). This is mediated by 
the tumour suppressor gene p53, which activates bax and bak, causing the release 
of cytochrome c from mitochondria. This forms an apoptosome with ATP, 
procaspase 9 and apoptotic protease activating factor 1 (APAF 1) that activates 
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caspase 9, causing activation of effector caspases such as caspase 3. 
Unfortunately, during carcinogenesis more than half of tumours acquire 
mutations of p53. [91, 92] This results in the development of resistance to 
activation of the intrinsic apoptotic pathway and hence, resistance to 
chemotherapy agents and radiotherapy. [91]  
Death ligands can induce apoptosis independently of p53 via the extrinsic 
apoptotic pathway. Tumor necrosis factor–related apoptosis-inducing ligand 
(TRAIL), is a type 2 transmembrane protein [93, 94] that has been shown to 
cause selective apoptosis of tumor cells, through the extrinsic apoptosis pathway. 
[95] On binding of the ligand to the TRAIL receptor, the receptor is 
oligomerized and Fas associated protein with death domain (FADD), and caspase 
8 are recruited, to form a death inducing signaling complex (DISC). This results 
in the activation of caspase 3 and cell apoptosis (Figure 1.4). Activation of the 
death inducing signaling complex can be inhibited by FLICE-like inhibitory 
protein (cFLIP), which prevents activation of caspase 8. 
There are five known receptors for TRAIL. Apoptosis is triggered after TRAIL 
binds as a homotrimer to death receptors 4 or 5 (DR4 or DR5). [96, 97] These 
receptors have a cytosolic death domain, however, there are other receptors than 
can bind TRAIL without leading to apoptosis (Figure 1.5). Decoy receptor 1 
(DcR1) lacks a cytosolic death domain and is attached to the cell membrane by a 
glycophospholipid anchor, whereas decoy receptor 2 (DcR2) has a cytosolic 
domain that is shorter and unable to trigger apoptosis. [98] Osteoprotegerin 
(OPG) is a secreted receptor that inhibits osteoclastogenesis and increases bone 
density. [99] It can bind to TRAIL with a weaker affinity than DR5, and is 
capable of blocking TRAIL-induced apoptosis. [100] However, its role as a 
decoy receptor is not fully established. 
The sensitivity of cancer cells to TRAIL and selective apoptosis of cancer cells 
over normal cells has been shown in several in vitro and in vivo studies. [101, 
102] TRAIL is therefore an attractive therapy for cancer patients, due to its 
ability to kill cancer cells selectively, whilst sparing normal tissue, and without 
the unpleasant systemic side effects of chemotherapy or radiotherapy, such as 
nausea and vomiting, and immunosuppression.  
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1.7.3. MSCs Expressing TRAIL 
The use of MSCs as a vehicle to deliver TRAIL to tumours harnesses the ability 
of MSCs to home to and incorporate into tumours, and also overcomes a major 
problem in the systemic delivery of TRAIL; the short in vivo half-life of 
recombinant TRAIL and TRAIL monoclonal antibodies. [103] 
MSCs can be transduced to express TRAIL using a lentiviral vector, and 
treatment of subcutaneous tumours in a murine model using these cells has 
resulted in significantly reduced tumour growth compared to controls. [104] 
Using these cells in a pulmonary metastases model resulted in complete 
clearance of metastatic disease in 38% of mice after 5 doses of MSC TRAIL, 
given at 7 day intervals. [104] 
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Figure 1.4: Traditional cancer therapies act via the intrinsic apoptotic pathway, causing DNA 
damage, activation of pro-apoptotic Bax and Bak and the release of cytochrome c from mitochondria. 
This in turn activates caspase 9, which cleaves procaspase-3 into caspase 3. Caspase 3 initiates 
apoptosis by cleaving intracellular proteins resulting in morphological and biochemical changes to the 
cell. The extrinsic apoptotic pathway is activated by the binding of a death ligand to a receptor (in this 
case TRAIL), causing receptor oligomerization and recruitment of Fas associated protein with death 
domain (FADD) and caspase 8. This cleaves and activates caspase 3, as well as cleaving and activating 
t-BID, which can bind to Bax and Bak, resulting in mitochondrial membrane permeabilization and 
cytochrome c release. Along with apoptotic protease-activating factor 1 (APAF1) and caspase 9, 
cytochrome c combines with ATP to form an apoptosome that cleaves and activates caspase 9, which 
then cleaves caspase 3, resulting in apoptosis.  The two pathways are interlinked and regulated by 
inhibitors (headless arrows) such as inhibitors of apoptosis (IAPs) and cellular FLICE-like inhibitory 
protein (cFLIP), as well as activators such as SMAC that deactivates IAPs, preventing them from 
inhibiting apoptosis. 
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Figure 1.5: TRAIL receptors- only DR4 and DR5 have active cytoplasmic death domains. Decoy 
receptor DcR1 lacks an intracellular region, while DcR2 has a shortened and inactive cytosolic region. 
TRAIL can also bind to Osteoprotegerin (OPG), a soluble decoy receptor, at low affinity. Figure 
adapted from Kimberley et al. “Following a TRAIL: Update on a ligand and its five receptors”. [99] 
1.8. A combined EBV-TCR T cell and MSC TRAIL therapy 
1.8.1. Advantages of a dual cell therapy 
While the field of adoptive immunotherapy with tumour antigen specific T cells 
for lung cancer has not yet been developed, it is likely that this therapy alone will 
not be sufficient to clear the entire tumour and associated metastases, particularly 
if there are large masses. This has been seen in multiple studies using tumour 
antigen specific TCR T cells in Hodgkin’s disease [63] and malignant melanoma. 
[51] 
In addition, the chimeric LMP2 specific EBV-TCR T cells have not yet been 
tested in mouse models of cancer. Although their effectiveness in vivo is 
unknown, in vitro assays have shown greater than 80% target specific killing at T 
cell to tumour cell ratios of 5:1 and above, and around 40% at cell ratios of 1:1. 
[64] A comparison between this study and the work carried out by Loebinger et 
al. looking at target cell killing with MSC TRAIL is difficult due to the different 
methods used for cell killing assays, however, using MSC TRAIL at ratios of 1:1 
with tumour cells also results in approximately 40% tumour cell lysis. [104] A 
significant difference between these two cell therapies is that the EBV-TCR T 
cell lysis of tumour cells is much quicker, occurring after 4 hours of incubation, 
whereas the MSC TRAIL tumour cell killing assay is measured after 48 hours of 
incubation. However, it seems likely that these two cell therapy methods are 
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equally effective, except that MSC TRAIL takes longer to cause their tumour cell 
killing effect. 
In this thesis I have used MSC TRAIL and EBV-TCR transduced T cells 
synergistically, as a dual cell therapy, targeting tumour cells expressing the 
LMP2 antigen in a murine model of pulmonary metastases. This approach to cell 
therapy has never been explored and could yield promising results, with the aim 
of improved tumour clearance to that produced by a single cell therapy.  
In particular, the inflammatory cytokines released by both CD4+ and CD8+ T 
cells could aid homing and engraftment of MSCs at the tumour sites, making 
MSC TRAIL treatment for pulmonary metastases more effective than the 38% 
complete clearance rate previously reported by Loebinger et al. [104] This 
benefit would be in addition to the tumour reduction caused by LMP2 antigen 
specific EBV-TCR T cells. 
1.8.2. The effect of MSCs on T cell function 
It is important to consider the effects of MSCs on T cell function, as MSCs are 
known to have immunosuppressive effects. For example, MSCs have been used 
successfully as immunomodulators in graft versus host disease (GVHD) in phase 
II clinical trials. [105] However, it is important to note that this early success 
with MSC immunomodulation was not repeated in larger phase III clinical trials, 
where there was no significant difference between MSC and placebo. [106] 
In particular, MSCs have been shown to inhibit T cell responses to stimuli, 
resulting in reduced proliferation, [107] and response to their cognate peptide. 
[108] The mechanisms underlying this inhibition remain unclear, but are thought 
to involve both soluble factors secreted by the MSCs and mechanisms needing 
cell contact. One example of soluble factors affecting T cell function is 
indoleamine 2,3-dioxygenase (IDO), secreted by MSCs in response to interferon-
gamma released in T-cell activation, which catalyses the conversion of 
tryptophan to kynurenine, suppressing allogeneic T cell responses. In this 
pathway, IDO catalyses oxidative cleavage of the 2,3 double bond in the indole 
ring of tryptophan to form N-formyl-kynurenine, which is then catalysed further 
into various metabolites, determined by downstream enzymes. Both in vitro and 
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in vivo studies have demonstrated that overexpression of IDO results in 
immunosuppression and reduced antigen-specific T cell responses. [109] Co-
culture experiments with MSCs and mixed lymphocytes resulted in IDO 
secretion, with depletion of tryptophan and production of kynurenine, and 
reduced proliferation of lymphocytes. [110] Proliferation could be restored with 
the addition of tryptophan into the cell culture media, confirming IDO-mediated 
tryptophan metabolism as the cause of reduced proliferation. 
In another study, MSCs were shown to selectively and irreversibly inhibit 
proliferation of T cells by down-regulating cyclin D2 expression. T cells were 
shown to arrest at the early G1 phase of the cell cycle, although this did not 
interfere with T-cell activation, and the suppressive effect on function was 
transient. [111] 
Whilst it is clear that MSCs suppress T cell proliferation by a number of different 
pathways, studies examining the effect of MSCs of cytotoxic T cell function are 
more controversial. One study shows inhibition by MSCs of the formation of 
cytotoxic T cells, but no actual inhibition of cytotoxic T cell function. [112] 
Another study reports inhibition of proliferation, cytotoxicity and IFN-γ 
production in naïve, antigen-reactive and memory T cells, by MSCs in a dose-
dependant fashion. [108] This effect was shown to be cell-contact dependent by 
control experiments using a transwell system where the numbers of pentamer 
positive CD8 T cells were not changed after exposure to MSC secreted soluble 
factors. The authors suggest that the MSCs may be physically hindering the T 
cells from contact with antigen, which could be seen to argue against their 
hypothesis of MSC inhibition, pointing instead to experimental flaws as they 
failed to control for increased cell numbers in their Chromium-51 cytotoxicity 
assay inhibiting T cell lysis.  
The EBV-TCR transduced CD4 and CD8 T cells used in these experiments were 
cultured separately from MSCs to avoid any inhibitory effects on T cell 
activation or expansion. Therefore, this system may avoid the inhibitory effects 
of MSCs altogether, especially since MSCs have not been shown to inhibit 
cytotoxic T cell function in vivo.  
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1.9. Cell Labeling and Tracking 
Along with rapidly developing advances in cell therapy for cancer, there is a 
pressing need to trace the cells in vivo as they home to tumours. There are many 
techniques available for cell labeling and tracking, none of which fulfill all of the 
ideal requirements needed for this purpose. 
An ideal cell-labeling agent should be biocompatible and nontoxic, and should 
not change or damage the structure and functionality of the cell. [113] This is 
especially important for cell therapies, where the cell must retain its capability to 
provide an effect against the tumour.  It is also desirable that the agent can be 
imaged with a high sensitivity and specificity, and that it provides a good 
contrast between background signal and contrast agent enhanced signal. Ideally, 
imaging the labeling agent will provide precise anatomical location of the cells 
and could be used to monitor signal, and hence, the efficacy of cell therapy, over 
a long period of time. 
Cell labeling techniques can be divided into direct and indirect methods of 
labeling. [114] Direct labeling involves using labels that can be phagocytosed or 
transported into the cell, [115] or attached to the cell membrane, and subsequent 
injection of labelled cells. The disadvantages of direct labelling are that the label 
can elute out of the cell, or be diluted in daughter cells as the cell divides and that 
dead cells cannot be distinguished from live cells and other cells that have taken 
up the label by phagocytosis of labeled dead cells, for example, macrophages. 
[116] 
Indirect labelling uses a reporter gene introduced into cells, which is translated 
into enzymes, receptors, symporters or proteins. [117] These cells can express 
the label over their entire lifetime, and this is also passed on to daughter cells, 
allowing the possibility of tracking expanding populations of cells, for example 
T cells during immunotherapy. [118] Since these proteins are transcribed only in 
live cells, live cells can be distinguished without background signal from dead 
cells. 
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1.10. Indirect Cell Labeling Methods 
1.10.1. Magnetic Resonance Imaging (MRI) 
MRI offers distinct advantages over the nuclear imaging modalities in terms of 
the achievable spatial resolution, and over both CT and nuclear imaging as it 
uses non-ionising radiation, although its sensitivity is limited. (Table 1-1) For 
MR imaging, cells have been transfected to express biotin on their cell surface 
membranes. This can be labelled with intravenously administered streptavidin 
iron oxide nanoparticles. [119] Alternatively, an adenoviral vector can be used to 
deliver ferritin transgenes to cells of interest, causing the cells to accumulate iron 
and become paramagnetic. [120] Both of these labelling methods result in 
shortened T2 and T2* and hence signal hypointensities in images, which can be 
difficult to localise and quantify. To overcome this problem, a reporter gene 
encoding lysine-rich protein has been developed, which provides MR contrast by 
the selective saturation on the resonant frequency of lysine (chemical-exchange 
saturation transfer). [121] 
1.10.2. Optical Imaging 
Bioluminescence imaging most commonly uses the luciferase enzyme, which 
catalyses the oxidation of the substrate luciferin, a reaction producing a photon of 
light that can be measured with a highly sensitive, charge-coupled device 
camera. (Chemical reaction Equation 1-1)[122] Luciferase can be transduced 
into cells using a lentiviral vector, after which the cell can be tracked for 
prolonged periods of time with multiple injections of substrate, with no 
background signal. 
€ 
Luciferase +  Luciferin +  ATP →  Luciferyl - AMP +  PPi
Luciferase.luciferin - AMP +  O2 →  Luciferase +  AMP +  CO2 +  Oxyluciferin +  light
where :  
ATP =  adenosine triphosphate
AMP =  adenosine monophosphate
PPi =  pyrophosphate
O2 =  oxygen
CO2 =  carbon dioxide
 
 
Equation 1-1: Reaction sequence of firefly luciferase catalyzing the substrate luciferin to produce 
yellow-green light (λmax = 560nm). [123, 124] 
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An advantage of bioluminescent cell tracking is the absence of ionizing 
radiation. However, this also results in limited tissue penetration as the signal is 
reduced 10-fold every centimeter of tissue depth, so that the maximum 
penetration depth is just 2 cm in tissue. The scattering of light in tissue also 
results in poor spatial resolution, which is dependent on, and is roughly equal to 
the signal depth, for example a signal depth of 3 mm results in a maximum 
achievable resolution of 3 mm. [125] Despite this disadvantage, it is a very 
sensitive technique, able to image 10-100 cells subcutaneously, or 106 cells at 
2cm depth. [126] In addition to firefly luciferase, there are 4 types of beetle 
luciferase with emission wavelengths ranging from green to orange, as well as 
renilla luciferase from the sea pansy and gaussia luciferase from the marine 
copepod. [118]  
There are numerous proteins available for fluorescent imaging that cover the 
entire spectrum of visible light, and these have been used for many years to study 
gene expression and promoters, to label proteins and study protein interactions, 
and as sensors to monitor the activity of enzymes. [127] However, the high 
background autofluorescence of tissue severely limits the sensitivity of 
fluorescence imaging in the visible spectrum. [128] This problem can be 
overcome with the use of filters for background subtraction, and by using 
infrared proteins, which minimize autofluorescence and have better tissue 
penetration. [129] Examples of far-red and infrared proteins that have been 
incorporated into cells using an adenovirus for in vivo fluorescence imaging are 
Neptune and Infrared protein. [130] However, optical imaging methods for cell 
tracking are limited to animal models because the maximum tissue penetration 
depth with infrared proteins is between 1 and 2 cm. [131] 
1.10.3. SPECT Imaging 
Single-photon emission computed tomography (SPECT) and positron emission 
tomography (PET), offer great advantages for cell tracking due to their high 
sensitivity, allowing radiolabels to be detected at picomolar or lower 
concentrations [114] and cells to be detected in the region of a few hundred cells, 
in a dedicated small animal PET scanner. [132] 
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The most important advantage of PET over SPECT imaging is its sensitivity. In 
PET imaging the radiotracers used decay by emitting a positron that is 
annihilated upon interaction with an electron, producing two gamma rays 
travelling at approximately 180 degrees apart, both with an energy of 511 keV. 
[133] The gamma rays are detected without the need for collimators, using 
coincidence-detection to accept or reject the photon. The lack of collimation 
improves sensitivity and results in an increased signal-to-noise ratio and 
improved temporal resolution. Another advantage of PET imaging is that the 
measured tissue activity can be quantified in Bq/mL tissue, after corrections for 
photon attenuation and scatter. [134] 
However, spatial resolution in PET is limited by photon non-collinearity, 
resulting from the net momentum of the annihilated positron and electron leading 
to small deviations from 180 degrees and hence, image blurring. [135] Spatial 
resolution is also limited by the distance the positron travels through tissue 
before annihilation, which depends on the isotope used and the tissue type, for 
example, the spatial resolution lost is three times higher in lung than in soft 
tissue. [136]  
An important advantage of SPECT imaging is that multiple radioisotopes can be 
used for simultaneous imaging using different energy windows, providing the 
isotopes decay with different energy levels. [137] Common examples of 
radionuclides used for SPECT imaging are Technetium-99m (140 keV, half-life 
6.0 hours), Indium-111 (171 keV and 245 keV, half-life 2.8 days) or Iodine-125 
(35 keV, half-life 59.4 days). These radionuclides can be attached to antibodies, 
receptor ligands and other molecules of interest, or used to label cells directly 
with the addition of a chelating agent. [129] Unfortunately, SPECT imaging is 
less sensitive than PET, due to the requirement for collimators to reject photons 
that are not within a small range of angles. The collimation also negatively 
impacts the spatial resolution, requiring that a balance be struck between 
sensitivity and resolution. [135] However, the design of pinhole collimators has 
improved the trade-off between sensitivity and spatial resolution, resulting in 
sub-millimetre image resolution for small animal SPECT scanners. 
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In contrast to PET, SPECT imaging has traditionally been regarded as non-
quantitative, however, the implementation of software algorithms to correct for 
photon scatter and attenuation, and improvements in hardware, have resulted in 
improvements in the accuracy of quantification. [138] 
In a high resolution, small-animal SPECT scanner, four pinhole collimators and 
four detectors, commonly consisting of Thallium-doped Sodium Iodide crystals, 
collect the incident gamma rays as they rotate on a gantry around the animal. 
[139] The resulting data is run through a filtered back-projection algorithm to 
reconstruct a 3D image. [140] Combining SPECT with CT imaging allows more 
accurate anatomical location of the SPECT signal, combining the strengths of CT 
(fast anatomical imaging) and SPECT (highly sensitive detection of radiotracer 
and the capability to do molecular imaging). [137] 
Reporter genes have been used to track cells using SPECT and PET, such as the 
Herpes simplex virus thymidine kinase type 1 (HSV1-tk), which does not occur 
naturally in cells. Radiolabeled thymidine analogues are phosphorylated by the 
Herpes simplex virus thymidine kinase type 1 (HSV1-TK) enzyme, and trapped 
inside the cell, where they accumulate. Examples of the substrates used are uracil 
nucleoside derivatives such as 5-iodo-2′-fluoro-2′-deoxy-1-β-d-
arabinofuranosyl-5-iodouracil (FIAU) labeled with Iodine-131, [141] and 
acycloguanosine derivatives such as 8-[Fluorine-18]-fluoropenciclovir 
([18F]FPCV). [142] Unfortunately, this reporter gene cannot be used in the brain 
because the substrates cannot pass the blood-brain barrier. It is also more 
difficult to quantify the expression of this reporter gene compared to others, as 
the signal produced by HSV1-TK is dependent on the amount of tracer 
metabolized by the enzyme, and not the concentration of the enzyme. Therefore, 
a kinetic study or tracer kinetic modelling is needed to accurately quantify 
expression. [143] In addition, there have also been immune responses in patients 
to the nonhuman HSV1-tk protein. [144] 
Another common reporter gene is the human norepinephrine transporter (hNET), 
expressed by presynaptic terminals in the nervous system and responsible for the 
transport of norepinephrine into the nerve cell. Transduced cells can accumulate 
a norepinephrine analogue, metaiodobenzylguanidine, labeled with iodine-131 
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for SPECT imaging or an iodine-124 labeled version for PET imaging [145] As 
it is a human protein, there are little concerns about its immunogenicity, and its 
probe is already in routine clinical use with a proven safety record. 
The human sodium/iodide symporter gene (hNIS) is responsible for active 
transport of sodium and iodide across the cell membrane and is highly expressed 
by the thyroid, with lower concentrations in other tissues, such as the salivary 
glands, stomach and thymus. The advantages to this system are that transfected 
cells can be imaged without the need to chemically engineer an analogue, simply 
using iodine-123 or iodine-131, and it is non-immunogenic to humans. [146] 
However, the iodine leaks out of cells except for those in the thyroid, which 
express thyroperoxidase for organification of the iodine, and iodine also cannot 
cross the blood-brain barrier. 
These reporter gene imaging techniques have now been translated into clinical 
settings, with Jacobs et al. reporting the first use of HSV1-tk reporter gene 
imaging using PET in patients with glioblastoma. [147] 
1.11. Direct Cell Labeling Methods 
1.11.1. Conventional Cell Radiolabeling 
Indium-111 has been used since 1976 [148] to radiolabel leukocytes for clinical 
applications, such as imaging infection, fever of unknown origin and 
osteomyelitis. 
The most commonly used compound for leukocyte labeling is indium-111 oxine. 
Oxine chelates indium-111 ions, to form 3:1 complexes. The indium complex 
has a neutral charge and the oxine is lipophilic, so the complex diffuses into 
leucocytes. The complex has a low stability and dissociates, the indium-111 
forming bonds with nuclear and cytoplasmic proteins that are stronger chelating 
agents in an exchange reaction, while the oxine diffuses out of cells. [149] 
Tropolone is a chelating agent also used with indium-111. Similarly it is 
lipophilic and forms 3:1 complexes, however, unlike indium-111 oxine leukocyte 
	   53	  
labeling, where cells must be removed from plasma, indium-111 tropolone has 
the advantage that cells can be labeled in plasma. [150] 
However, despite the ease of use of indium-111 and its labeling efficiency of 50-
80% within cells, its disadvantage is the high radiation dose given to labeled 
cells. This is primarily due to low energy Auger electrons emitted during 
radioactive decay, rather than external gamma radiation from extracellular label. 
[151] This high dose has lead researchers to search for a Technetium-99m 
complex (99mTc).  
99mTc-hexamethylpropylene amineoxine (99mTc-HMPAO) labeling of leukocytes 
was first proposed in 1986. [152] This compound is also lipophilic, so crosses 
leukocyte cell membranes to label the cell, although its labeling efficiency is 
only 30-50%. [153] It also elutes out of cells after labeling, unlike indium-111, 
which is trapped inside the cell. An advantage of 99mTc-HMPAO is that it gives a 
lower total nuclear radiation dose to cells than 111In (0.05 Gy/MBq rather than 
1.4 Gy/MBq), [154] leading to increased leukocyte survival. It can also be 
produced less expensively by a bench-top eluting generator, and has a half-life of 
6 hours. However, the short half-life and elution of the label out of cells, results 
in a rapidly decreasing signal and reduced specificity of the signal. [155] 
Both methods of direct cell labeling have been extensively used in both clinical 
and preclinical studies, for example, indium-111 oxine has recently been used to 
image MSCs in vivo using SPECT/CT after their injection into the tibia of rats. 
[156] 
1.11.2. Cell Labeling with Nanoparticles for MRI 
Superparamagnetic iron oxide nanoparticles (SPIOs) have been used to label 
cells for in vivo tracking using MRI. [85, 157] These particles cause local 
inhomogeneities in the magnetic field, causing rapid dephasing of spins and a 
reduced tissue T2 and T2* relaxation time, leading to a reduced signal intensity 
in a T2 or T2*-weighted image. [158] However, this reduced signal can be hard 
to detect in tissues that already have low signal, for example, the lungs. [159] 
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1.11.3. Summary of Cell Tracking Methods 
In conclusion, there is no perfect modality for cell tracking as each modality 
presents its own advantages and limitations (Table 1-1), and similarly no ideal 
method of cell labeling.  
Indirect cell labeling methods are difficult and time-consuming, requiring the 
engineering of reporter genes and vectors for their delivery into cells. Other 
limitations with this technique arise from endogenous background signal and 
available tracers that are either expensive to make or do not have favorable 
kinetics or distribution. However, an advantage of these systems is that once the 
reporter has been incorporated into cells, they can be tracked repeatedly over 
time and cell expansion in vivo can be monitored.  
Yaghoubi et al. first used a reporter gene to image a cell therapy in a patient in 
2009, using the Herpes virus 1 thymidine kinase reporter for PET imaging of 
cytotoxic T cells. [160] However, it is likely that overcoming regulatory hurdles 
will be a significant challenge for reporter gene imaging in patients. [114] 
Direct cell labeling methods are easier, quicker and very clinically translatable, 
but only allow short-term tracking (over 5-7 days with indium-111 oxine [161]), 
due to the elution of label from the cells and the short half life of the 
radioisotopes. Direct cell labeling using radiopharmaceuticals is an established 
technique for tracking leukocytes in the clinic, and has also recently been used to 
track defined cell populations such as neutrophils and eosinophils. [162] Direct 
cell labeling for tracking cell therapies in patients has been used for 
approximately a decade, after Blocklet et al. used indium-111 and technetium-
99m to monitor antigen-loaded dendritic cells as a cancer vaccine. [163] MRI 
techniques for direct cell labeling have lagged behind the nuclear medicine 
modalities but are now being used in clinical studies, for example, dendritic cell 
labeling with SPIO for MRI tracking of a cell therapy against melanoma. [164] 
However, there is still an ongoing need for labeling agents that allow medium or 
long-term cell tracking and that do not elute quickly out of the cells of interest. 
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Modality Advantages Disadvantages 
MRI High spatial resolution Sensitivity to tracers 
 Non-ionising radiation Quantification difficult 
 Reporter genes can allow 
tracking of cells over 
time 
Iron oxide nanoparticle based 
contrast agents reduce signal 
so tracking can be difficult 
 High soft tissue contrast Expensive 
Bioluminescence High SNR Limited depth penetration 
 Unlimited tracking over 
time 
Low spatial resolution (depth 
dependant) 
 Indicates cell survival Limited clinical applicability 
 Quantification possible Cells must be transduced ex-
vivo 
Nuclear imaging High sensitivity Ionising radiation 
 Quantification possible Low spatial resolution 
 Correlation with anatomy 
when combined with CT 
Conventional cell labeling 
techniques can result in a 
high radiation dose to cells 
 Reporter genes allow 
tracking of cells over 
time 
 
Table 1-1: Advantages and disadvantages of cell tracking methods 
1.12. Cell Labeling Using Cell Surface Thiols 
Thiols are found on the side chain of cysteine (an amino acid with an uncharged 
polar side chain- therefore, zero net charge at neutral pH). The side chain has a 
sulfhydrl group (-SH), which is an important component of the active site of 
many enzymes. Under oxidizing conditions the –SH groups of two cysteines can 
spontaneously form a dimer, cystine, which contains a covalent cross-link called 
a disulfide bond (-S-S-). [165] A disulfide linkage contributes to the stability of 
the three-dimensional shape of the protein molecule.  
Oxidation and reduction of thiol proteins on the cell membrane is thought to be 
the predominant mechanism in cellular signal transduction pathways for reactive 
oxidants. [166] Cells are exposed to many different reactive oxidant species that 
can act as initiators or second messengers for thiol- based redox signaling, which 
is fundamental to a wide range of receptor-mediated pathways. 
It has been shown that oxidation decreases cell surface membrane thiols and 
reduction increases cell surface membrane thiols, by reducing disulfide bridges 
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via thiol-disulfide exchange reactions. [167] Studies have shown that thiol 
groups are expressed by freshly isolated peripheral blood mononuclear cells in 
the range of 3-18 x 109 thiol groups per cell, measured using a 5,5′-dithiobis(2-
nitrobenzoic acid) (DTNB) assay. [168, 169] In particular, freshly isolated 
lymphocytes from patients have been shown to express 4-15nmol thiol groups 
per 10 million cells, equating to 0.25-0.93 x 109 thiol groups per cell, measured 
using AlexaFluor®-maleimide fluorescent staining and flow cytometry analysis. 
[167] 
Recently there has been increasing interest in using these thiol groups as a target 
for cell labeling. [167, 170, 171] Maleimide is a compound commonly used for 
this purpose, as its double bonds readily and selectively react with the disulfide 
bonds in cysteine molecules, forming a stable carbon-sulphur bond. Other 
conjugation groups that have also been used are bromobimanes [172] and 
iodoacetamides. [173] 
The maleimide labeling strategy will be explored in this thesis using a novel tri-
functional probe, consisting of a fluorescent molecule, the radioisotope Iodine-
125 (125I) and a maleimide group, developed by UCL’s Radiochemistry 
Department (Dr Ran Yan, Dr Erik Arstad). The fluorescent reporter will allow 
quantification of cell labeling in vitro using flow cytometry, as well as showing 
the location of labeled cells in tumours ex vivo after tissue preparation for 
histology. The radioisotope reporter allows the cells to be tracked in vivo using 
SPECT imaging (Figure 1.6, Figure 1.7).  
 
Figure 1.6: Chemical structure of the I125-Dansyl maleimide probe 
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Figure 1.7: Schematic diagram of the structure of the I125-Dansyl maleimide probe 
This dual imaging potential allows two imaging modalities with different and 
distinct advantages to be combined, to look at labeled cells at a cellular and a 
macroscopic level. This multi-scale, dual imaging approach has previously been 
used to look at colorectal tumours using the carcinoembryonic antigen (CEA) 
specific antibody A5B7 as the binding group, with an 125I reporter and a 
fluorescent rhodamine reporter. [174] However, maleimide labeling of a cell 
therapy with a tri-functional probe is a novel approach to tracking a cell therapy. 
1.13. Summary 
The concept of two engineered cell therapies working in tandem to target lung 
cancer is intriguing, and could result in better tumour clearance than that 
observed with a single cell therapy alone. This thesis combines tumour antigen 
specific T cells with MSC TRAIL to provide a completely novel approach in cell 
therapy. As discussed previously in the cell therapy sections, MSC TRAIL alone 
or tumour antigen specific T cells alone are not capable of consistently clearing 
tumours. This is likely due to several factors, including, but not limited to, 
antigen escape variants and the immunosuppressive tumour environment. It is 
possible that cytokines secreted by the T cells will aid MSC homing and 
engraftment, leading to improved tumour clearance, and that MSC TRAIL could 
kill residual tumour with antigen escape variants. 
Furthermore, I will test novel and conventional direct cell labeling strategies to 
enable imaging of these therapies in vivo. The ability to track a cell therapy in 
vivo would answer many questions about the location and persistence of 
transfused cells. Indirect cell methods present many challenges, including the 
difficulty translating them from animal models into patients. Efforts to develop 
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reporter genes strategies and their optimization are ongoing at the Centre for 
Advanced Biomedical Imaging at UCL, and are outside the scope of this thesis. 
Therefore, a direct cell labeling method will be simpler, quicker and more 
clinically translatable. 
Contributions arising from this thesis are as follows:  
• The first in vitro and in vivo application of a dual cell therapy for cancer. 
• The first in vivo studies using the chimeric LMP2-specific EBV-TCR. 
• The first use of T cells with a tumour antigen specific TCR to target lung 
cancer in vivo. 
• The first known application of bioluminescence imaging to track tumour 
antigen specific TCR T cells homing to lung metastases. 
• Testing a novel tri-functional probe targeting cell surface thiol groups for 
labeling cell therapies. 
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1.14. Hypothesis 
A combination therapy of EBV-TCR T cells and MSC TRAIL, when injected 
into mice bearing lung metastases, will result in better tumour clearance than in 
mice injected with a single cell therapy. 
Tri-functional probes with a fluorescent reporter and a radioisotope reporter will 
enable imaging of these cells homing to lung metastases in vivo. 
1.15. Aims 
The aims of this work are as follows: 
1. Transduce T cells to express the EBV-TCR and test their efficacy in 
vitro. 
2. Explore conventional cell radiolabeling strategies and assess their 
suitability for T cell tracking. 
3. Test the novel tri-functional probe for T cell tracking and compare to 
conventional cell radiolabeling strategies. 
4. Combine EBV-TCR T cells and MSC TRAIL as a therapy for in vivo 
murine models of lung metastases, and image the cells homing to the 
lungs. 
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2. Materials and Methods 
This chapter describes all the experimental procedures, reagents and equipment 
used to gather data for this thesis. 
2.1. Cell culture 
All sterile tissue culture media, sterile tissue culture grade trypsin/EDTA, tissue 
culture antibiotics and fetal bovine serum (FBS) were purchased from Invitrogen 
(Paisley, UK) unless otherwise stated. Sterile tissue culture flasks and plates 
were obtained from Nunc (Roskilde, Denmark). All the cell types used in 
experiments are described below. (Table 2-1) 
 
Cell name Cell type Purpose 
MDA-MB-231 Human breast 
adenocarcinoma cell line 
Used in vivo as a model for 
lung metastases 
Jurkat cells Human acute T cell 
leukaemia cell line 
Used in place of EBV-TCR T 
cells for preliminary 
experiments in cell labelling 
Peripheral blood 
mononuclear 
cells (PBMCs) 
Human donor lymphocytes 
(70-90%), monocytes and 
dendritic cells 
Used to produce EBV-TCR T 
cells 
MSC TRAIL Human mesechymal stem 
cells expressing full length 
TRAIL 
Used as a cancer cell therapy 
Phoenix Ampho 
cells 
Human kidney epithelial 
cell line 
Highly transfectable cell line 
used to produce retrovirus for 
transductions 
T2 cells Human lymphoblastic cell 
line  
MHC class II negative cell 
line used to present exogenous 
peptide to T cells during 
restimulation 
Table 2-1: Summary of the different cell types used during experiments. 
MDA-MB-231 cells were the cancer cells used for in vitro and in vivo studies, as 
these cells reliably form lung metastases in xenograft mouse models. 
Adenocarcinoma is the commonest form of non-small cell lung cancer, and these 
tumours tend to metastasize early throughout the lung, hence the choice of this 
tumour model. The cell membrane of MDA-MB-231 tumour cells have also been 
shown to be a potent chemoattractor for MSCs, relative to other cancer cell lines. 
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[175] MDA-MB-231 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with 4 mM L-glutamine, 50 units/mL penicillin and 50 μg/mL 
streptomycin and 10% (v/v) fetal bovine serum (FBS) and were incubated at 
37°C in a humidified, 5% CO2 atmosphere. They were passaged at 1:12 twice 
weekly, by washing twice with phosphate buffered saline (PBS), then using 3 
mL trypsin EDTA to lift off adherent cells. 
Jurkat leukaemia cells were obtained from the Institute of Child Health and were 
cultured in Roswell Park Memorial Institute 1640 media (RPMI) with 4 mM L-
glutamine, 50 units/mL penicillin and 50 μg/mL streptomycin and 10% (v/v) 
fetal bovine serum (FBS) added, and were incubated at 37°C in a humidified, 5% 
CO2 atmosphere. They were passaged at 1:10 twice weekly, by aspirating and 
discarding old media and replacing it with fresh media. 
Human donor peripheral blood mononuclear cells (PBMCs) were obtained from 
the Royal Free Hospital Biobank, and cultured at the Immunology Department of 
the Royal Free Hospital, London. PBMCs were defrosted into RPMI media, with 
4mM L-glutamine, 50 units/mL penicillin and 50 μg/mL streptomycin and 10% 
(v/v) fetal bovine serum (FBS) and were incubated at 37°C in a humidified, 5% 
CO2 atmosphere. OKT3 CD3 antibody and interleukin-2 (IL-2) (Chiron) were 
added into the cell suspension at 30 ng/mL and 600 units/mL respectively, to 
stimulate expansion of T cells. After transduction, the media was aspirated every 
2-4 days, and replaced with fresh RPMI media, with 200 units/mL IL-2 added. 
Human mesenchymal stem cells (MSC) expressing full length TRAIL, were 
obtained from Krishna Kolluri and Dr Zhengqiang Yuan in the UCL Division of 
Medicine Lungs for Living Lab. These were cultured in triple layer flasks in 
Alpha Modified Eagle’s Media (αMEM) with 16% FBS, 4mM L-glutamine, 50 
units/mL penicillin and 50 μg/mL streptomycin added. Before use in 
experiments, they were washed twice with PBS and harvested using 10 mL 
trypsin-EDTA. 
Phoenix Ampho cells were cultured in Iscove’s Modified Dulbecco’s Medium 
(IMDM) with 10% FBS, 4mM L-glutamine, 50 units/mL penicillin and 50 
μg/mL streptomycin added. They were defrosted from stock vials at least one 
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week before use and were not used for more than two transductions. They were 
passaged twice weekly using trypsin-EDTA to lift off the adherent cells and 
replated at 1:5 to 1:8 ratios to keep cell confluence below 80%. 
T2 cells were cultured in RPMI media as described above and were passaged 
twice weekly at a 1:10 to 1:12 ratio by aspirating old media and replacing it with 
fresh media. 
2.2. T cell transductions 
Retroviral transductions were performed to generate EBV-TCR T cells, using a 
plasmid supplied by Dr Shao-An Xue. (Figure 2.1) A new T cell transduction 
was usually performed before each experiment, using several donor PBMCs. 
Before starting the transductions, a large quantity of viral plasmid was produced 
using the standard QIAGEN Maxi Prep kit and protocol. 
 
 
Figure 2.1: Plasmid used in transductions to create EBV-TCR T cells 
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To start, Phoenix Ampho packaging cells (Nolan lab, Stanford University, USA) 
were plated at 2 x 106 cells in a 10 cm Petri dish in 8 mL Iscove’s Modified 
Dulbecco’s Medium (IMDM) with 10% FBS, 4mM L-glutamine, 50 units/mL 
penicillin and 50 μg/mL streptomycin added. 
The following day, these cells were transfected with plasmid so that they produce 
retrovirus containing the EBV-TCR plasmid. On the morning of the transfection 
day, PBMCs from the BioBank were activated after defrosting and plated in a 6 
well plate at 1 million cells/ml of RPMI, 8 mL per well, with OKT3 30 ng/mL 
and IL-2 600 units/mL added. Transfection of the Ampho cells was carried out in 
the afternoon. Thirty minutes prior to transfection, the medium was removed and 
replaced with 5 mL fresh IMDM. A Fugene transfection mix was prepared; in 
one eppendorf 300 μl of Opti-MEM® medium (Invitrogen, Paisley, UK) was 
mixed with 10 μl Fugene HD (Promega, Southampton). In a second eppendorf, 
1.5 μg pCl-amp and 2.6 μg DNA was mixed with 46.1 μl distilled water. The 
second solution was added to the first and the mixture was left at room 
temperature for 15-20 minutes. After 15-20 minutes the mixture was added drop 
wise to the Ampho cells, and the plates gently swirled, before being placed back 
in the incubator overnight.  
The following day the media on the transfected Phoenix Ampho cells was 
replaced with 5 mL fresh RPMI, and a 24 well plate was coated with 
RectroNectin® (Takara Bio Incorporated, Japan) 750 μl of 30 μg/ml in each well. 
The plate was covered and left overnight in the refrigerator. RectroNectin® is a 
recombinant polypeptide containing functional domains capable of binding 
viruses and cell surface proteins, and is used to improve transduction efficiency. 
On the transduction day, the RectroNectin® was removed from the plate and 
blocked with 2% bovine serum albumin (BSA) in PBS, 500 μL/well for 30 
minutes at room temperature, after which the plate was washed twice with PBS. 
Activated PBMCs were plated in a 24 well plate at 1 million cells/mL of RPMI 
and additives, with 600 units/mL of IL-2 added. The viral supernatant from the 
Phoenix Ampho cells was carefully removed and spun at 1500 rpm for 5 minutes 
to remove cells and cell debris. One millilitre of viral supernatant was added to 
each well of T cells and the cells were incubated overnight at 37°C and 5% CO2. 
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The next day, viral supernatant was carefully removed from the T cell wells and 
replaced with fresh RPMI with IL-2 100 units/mL added. Transduced T cells 
were used 2-3 days post-transduction.  
2.3. Flow cytometry for measuring EBV-TCR expression 
In a flow cytometer, cells in suspension are aspirated and sheath fluid is used to 
hydrodynamically focus the cells into a thin stream of liquid, one cell wide, so 
that each cell can be read individually. Laser light is focused onto the stream of 
cells, and there are detectors at the opposite side of the stream, and perpendicular 
to the laser source. Cells in the stream scatter the light source, and the forward 
and side scatter is used to look at properties of the cell, such as granularity and 
size. Different coloured lasers can be used to excite a range of fluorophores, so 
that several parameters can be measured at once. [176] 
To determine transduction efficiency (expression level of introduced TCR), 
transduced T cells were stained with anti-CD4.APC-Cy7 (1:50) for T helper 
cells, anti-CD8.PE-Cy7 (1:50) for cytotoxic T cells, anti-murine cβ.APC (2:50) 
for the murine constant region of the β-chain, and CLG pentamer.PE (2:50) a 
pentamer specific for the EBV-TCR. The pentamer consists of 5 MHC-CLG 
peptide complexes, arranged in a circular configuration so that all the MHC 
molecules can interact with CD4 or CD8. Combining MHC molecules in this 
fashion has been shown to increase binding stability between the probe and the 
TCR, as T cells generally have a low binding affinity for their cognate peptide-
MHC complex. [177] The MHC molecules are connected via a linker protein to 
5 fluorescent PE molecules, producing both high avidity binding and bright 
staining of EBV-TCR positive T cells. All the fluorescent antibodies were 
purchased from InvitrogenTM (Paisley, UK) and the CLG pentamer was 
purchased from ProImmune Ltd. (Oxford, UK).  
In addition to routine quality control checks, a daily calibration was performed 
on the flow cytometer using latex beads before running any experiments. Before 
running the samples, appropriate single colour controls were used to calculate the 
compensation needed to correct for spectral overlap. These were an unstained 
control, anti-CD8.FITC (2:50), anti-CD8.PE (2:50), anti-CD8.PE-Cy7 (1:50), 
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anti-CD4.APC-Cy7 (1:50) and anti-CD4.APC (2:50). After washing with PBS 
and resuspending in FACS buffer, the cells were run on a BD™ LSR II flow 
cytometer using FACSDiva™ software. All flow cytometry data was analyzed 
using TreeStar FlowJo software. 
2.4. T cell stimulation 
Peptide stimulation is used to activate and expand the population of T cells that 
express the specific TCR of interest. Autologous donor PBMC cells and T2 cells 
were used to stimulate EBV-TCR transduced T cells. T2 cells suspended at 
200,000 cells/40 μL in an eppendorf tube were loaded with CLG peptide at 100 
μM concentration, and incubated for 2 hours at 37°C, 5% CO2. 2 x 105 T2 cells 
and 2 x 106 feeder PBMCs were used per well, and these were irradiated for 14 
and 7 minutes respectively (80 Gy and 50 Gy), to prevent cell proliferation. The 
irradiated cells were added to transduced T cells plated at 5 x 105 cells per well, 
and plated in a 24 well plate with 2 μL/mL IL-2 added. The cells were then left 
to incubate at 37°C and 5% CO2, for the EBV-TCR transduced cells to expand. 
The percentage of cells expressing the EBV-TCR was monitored 4 days post-
stimulation using flow cytometry as described above. Five to seven days post-
stimulation, cells were used in chromium-51 and co-culture assays. 
2.5. Tumour cell transduction 
Phoenix ampho cells were also used to make virus for the transduction of MDA-
MB-231 cells with LMP2 antigen. The viral construct also included green 
fluorescent protein (GFP) as a transduction marker. Transduction was carried out 
as described above, except that MDA-MB-231 cells replaced PBMCs, and were 
plated at a density of 100,000 cells per well, in 1 mL DMEM with 1 mL viral 
supernatant added to each well. Flow cytometry was performed to check the 
transduction efficiency of the cells, using green fluorescent protein (GFP) to 
measure LMP2 expression, and untransduced MDA-MB-231 cells as a control. 
2.6. Chromium release assay for EBV-TCR transduced T cells 
This assay is used to assess TCR-antigen mediated cytotoxicity. It should ideally 
be performed 5-6 days after peptide-stimulation of the transduced T cells. The 
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day before, target cells are plated at 1.5 x 105/mL. On the day of the experiment, 
target T2 cells are counted and loaded with 10 μM relevant CLG or irrelevant 
NLV peptide for 1 hour at 37°C and 5% CO2. Then cells are labeled with 1.85 
MBq chromium-51 (51Cr) and incubated for an additional hour. Following 
incubation, cells are washed 3 times to remove excess 51Cr. T cells are counted, 
washed and resuspended in RPMI at 1.25 x 105 cells in 100 μL before being 
added to a 96-well plate in a dilution series down to a concentration of 3.75 x 103 
cells per 100 μL (in triplicate). Then target cells are added to each well at 5,000 
cells per well, including 2 rows at the bottom for minimum 51Cr release (target 
cells only) and maximum release (target cells plus 100 μL 1% trifluoroacetic 
acid for cell lysis). The plate is then centrifuged at 1300 rpm for 3 mins, after 
which it is placed in a designated radioactive incubator for 4 hours at 37°C and 
5% CO2. After incubation the plate is centrifuged again, and a new 96-well plate 
is prepared with 100 μL of scintillant added to each well. Fifty microlitres of 
supernatant is added to the scintillant and the plate is clearly labeled and left 
overnight in a designated room. The following morning, the plate is read in a 
Wallac 1450 Microbeta Plus analyser and the percentage cell lysis calculated as: 
€ 
Cell lysis =  sample lysis - spontaneous lysis( ) x 100
maximum lysis - spontaneous lysis( )
   [55] 
Equation 2-1: Equation used to calculate target cell lysis in the Chromium-51 release assay. 
To assess the TCR-antigen mediated cytotoxicity against the transduced LMP2-
GFP MDA-MB-231 cells, this assay was repeated using these cells in place of 
T2 cells, and omitting the peptide-loading step. 
2.7. IL-2 and IFN-γ Enzyme-linked immunosorbent assay (ELISA) 
ELISAs to measure IL-2 and IFN-γ secretion by activated EBV-TCR T cells 
were performed according to manufacturer’s instructions (Abcam, UK). Briefly, 
the relevant capture antibody was appropriately diluted and used to coat a 96-
well ELISA plate overnight at 4°C. The plate was then washed well with wash 
buffer and blocked with 200 μL assay diluent, whilst a dilution series of IL-2 and 
IFN-γ standards were prepared, starting at 500 pg/mL and 300 pg/mL 
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respectively. Assay diluent served as a zero standard. After blocking the plate 
was again washed with wash buffer, and 100 μL of each standard was added to 
the wells (in duplicate), including zero standards. Stimulated EBV-TCR T cell 
supernatant samples were diluted 1:5 in assay diluent, then 100 μL was added to 
the wells (in triplicate). EBV-TCR T cells were stimulated 24 hours before the 
assay by plating 1 x 105 T cells with 1 x 105 CLG peptide loaded T2 cells in 200 
μL RPMI media in a 96-well plate. 
After adding the samples, the plate was sealed and left room temperature for 2 
hours, and then washed 5 times with wash buffer. The working detector was 
prepared by diluting appropriate concentrations IFN-γ/ IL-2 detection antibody 
in assay diluent and adding avidin-horseradish peroxidase conjugate. After 
washing, 100 μL working detector was added and the plate was sealed and left at 
room temperature for 1 hour. The plate was then washed 7 times in wash buffer, 
100 μL of 3,3’,5,5’-tetramethylbenzidine substrate solution was added to the 
wells and the plate incubated at room temperature, in the dark, for 10-30 
minutes. When the colour had developed, 50 μL stop solution was added to the 
wells. The absorbance of each well of the plate was then read on an optical 
density reader at 450 nm. The results from the assay standards were used to plot 
a standard concentration curve using excel software, which was used to calculate 
the concentration of the samples. 
2.8. Co-culture experiments 
For all co-culture experiments, passage 9 or 10 MSC TRAIL were used. In 24-
well plates, 5 x 104 MDA-MB-231 LMP2 cells were plated with a reducing ratio 
of MSC TRAIL, from 1:1 to 16:1. Control wells of tumour cells only, and 
tumour cells plated with MSCs that did not express TRAIL were included. Cells 
were plated in αMEM and left in a humidified incubator at 37°C, 5% CO2, for 
48 hours. Following incubation the cells were trypsinized, and all media and PBS 
was saved in order to keep the dead tumour cells for analysis. The cells were 
stained with Annexin V PE.Cy7 and PI to measure apoptosis and death, 
respectively. Briefly, the cells were suspended in 100 μL Annexin binding buffer 
and 5 μL Annexin V solution was added. The cells were left at room temperature 
in the dark for 20 minutes, after which another 400 μL of Annexin binding 
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buffer was added to the cells. Before running on the flow cytometer, 2 μL of 1 
μg/mL PI solution was added. 
The cells were run on a BD Biosciences™ LSR II flow cytometer using 
FACSDiva™ software, with appropriate signal colour controls used to set 
compensation. The tumour cells were identified by their expression of GFP, and 
gates were set defining the tumour cell population. The data was analysed using 
FlowJo software to give percentages of live, dead, apoptotic and dual stained 
tumour cells. 
In order to complete further co-culture experiments exploring combined MSC 
TRAIL and EBV-TCR T cell killing, it was first necessary to establish the effect 
of culturing T cells in αMEM, rather than in RPMI (T cell media). 1 x 106 
PBMCs were plated in 50:50 αMEM and RPMI, and 100% αMEM with IL-2 
added to the media. After 48 hours a trypan blue death count was used to check 
cell survival. 
To assess the affect of MSC TRAIL on EBV-TCR T cell survival, these cells 
were plated at a 1:1 ratio in a 24-well plate in αMEM for 48 hours. Following 
this, the T cells were stained with Annexin V and PI for apoptosis and death, as 
described above, and the cells were run on a BD™ LSR II flow cytometer as 
described above. 
2.9. Conventional cell radiolabeling protocols 
The cell labeling protocols followed for conventional radiolabeling were those 
used in clinical practice by the Radiopharmacy of the Institute of Nuclear 
Medicine at University College Hospital, London, and will be described in the 
relevant section. Cell labeling agents 99mTc-HMPAO and Indium-111 Tropolone 
were supplied by the Radiopharmacy at the Institute of Nuclear Medicine, 
University College Hospital. 
2.10. Cell labeling with 99mTc-HMPAO 
The 99mTc-HMPAO complex is lipophilic and in aqueous solution degrades into 
free 99mTc-pertechnetate and a hydrophilic 99mTc-HMPAO complex over time, 
hence it must be used to label cells within 20 minutes of preparation. The exact 
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mechanism of labeling is not understood but two methods have been proposed: 
1) binding of 99mTc-HMPAO to non-diffusible organelles or cytoplasmic 
proteins, and 2) intracellular conversion of the lipophilic complex into the 
hydrophilic complex by reducing agents, such as glutathione, leading to 
sequestration within cells. [155] 
For cell labeling, the 99mTc-HMPAO solution was freshly prepared and used 
within 20 minutes. A vial containing exametazime 0.5 mg (CeretecTM) was 
reconstituted with fresh 99mTc generator eluate (5mL in 0.9% saline) to form the 
labeling solution. Jurkat cells (40 x 106) were washed twice in PBS, before being 
spun down into a cell pellet. Immediately after the PBS on the cell pellet was 
discarded, the entire dose of 99mTc-HMPAO (123 MBq) was added onto the 
pellet and the cells were left at room temperature for 10 minutes, with occasional 
shaking. Afterwards, the cells were washed again with 10 mL PBS and the 
activity was counted in the cell pellet and the supernatant using a dose calibrator 
(Capintec). The cells were then resuspended in 1 mL PBS, left for 30 minutes, 
spun down again followed by gamma counting of the cell pellet and supernatant. 
Radioactivity in the cell pellet and the supernatant was measured over time, up to 
24 hours. Death rates in the cells were also measured at each time point, in 
triplicate, using trypan blue. 
2.11. Cell labeling with 111In tropolone 
The 111indium-tropolone complex is neutral and lipid-soluble, allowing it to 
diffuse across the phospholipid bilayer to label cells. The mechanism of action 
for cell labeling is not fully defined, but is thought to involve an exchange 
reaction between tropolone and cytoplasmic components that are stronger 
chelating agents, such as lactoferrin. This theory is supported by the low stability 
constant of the 111indium-tropolone complex. [178] 
Jurkat cells (40 x 106) were washed twice with PBS then spun into a cell pellet 
and the PBS was discarded. Following the washes, 150 μL of tropolone solution 
was mixed with 30 MBq of indium-111 solution (volume 425 μL) and this was 
added to resuspend the cell pellet. The cells were incubated for 10 minutes at 
room temperature and agitated periodically, then washed with PBS and the 
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radioactivity measured in the cell pellet and supernatant using a dose calibrator. 
As before, the activity in the cell pellet and supernatant was measured over time. 
Death rates in the cells were also measured at each time point, in triplicate, using 
trypan blue. 
Mesenchymal stem cells (5 x 106) were labeled in a similar fashion, with 20 
MBq activity of Indium-111. For T cell imaging, EBV-TCR luciferase T cells (6 
x 106 per mouse) were labeled separately with approximately 15 MBq of Indium-
111. 
2.12. Maleimide probe labeling protocol 
The maintenance of extracellular thiol groups is supported by 
oxidation/reduction reactions and disulfide exchanges in the cell surface 
microenvironment. [179] Maleimide reacts specifically and irreversibly with 
thiol groups at a pH of 6.5-7.5, resulting in a stable thioether carbon-sulfur bond. 
Jurkats or T cells were taken from suspension, washed twice with PBS and 
resuspended in PBS at 1 million cells/mL. The relevant concentration of the 
probe was spiked into the suspension and the cells left for 1 hour in the incubator 
at 37.5°C. The cells were finally washed twice in PBS, and then used for the 
experiment. 
Rhodamine maleimide and Dansyl triazole maleimide will be the probes 
discussed in this thesis. For Rhodamine maleimide labeling the concentrations 
used were 1 nM - 1 μM. For Dansyl triazole maleimide cell labeling the 
concentrations used were between 1 μM to 1 mM. The choice of labeling 
concentration will be discussed further in chapter 5. 
Secondary antibodies for flow cytometry were added after maleimide labeling as 
per the manufacturers protocol. Annexin-V Alexa Fluor®-647 or Annexin-V 
Alexa Fluor®-488 (Invitrogen), was used to measure apoptosis, and Propidium 
Iodide (PI) (Invitrogen) or 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen), 
was used to measure cell death. Cells were transported on ice before flow 
cytometry. 
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2.13. CellTracker™ CM-DiI and DiR labeling 
These membrane-bound fluorescent probes were used to label cells before 
injection for the in vivo experiments. Cells were labeled at 1 μL probe per 106 
cells in 1 mL of serum–free media, for 15 minutes at room temperature, as per 
the maunfacturer’s instructions (life technologiesTM, Paisley, UK). They were 
then washed twice in 10 mL PBS, before being resuspended in the desired 
volume ready for use. 
2.14. Flow cytometry for maleimide-binding probes 
A flow cytometer was used to analyse the percentage of maleimide labeled cells, 
and to measure other parameters, such as apoptosis (Annexin-V) and death 
(DAPI/PI). Rhodamine maleimide exhibits fluorescence at 610 nm and Dansyl 
triazole maleimide exhibits fluorescence at 525 nm, therefore, secondary 
fluorescent labels were chosen carefully so their fluorophores could be read in 
different channels, to avoid signal overlap. Unstained and single-stained controls 
were run for each experiment to determine gating parameters and compensation, 
after which the samples were run. 
2.15. Fluorescent and confocal microscopy of labeled cells 
For fluorescent microscopy, labeled cell samples were spun down at 1500 rpm 
for 5 minutes, and then re-suspended in 150 μl PBS. The suspension was 
dropped onto a SuperFrost® glass slide, and a number 1 coverslip  (both VWR 
International, Lutterworth, UK) was placed on top. A Zeiss Axioskop 2, 
combined fluorescent and light microscope system was used to image cells in 
combination with QImaging software. 
For confocal microscopy, cells labeled with the maleimide probes were 
counterstained with DAPI or Annexin V, and then spun down and resuspended to 
106 cells in 200 μL. Using a Shandon Cytospin 2, 106 cells were spun onto a 
SuperFrost® glass slide at 400 rpm for 4 minutes, then the cells were covered 
with Immuno Mount™ (GeneTex Inc., Irvine, CA, USA) and a number 1 
coverslip was placed on top. The cells were imaged with a Leica TCS SP2 
upright confocal microscope (Leica Microsystems, Milton Keynes, UK). 
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2.16. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) assay for 
quantifying cell surface thiols 
Jurkat cells were grown in suspension until they reached confluencies of 
200,000, 400,000 and 800,000 cells per mL (in triplicate). Jurkat cells were then 
taken from suspension and washed twice with PBS, before being resuspended at 
1 million cells/ 1ml PBS in eppendorf tubes, with 200 μM DTNB added. After a 
5-minute reaction time, the cells were spun down and 100 μl of cell suspension 
from each was removed and added to a 96 well plate. The absorbance 2-nitro-5-
thiobenzoic acid (TNB) a yellow coloured product, was measured using a plate 
reader set to 412 nm wavelength. The thiol groups present in the sample were 
quantified by reference to the extinction coefficient of TNB. (Equation 2-2) As 
the sample contained a known number of cells, the number of thiol groups per 
cell could be calculated. 
€ 
Molar absorptivity (M-1cm-1) =  Absorbance
Path length (cm) x Concentration (mol/L)( )
  [180] 
Equation 2-2: Equation used to calculate the concentration of thiol groups in the samples and hence 
the number of thiols per cell. 
2.17. 125I-Dansyl Triazole Maleimide labeling experiments 
Jurkat cells were taken from suspension, washed twice with PBS and 
resuspended at 1 million cells in the required volume of PBS. Cells were then 
taken to the designated radioactive room for labeling. The 125I-DM powder was 
dissolved in 500 μL dimethyl sulfoxide (DMSO), as it is insoluble in water, and 
the total activity measured using a dose calibrator (Capintec). The required 
activity was spiked into the cell suspension and the cells left for 1 hour in the 
incubator at 37.5°C. Following labeling, the cells were washed twice in PBS and 
re-suspended in media. All tubes used and supernatants were kept for gamma 
counter or dose calibrator measurements, in order to accurately measure labeling 
efficiency. 
For initial cell labeling experiments the activity added to the cell suspension was 
8 MBq (67 μL) or 2 MBq (16.8 μL). Labeling efficiency and activity over time 
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could then be measured using the dose calibrator. For cell labeling experiments 
with low activities, a gamma counter was used to measure the activities of the 
cell pellet and supernatant. The activity of probe used was within the range of 
125I measured accurately by the gamma counter as determined with a calibration 
experiment (Figure 2.2). Hence, 0.6 MBq of initial labeling activity was used for 
the experiments, accounting for a low labeling efficiency. The activity on the cell 
pellet, on the tube and in the supernatant was measured using the gamma 
counter, and the labeling efficiency was calculated using Equation 2-3. 
€ 
Labelling efficiency (%) = CPM cell pelletCPM tube +  CPM supernatant +CPM cell pellet( )  x100
Where :
CPM = counts per minute
 
Equation 2-3: Equation used to calculate the labeling efficiency in all radiolabeling experiments. 	  
 
Figure 2.2: Calibration of the gamma counter for Iodine-125 using measurements of activity from the 
gamma counter and dose calibrator at CABI.  A linear regression was performed using excel software 
(see equation). 
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2.18. In vivo Bioluminescence Imaging 
Mice were anaesthetized with 2% isoflurane in 28% oxygen throughout imaging. 
An aqueous solution of D-luciferin (Regis Technologies Inc, Morton Grove, IL, 
USA) at 150 mg/kg in a volume of 200 µl was injected i.p. 10 minutes in 
advance. Imaging was performed using an IVIS® Lumina II (Caliper Life 
Sciences, Hopkinton, MA, USA) with the following parameters: f/stop 2 
(aperture), maximum field of view (23 x 23 cm), acquisition time 60 s and 180 s. 
Quantification of the bioluminescent signal was performed using a region of 
interest (ROI) covering the whole thorax using Living Image 4.0 software 
(PerkinElmer). 
2.19. In vivo Fluorescence Imaging 
Mice were anaesthetized throughout imaging with 2% isofluorane. Fluorescence 
imaging was performed using an IVIS® Lumina II with an f/stop 2, maximum 
field of view, excitation wavelength 645 nm, ICG emission bandwidth and an 
exposure time of 10 seconds. 
2.20. SPECT/CT Imaging 
After labeling with the hot dansyl maleimide probe, 1 x 106 cells in PBS were 
spun down into a pellet in a microcentrifuge tube, and imaged using a 
NanoSPECT/CT system (Mediso, Budapest, Hungary) (Figure 2.3). CT was 
performed first, using a 45 kV X-ray source, with 500 ms exposure time in 180 
projections, a pitch of 0.5 and an acquisition time of 11 min. SPECT using a 4-
head scanner with 4 × 9 1.4 mm pinhole apertures in helical scan mode with an 
exposure time of 2400 s, obtained over 24 projections (100 s per projection), 
total acquisition time of 72 minutes. CT images were reconstructed in a 
352 × 352 matrix using Bioscan InVivoScope version 1.44 (Bioscan, USA) 
software. SPECT images were reconstructed in a 256 × 256 matrix using 
HiSPECT (ScivisGmbH, Bioscan). Images were overlaid using InVivoScope 
software. 
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Figure 2.3: The NanoSPECT/CT system used for imaging, with physiological monitoring systems for 
in vivo imaging. 
To track MSCs labeled with indium-111 tropolone, 5 x 106 MSCs were 
incubated for 10 minutes with 20.45 MBq Indium-111 (334 μL) and 150 μL 
tropolone, resulting in a labeling efficiency of 25.28% (5.17 MBq on the cell 
pellet after 2 washes with PBS). The control mouse received an intravenous 
injection of 5.08 MBq indium-111 in PBS, whereas the experimental mouse 
received an intravenous injection of 5 x 106 MSCs labeled with 5.17 MBq 
indium-111 tropolone in PBS. 30 minutes after intravenous injection the mice 
were imaged in a NanoSPECT/CT system. CT images were acquired first, using 
a 45 kV X-ray source, with 500 ms exposure time in 180 projections, a pitch of 
0.5 and an acquisition time of 11 min. SPECT images were acquired using an 
exposure time of 1200 s, obtained over 24 projections (50 s per projection), using 
a 4-head scanner with 4 × 9 1 mm pinhole apertures in helical scan mode with a 
total acquisition time of 36 min. Image processing was carried out as described 
above, using HiSPECT and InVivoScope software. 
To assess T cells survival during SPECT/CT tracking using indium-111 
tropolone, PBMCs were transduced with EBV-TCR luciferase. These were 
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restimulated three times until the percentage of T cells expressing EBV-TCR 
luciferase was approximately 65%. Subcutaneous tumour bearing NSG mice 
(n=3) with small lung metastases were injected with 6 million T cells labeled 
with 150 μL tropolone and 173 μL indium-111 in saline solution, resulting in 
cell pellet activity of 10.62±1.37 MBq and an average labeling efficiency of 
50.87±2.25%.  Mice were imaged in a nanoSPECT/CT scanner (as described 
above), immediately after cell injection. To monitor cell survival in vivo, 
bioluminescence imaging was performed using a BioSpace Photon Imager 
(Paris, France) with the following parameters; acquisition time 5 minutes, 35 mm 
lens, f/stop 1.4. Fifteen minutes before imaging the mice received an 
intraperitoneal injection of the substrate D-luciferin (3 mg in 200 μL PBS). 
SPECT/CT and bioluminescence imaging was repeated using the same 
parameters at 24 hours to check the survival and location of the T cells. 
2.21. Tumour models 
Six-week old NOD/SCID mice (Harlan, Bicester, UK) were kept in filter cages 
in the Biological Services facility at the Centre for Advanced Biomedical 
Imaging, University College London, or in the Biological Services Unit at the 
Royal Free Hospital, depending on the location of the experiment. The mice 
were kept in a 12-hour light/dark cycle, with access to autoclaved food and water 
ad libitum. All studies were performed in accordance with UK Home Office 
procedural and ethical guidelines. For identification purposes, some in each cage 
mice received ear punches in the left ear, the right ear, or both. 
For subcutaneous tumours, 106 MDA-MB-231 cancer cells transduced to express 
the LMP2 tumour antigen were injected subcutaneously into the right flank. The 
cells were suspended in 200 μL PBS and kept on ice before injection. The 
resulting tumours were measured every 3-5 days with calipers, and the tumour 
volume was calculated as 4/3πr3, where r denotes the radius measured in 3 
orthogonal directions.  
For the lung metastases model, 106 MDA-MB-231 LMP2 cancer cells were 
injected into the tail vein. The cells were suspended in 200 μL PBS and kept on 
ice until use. 
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2.22. Histological processing 
Mice were sacrificed by sodium pentobarbital overdose (200 μL intraperitoneal 
injection), followed by laparotomy and exsanguination. To harvest the lungs the 
thoracic cavity was opened and the trachea was exposed and intubated using a 
22G venflon. The lungs were insufflated with 4% (w/v) paraformaldehyde 
(PFA), following which the trachea was ligated and the trachea and lungs were 
removed from the thorax. The livers were removed after the lungs; both were 
weighed and then placed into 4% PFA overnight, followed by transfer to 70% 
ethanol solution. The livers and lungs were dissected into separate lobes, and 
then the samples were run overnight in a tissue-processing machine (Tissue-
Tek®, Sakura, USA), with a programme consisting of multiple dehydration steps, 
clearing and paraffin wax infiltration. Following this the samples were embedded 
into blocks of paraffin wax, and 3 μm sections were cut using a microtome 
(Leica, Germany). Sections were placed on polylysine slides (VWR, 
Leicestershire, UK) for staining. 
2.23. Haematoxylin and Eosin (H&E) staining 
The prepared slides were run on an automatic tissue stainer with an H&E 
programme, followed by coverslipping on an automatic coverslipper (both 
Tissue-Tek®, Sakura, USA). The stained slides were imaged on a Nanozoomer-
XR C12000 digital slide scanner (Hamamatsu, Hertfordshire, UK). 
2.24. Immunofluorescence 
For immunohistochemical staining, sections were dewaxed using an automatic 
tissue stainer. CM-DiI™ stained cells retained their fluorescence after 
histological processing, however the GFP signal from the MDA-MB-231 cells 
was amplified using anti-GFP immunostaining.  Anti-luciferase immunostaining 
was used to locate luciferase expressing EBV TCR T cells. 
Labeled slides with 3 μm sections of lung were dewaxed using an automatic 
tissue stainer, and were then washed in PBS. A hydrophobic circle was drawn 
around the area for staining using a PAP pen (Sigma-Aldrich, UK). An antibody 
blocking solution consisting of 5 mL FBS and 500 μL fish skin gelatin, in 45 mL 
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PBS, was applied to the slides to block non-specific background staining, and 
this was left for 1 hour at room temperature. Primary antibodies used were anti-
GFP chicken Igγ (Invitrogen) (1:200) and rabbit polyclonal antibody to firefly 
luciferase (Abcam) (1:2000). A solution of these primary antibodies was made 
up in antibody blocking buffer and this was applied to the slides after antibody 
blocking. The slides were then left overnight in the dark at 2°C. 
The following day the slides were washed for 5 minutes in PBS and then stained 
for 3 hours at room temperature in the dark with a solution of secondary 
antibodies (1:300), made up in antibody blocking solution. The secondary 
antibodies used were Rabbit anti-chicken Igγ FITC (Invitrogen) and donkey anti-
rabbit IgG AlexaFluor 647 (Invitrogen). Following secondary antibody staining 
the slides were washed in PBS then counterstained with 1 μg/mL DAPI at room 
temperature for 5 minutes. They were then washed again in PBS for 5 minutes, 
followed by mounting with Mowiol and a size 1 coverslip. 
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3. Engineering T cells with tumour antigen specific T cell 
receptors 
The first aim of this project was to engineer T cells with the EBV-TCR, in order 
to provide a tumour antigen specific cell therapy targeting LMP2-expressing 
cancer cells. This chapter presents data investigating the ability of transduced 
EBV-TCR T cells to release cytokines upon antigen stimulation and their ability 
to kill LMP2-expressing tumour cells in vitro. This is an important step, as it was 
necessary to verify the results observed by Hart et al. [64] before proceeding to 
in vitro combined tumour cell killing assays and in vivo work (Figure 3.1).  
In tandem, I assessed the ability of MSC TRAIL to kill LMP2 expressing MDA-
MB-231 tumour cells. Previous work by Loebinger et al. [104] had primarily 
investigated the action of MSC TRAIL against HeLa colorectal carcinoma cells 
in vitro, rather than MDA-MB-231 cells, before proceeding into an in vivo model 
of lung metastases using MDA-MB-231 cells. Furthermore, for EBV-TCR 
killing it was necessary to transduce the MDA-MB-231 cell line so the cells 
expressed the LMP2 antigen. Therefore, it was necessary to repeat the MSC 
TRAIL cancer cell killing assays, to prove that they were active against LMP2-
expressing MDA-MB-231 cancer cells. 
Finally, this chapter presents novel work examining the in vitro tumour cell 
killing potential of EBV-TCR T cells combined with MSC TRAIL. 
 
 
Figure 3.1: Experimental workflow for chapter 3. 
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3.1. Transduction of donor PBMCs to produce EBV-TCR T cells 
The EBV-TCR specifically and with high affinity binds to the antigen latent 
membrane protein 2 (LMP2), which is characteristically expressed by EBV-
associated tumours. This protein is poorly immunogenic and in patients normally 
leads to only weak cytotoxic T cell responses against the LMP2 antigen. 
However, rather than relying on the host T cell reactivity to LMP2, a new LMP2 
specific TCR has been engineered, which redirects the antigen specificity of the 
engineered cells. The inserted EBV-TCR binds with high affinity to the LMP2 
antigen, so the cells can be transferred as an adoptive immunotherapy. 
Human donor peripheral blood mononuclear cells (PBMCs) were transduced 
with a modified retrovirus as described above in section 2.2 to express the EBV-
TCR. Briefly, Phoenix Ampho cells were transfected with the EBV-TCR 
plasmid in order to produce retrovirus containing EBV-TCR plasmids. These 
were then collected and added to freshly defrosted PBMCs where the T cells had 
been activated and caused to proliferate by stimulation with interleukin-2 (IL-2) 
and anti-CD3 antibody. After 24 hours the media was changed and the 
transduction efficiency could be verified. 
Flow cytometry was performed after each transduction to measure the percentage 
of EBV-TCR expression on T cells, using a fluorescent CLG pentamer that binds 
specifically to the EBV-TCR, and a fluorescent antibody against the murine 
constant region of the TCR β-chain (murine cβ). Additionally, fluorescent 
antibodies against CD4 and CD8 were used to assess the percentages of helper 
and cytotoxic T cells (discussed in section 2.3).  
During flow cytometry analysis, the population of live cells was identified and a 
gate was drawn around them. Looking at live cells only, the percentage of CD4 
and CD8 expressing cells was measured. Within each population of CD4 positive 
or CD8 positive cells, the expression of the murine cβ and the binding to CLG 
pentamer was measured. Cells were considered transduced with the EBV-TCR 
gene if they were double positive for murine cβ and CLG pentamer binding. 
After transduction, approximately 35% of CD4 and CD8 positive cells were 
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expressing the EBV-TCR, compared to 0% in the controls (Figure 3.2 and Figure 
3.3). 
 
Figure 3.2: Mock untransduced cells stained with murine cβ and CLG pentamer. 
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Figure 3.3: Transduced CD4 and CD8 positive cells are 34.5% and 37.2% respectively, dual positive 
for murine cβ and CLG pentamer, indicating expression of the EBV-TCR.   
3.2. T cell stimulation increases the percentage of EBV-TCR 
positive T cells 
Peptide stimulation is used to increase the percentage of EBV-TCR positive T 
cells, as described in section 2.4. In this protocol, T2 cells loaded with CLG 
peptide were used to stimulate proliferation and expansion of transduced cells. 
T2 cells are a human T cell leukemia/B cell line hybrid, which act as potent 
antigen presenting cells when loaded with peptide. Peptide loading is achieved 
by simply incubating the T2 cells with a high concentration of peptide for 2 
hours at 37°C. 
After CLG peptide loading, T2 cells were plated together with feeder PBMCs, 
IL-2 and the transduced T cells. T2 cells and feeder PBMCs were irradiated 
before plating to eliminate their expansion. After stimulation, flow cytometry 
analysis on these T cells showed 45.6% of CD4 positive T cells and 59.3% of 
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CD8 positive T cells expressed the EBV-TCR, indicating expansion of EBV-
TCR expressing T cells (Figure 3.4). The percentage of T cells expressing the 
EBV-TCR after transduction and one round of stimulation was similar across 
different donor PBMCs (Figure 3.5). This data suggests that PBMCs from 
different donors can reliably be transduced to express the EBV-TCR, and that 
this expression can be increased using peptide stimulation. 
 
Figure 3.4: After one stimulation, the percentage of CD4 cells expressing the EBV-TCR increased to 
45.6%, and CD8 to 59.3%. 
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Figure 3.5: Percent EBV-TCR positive after transduction and stimulation in PBMC samples from 
three different donors. 
 
3.3. In vitro T cell functional assays 
3.3.1. Cytokine secretion assays 
To assess the function of transduced EBV-TCR T cells, the secretion of 
cytokines after stimulation with antigen was measured. An ELISA measuring 
secretion of interleukin-2 and interferon-gamma was performed on EBV-TCR T 
cells. Transduced T cells (approximately 50% positive for the EBV-TCR after 
two stimulations) were plated overnight with T2 cells coated with irrelevant 
peptide (NLV) or relevant peptide (CLG). There was a significant increase in 
production of both cytokines when the transduced T cells were incubated with 
T2 cells expressing relevant peptide compared with control T2 cells expressing 
irrelevant peptide (Figure 3.6). Consequently, the EBV-TCR T cells produce 
cytokines in a peptide-specific manner. 
3.3.2. Luciferase imaging of EBV-TCR T cells 
Bioluminescence imaging of the T cells was performed in vitro to test the 
function of the luciferase plasmid before moving into in vivo experiments (Figure 
3.7). Luciferase expressing EBV-TCR T cells, stimulated three times to 
	   85	  
approximately 65% positive for the EBV-TCR, were plated in a 24-well plate in 
a dilution series from 2 x 106 cells to 31,250 cells, suspended in 2 mL RPMI 
media. Cells were treated with 2 mg D-luciferin for 15 minutes, before being 
imaged in a Xenogen IVIS® Lumina II system (f/stop 2, acquisition time 60 s). 
The resulting data was analyzed using PerkinElmer Living Image 4.0 software to 
measure photon radiance within regions of interest (ROI), represented by the red 
circles. The photon radiance was above the background signal of 2.11 x 104 at all 
dilutions, although the scale on the image was adjusted to display the highest 
concentration of EBV-TCR T cells. The in vivo dose of these T cells will be 
above 2 x 106, therefore it is possible that in vivo bioluminescence imaging could 
be used to assess the location and persistence of injected EBV-TCR T cells, if a 
large proportion of cells home towards a tumour or to lung metastases. 
 
Figure 3.6: IL-2 and IFN-gamma ELISA of cytokine concentration in the cell culture media after 
incubation of transduced EBV-TCR T cells with T2 cells coated with irrelevant (NLV) or relevant 
(CLG) peptide, n=3 different donor PBMCs. EBV-TCR T cells secrete cytokines in peptide-specific 
manner. 
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Figure 3.7: A dilution series of EBV-TCR luciferase T cells, suspended in T cell media (2 x 106, 1 x106, 
500,000, 250,000, 125,000, 62,500). Cells were treated with 2 mg D-Luciferin in 200 µL PBS, for 15 
minutes, before being imaged in a Xenogen IVIS® Lumina II system (f/stop 2, acquisition time 60 s). 
The red circles represent ROI drawn over each well and the signal is measured as photon radiance. 
The background signal was 2.11e+04 and the photon radiance scale was adjusted to optimize the 
image for the first EBV-TCR T cell dilution. Control wells contained PBS (second well from left, top 
row), RPMI media (right well, top row) and control untransduced PBMCs in a dilution series from 2 
x 106 to 2.5 x 105 (second row, left to right). 
3.3.3. EBV-TCR T cell killing assays 
A chromium-51 assay was used to assess the capability of the transduced EBV-
TCR T cells to kill target cells. To quantify the cytotoxicity of different 
concentrations of T cells, target cells are labeled with chromium-51, which is 
then released into the media when the cell is lysed by a cytotoxic T cell. The 
resulting chromium-51 activity in the media can be measured using a scintillation 
counter.  
This assay was performed first with relevant and irrelevant peptide loaded T2 
cells, to test specific TCR-antigen mediated killing (Figure 3.8). Plating T2 cells 
coated with CLG peptide with transduced EBV-TCR T cells resulted in between 
60.19% (±14.0%) to 100% (±8.88%) lysis of T2 tumour cells at all dilutions of T 
cells. Plating T cells with T2 cells coated with irrelevant peptide (NLV) resulted 
in a low, non-specifc tumour cell lysis average of 17.0% (±2.67%). Therefore, 
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EBV-TCR T cells can kill target cells in a peptide-specific fashion. This also 
occurs in a dose-dependent fashion, with lower ratios of EBV-TCR T cells to T2 
cells causing less percentage lysis. 
Tumour cells express fewer antigens on their cell surface membrane than T2 
cells coated with peptide. In order to assess the capability of transduced T cells to 
kill tumour cells, it was first necessary to transduce the tumour cell line of choice 
to express the LMP2 antigen. The EBV-TCR selectively binds to the LMP2 
antigen to cause cell death. The cancer cell line used for all in vitro and in vivo 
experiments was the human breast cancer cell line MDA-MB-231. This tumour 
cell line will form lung metastases several weeks after subcutaneous injection of 
tumour cells, or directly if the cells are injected intravenously. The MDA-MB-
231 cells were transduced with a retroviral vector to express latent membrane 
protein-2 (LMP2) and green fluorescent protein (GFP). GFP signal could then be 
measured using flow cytometry to assess the number of transduced cells, which 
was 63.6% (Figure 3.9). 
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Figure 3.8: Chromium-51 assay showing TCR-antigen mediated killing against T2 cells expressing 
relevant peptide (T2+CLG) and non-specific background lysis of T2 cells coated with irrelevant 
peptide (T2+NLV), n=3 different donor PBMCs. 
 
 
 
Figure 3.9: Flow cytometry analysis of MDA-MB-231 cells after transduction with LMP2-GFP. 
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Figure 3.10: Flow cytometry analysis of MDA-MB-231 cells after clonal expansion for LMP2-GFP. 
The successful cell colony after clonal expansion (right) is 99.4% positive for LMP2-GFP. These cells 
were expanded and used for further in vitro and in vivo experiments. 
After transduction it was necessary to do a clonal expansion to isolate and 
expand a pure LMP2-GFP expressing population, resulting in a population of 
cells where 99.4% expressed LMP2-GFP (Figure 3.10). This allowed more 
accurate in vitro and in vivo testing of the transduced EBV-TCR T cells, since 
the T cells could target all tumour cells, rather than a population of tumour cells. 
After expansion of a clonal population of the LMP2-GFP positive tumour cells, 
the chromium-51 assay was repeated using control MDA-MB-231 cells and 
MDA-MB-231 LMP2-GFP cells, to assess T cell killing of tumour cells. These 
cells express a lower concentration of surface antigen than peptide loaded T2 
cells, resulting in a lower maximum percentage lysis of 76.04% (±8.64%), 
compared with an average background lysis of 9.10% (±2.22%) (Figure 3.11). 
However, this data shows that EBV-TCR T cells can specifically lyse MDA-
MB-231 LMP2 cells, compared to a low background lysis of MDA-MB-231 
control cells, and that this occurs in a dose-dependent fashion. 
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Figure 3.11: Chromium-51 assay showing T cell TCR-antigen mediated tumour cell killing. 
Background lysis of control tumour cells is low, however, lysis of LMP2 expressing tumour cells is 
high, n=3 different donor PBMCs. 
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3.4. In vitro co-culture assays of combined EBV-TCR T cells and 
MSC TRAIL tumour killing 
To test the combined killing capacity of EBV-TCR T cells and MSC TRAIL, I 
used co-culture experiments followed by analysis of apoptosis and death using 
flow cytometry. Annexin V is a probe used to detect cells expressing 
phosphatidylserine on their cell surface membrane, an event that occurs soon 
after induction of apoptosis. Fluorescent conjugates of Annexin V can be used 
with a flow cytometer to indicate the percentage of apoptotic cells. Propidium 
iodide and 4’6-diamidino-2-phenylindole (DAPI) are fluorescent nuclear staining 
dyes that can be used for flow cytometry to indicate dead cells, since they cannot 
enter live cells. Cells that were Annexin V negative and PI/DAPI negative were 
recorded as live, cells that were Annexin V positive but PI/DAPI negative were 
recorded as apoptotic, and cells that were Annexin V and PI/DAPI positive were 
considered to be dead.  
Co-culture experiments were necessary due to the time taken for MSC TRAIL to 
produce measurable tumour cell death (48 hours). The co-culture assay was 
previously developed by Loebinger et al. [104] and was modified to include 
EBV-TCR T cells. In contrast, the chromium-51 assay for T cell cytotoxicity 
requires just 4 hours.  
A typical co-culture experiment consisted of 5 x 104 MDA-MB-231 LMP2 
tumour cells plated with a decreasing ratio of MSC TRAIL or EBV-TCR T cells 
in a 6-well plate. The cells were left for 48 hours in αMEM media in the 
incubator, before being trypsinised and stained for flow cytometry. Appropriate 
single colour controls were used to set compensations and gates. 
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3.4.1. MSC-TRAIL only co-culture experiments 
Co-culture experiments were performed to test if MSC TRAIL could kill MDA-
MB-231 LMP2 tumour cells. In these experiments, 5 x 104 MDA-MB-231 LMP2 
tumour cells were plated with 5 x 104 MSC TRAIL (1:1 ratio), 2.5 x 104 MSC 
TRAIL (1:2 ratio), 1.25 x 104 MSC TRAIL (1:4 ratio), 6.25 x 103 MSC TRAIL 
(1:8 ratio) and 3.125 x 104 MSC TRAIL (1:16 ratio), in αMEM media. 
All the MSC TRAIL cells used in these experiments were passage 8 or 9. During 
the analysis of flow cytometry data, all cells were taken, but debris was excluded 
in the side scatter, forward scatter plots. Tumour cells were distinguishable from 
MSC TRAIL by their expression of GFP (Figure 3.12).  
The results show that MSC TRAIL can kill MDA-MB-231 cells in a dose-
dependent fashion similar to that observed with T cell killing (Figure 3.13). 
Control tumour cells showed a baseline apoptosis of 14.8% (±0.38%) and death 
of 2.6% (±1.46%), whereas tumour cells plated with MSC not expressing TRAIL 
showed a small but not significant rise in apoptosis and death, with apoptosis of 
17.9% (±2.41%) and death of 6.0% (±0.53%).  
Tumour cells treated with a 1:1 ratio of MSC TRAIL showed a significant 
increase in apoptosis and death, with apoptosis of 50.06% (±1.09%) and death of 
12.16% (±1.94%). This rate of apoptosis and death is higher than that observed 
by Loebinger et al. [104] with HeLa cancer cells at the same ratio. Tumour cells 
plated at 2:1, 4:1 and 8:1 ratios with MSC TRAIL also showed a significant 
increase in apoptosis (p<0.01).  
Tumour cells plated at a ratio of 2:1 with MSC TRAIL showed apoptosis of 
40.27% (±1.13%) and death of 5.66% (±0.50%), and those plated at a ratio of 4:1 
showed apoptosis of 35.13% (±1.38%) and death of 2.21% (±0.35%). Lastly, 
tumour cells plated at a ratio of 8:1 with MSC TRAIL showed apoptosis of 
28.93% (±1.36%) and death of 1.77% (±0.15%), whereas those plated at 16:1 
with MSC TRAIL showed apoptosis of 15.27% (±2.66%) and death of 0.826% 
(±0.10%), very similar to control cell death and apoptosis rates. 
Therefore, MSC TRAIL is capable of killing MDA-MB-231 cancer cells 
expressing the LMP2 antigen, in a cell ratio dependent effect. A significant 
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increase of tumour cell apoptosis and death was observed even at high tumour 
cell to MSC TRAIL ratios of 4:1 and 8:1. However, at a tumour cell to MSC 
TRAIL ratio of 16:1, tumour cell apoptosis and death was not significantly 
altered compared to control tumour cells, or tumour cells plated with MSC.  
This cell ratio effect accounts for the significantly reduced subcutaneous tumour 
growth seen by Loebinger et al. when MSC TRAIL was co-injected with MDA-
MB-231 tumour cells, as the tumour cell to MSC TRAIL ratio was 2.66:1. [104] 
However, if the MSC TRAIL was activated 25 days after co-injection, there was 
no change in tumour growth compared to controls, probably as the MSC TRAIL 
to tumour ratio was then too low. Unfortunately, this low ratio of MSC TRAIL to 
tumour cells is likely to occur with the in vivo lung metastases model. It is 
encouraging that Loebinger et al. saw a significant reduction or clearance in lung 
metastases after 4 intravenous doses of MSC TRAIL in their in vivo model. The 
suggests that other factors in vivo assist MSC TRAIL mediated cancer cell death, 
possibly cytokines in the extracellular environment. 
The combination of MSC TRAIL with EBV-TCR T cells may therefore increase 
the clearance of lung metastases, as the activated EBV-TCR T cells will secrete 
cytokines and lyse cancer cells, reducing the tumour cell to MSC TRAIL ratio. 
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Figure 3.12: Representative flow cytometry plots of the MSC TRAIL and tumour cell co-culture 
experiments. Only debris was excluded in the side scatter, forward scatter plots, then the LMP2-GFP 
positive tumour cells were gated on and the population staining for Annexin V and PI was recorded. 
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Figure 3.13: Bar chart showing the results of co-culture experiments measuring MDA-MB-231 LMP2 
cell death and apoptosis using Annexin V and PI, 48 hours after plating with MSC TRAIL 
(*significant difference in apoptosis against control, p<0.01). 
3.4.2. Choice of culture media does not effect PBMC survival 
Before starting co-culture experiments testing combined killing of EBV-TCR T 
cells and MSC TRAIL it was first necessary to establish if culturing T cells in 
αMEM would result in any survival disadvantage. To test this, 106 PBMCs in 
triplicate were plated in a 24-well plate in RPMI only, 50:50 RPMI and αMEM, 
and αMEM only, with Roche IL-2 added. After 48 hours, trypan blue viability 
counts were performed to assess cell survival (Figure 3.14). Trypan blue cannot 
cross intact cell membranes, hence only dead cells are stained. There was no 
significant difference in death rates between the groups; therefore, αMEM with 
IL-2 supplements was used in subsequent co-culture experiments. 
3.4.3. MSC TRAIL does not effect EBV-TCR T cell survival in vitro 
The next co-culture experiment determined whether plating with MSC TRAIL 
resulted in any survival disadvantage for the EBV-TCR T cells. EBV-TCR T 
cells alone and MSC TRAIL and EBV-TCR T cells combined at a 1:1 ratio, were 
plated in a 24-well plate in αMEM for 48 hours. Following this the cells were 
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stained with Annexin V and PI to assess apoptosis and death, and the cells were 
run on a flow cytometer. There was no significant difference in cell survival 
between the groups plated with or without MSC TRAIL after 48 hours (Figure 
3.15). 
 
Figure 3.14: Trypan blue assessment of T cell survival after 48 hours of culture in different culture 
media. There is no significant difference in cell death between any of the groups, n=3. 
 
Figure 3.15: Bar chart showing T cell survival (live cells and apoptotic/dead cells), 48 hours after 
plating with MSC TRAIL at a 1:1 ratio, n=3. 
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3.4.4. EBV-TCR T cell co-culture experiments 
Before assessing combined tumour cell killing with EBV-TCR T cells and MSC 
TRAIL in vitro, the capability of EBV-TCR T cells alone to cause tumour cell 
apoptosis and death in a 48 hour co-culture experiment was characterized. 
Previous chromium-51 assays demonstrating tumour cell lysis used a T 
cell/tumour cell incubation period of just 4 hours, and greater ratios of T cell to 
tumour cell than what was used in co-culture experiments. Therefore, co-culture 
experiments were performed with the same ratios of EBV-TCR T cell to tumour 
cell as the co-culture experiments performed with MSC TRAIL, to allow a direct 
comparison. 
In these experiments, 5 x 104 MDA-MB-231 LMP2 tumour cells were plated 
with 5 x104 EBV-TCR T cells (1:1 ratio), 2.5 x 104 EBV-TCR T cells (1:2 ratio), 
1.25 x 104 EBV-TCR T cells (1:4 ratio), and 6.25 x 103 EBV-TCR T cells (1:8 
ratio). Cells were plated in αMEM, with 2 μl/mL IL2 added. 
Flow cytometry was performed as described above, with gates to identify the 
GFP positive tumour cell population, and measure their death and apoptosis. The 
results demonstrate 86.50% (±1.50%) tumour cell death and 6.82% (±0.68%) 
apoptosis at a 1:1 EBV-TCR T cell, to tumour cell ratio. At a 1:2 ratio, there was 
78.63% (±3.71%) tumour cell death and 10.17% (±1.48%) apoptosis, and at a 1:4 
ratio there was 74.93% (±2.21%) tumour cell death and 10.09% (±0.56%) 
apoptosis. Finally, at a 1:8 ratio there was 65.43% (±1.22%) cell death and 
16.07% (±0.64%) apoptosis (Figure 3.16). 
These results show markedly superior tumour cell killing using the EBV-TCR T 
cells, when compared with MSC TRAIL. The EBV-TCR T cells caused a 
significant increase in cell death at all ratios within the 48-hour incubation, 
whereas incubation with MSC TRAIL resulted in a significant increase of 
apoptosis at all ratios, and a significant increase in cell death only at the 1:1 ratio. 
If cell death and apoptosis are combined, EBV-TCR T cells again result in a 
much greater cell death/apoptosis rate than MSC TRAIL (93.32% versus 62.22% 
at a 1:1 ratio). 
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Figure 3.16: Bar chart of results from co-culture experiments measuring MDA-MB-231 LMP2 cell 
death and apoptosis, with PI and Annexin V, 48 hours after incubation with EBV-TCR T cells (n=3). 
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3.4.5. Combined EBV-TCR T cell and MSC TRAIL co-culture experiments 
The last set of co-culture experiments sought to determine whether adding EBV-
TCR T cells to MSC TRAIL enhanced in vitro tumour cell death. In these 
experiments 5 x 104 MDA-MB-231 LMP2 tumour cells were plated with 
reducing ratios of MSC TRAIL and EBV-TCR T cells as described above, from 
1:1:1 to 1:1:4. As before, these were plated in triplicate and left in the incubator 
for 48 hours, followed by the retrieval of all cells and subsequent Annexin V and 
PI staining. T cells had received four rounds of restimulation and were 
approximately 65% positive for the EBV-TCR. Passage 9 or 10 MSC TRAIL 
were used for all experiments. 
Flow cytometry analysis of the cells was performed as described above, with 
gates drawn on the GFP positive tumour cell population, and apoptosis and death 
measured in the tumour cell population (Figure 3.17). The results show that in a 
1:1:1 ratio (5 x 104 cells), 91.43% (±0.17%) of tumour cells are dead, with 3.74% 
(±0.43%) of cells undergoing apoptosis, compared with a control tumour cell 
apoptosis of 14.80% (±0.38%) and death of 2.27% (±1.47%). With 2.5 x 104 T 
cells and MSC TRAIL, at a 1:1:2 ratio, 79.77% (±0.41%) of tumour cells were 
dead, and 7.33% (±0.81) were apoptotic. At the lowest ratio of 1:1:4 (1.25 x 104 
T cells and MSC TRAIL), 67.03% (±1.28%) of tumour cells were dead, and 
9.72% (±0.47%) were apoptotic.  
The results show superior killing of tumour cells compared with MSC TRAIL 
alone. However, while the combined cell death and apoptosis rates at the 1:1:1 
and 1:1:2 ratios are comparable with those observed with EBV-TCR T cells 
alone at similar ratios, cell death and apoptosis are slightly reduced at a 1:1:4 
ratio compared with a 1:4 ratio of tumour cells to EBV-TCR T cells (76.76% 
versus 85.03%). However, this difference was not significant using a paired 
sample student’s t-test. 
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Figure 3.17: Bar chart of co-culture experiment results showing MDA-MB-231 LMP2 cell death and 
apoptosis measured with Annexin V and PI, after 48 hours of incubation with EBV-TCR T cells and 
MSC TRAIL, n=3. 
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3.5. Summary 
This chapter has demonstrated that: 
• Donor PBMCs can readily be transduced to express the EBV-TCR 
• Peptide stimulation increases the percentage of EBV-TCR positive CD4 
and CD8 T cells 
• Transduced EBV-TCR T cells secrete cytokines when stimulated by the 
target cells expressing the relevant peptide, but not when exposed to 
irrelevant peptide. 
• Transduced EBV-TCR T cells can specifically kill T2 cells labeled with 
CLG peptide and MDA-MB-231 cells transduced to express the LMP2 
antigen via antigen-TCR mediated cell killing. 
• MSC TRAIL kills MDA-MB-231 LMP2 tumour cells in a dose 
dependent fashion, with a 1:1 ratio causing the greatest increase in cell 
death and apoptosis, and a 16:1 ratio resulting in only baseline apoptosis 
and death. 
• MSC TRAIL do not cause any significant adverse effects on EBV-TCR T 
cell death and apoptosis during co-culture. 
• EBV-TCR T cells provide superior tumour cell killing to MSC TRAIL at 
all ratios. 
• MSC TRAIL in combination with EBV-TCR T cells provide far superior 
tumour cell killing compared with MSC TRAIL alone, but no significant 
killing benefit to EBV-TCR T cells alone. 
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3.6. Discussion 
Adoptive cell transfer is a promising technique in cancer immunotherapy. 
Retroviral insertion of genes coding for TCRs with high antigen affinity and 
specificity can result in the generation cytotoxic T cells which are highly active 
against tumour antigens. In this chapter I have shown that human donor PBMCs 
can be consistently transduced to express the EBV-TCR, and that during peptide 
stimulation the population of EBV-TCR positive T cells are expanded. These 
cells can efficiently kill T2 cells coated in the relevant peptide target and produce 
cytokines. More importantly these cells are also able to specifically kill tumour 
cells expressing the LMP2 antigen, in a dose-dependant fashion. Further 
increases in target cell lysis may have been possible with a pure population of 
EBV-TCR T cells, however, enrichment by FACS sorting inevitably resulted in 
T cell death so this was abandoned after 3 attempts. 
In addition, MSC TRAIL can also kill tumour cells, and do not have any adverse 
effects on T cell survival in vitro. In fact, TRAIL expression is seen in many 
cells of the innate and adaptive immune system, including dendritic cells, natural 
killer cells, T cells and macrophages, and its expression is dependent on their 
stimulation. [181] Many studies have shown that activated CD8+ T cells express 
membrane-bound TRAIL, and that this expression is induced by anti-CD3 and 
type I interferon. [182, 183] Resting T cells have also been shown to express the 
decoy TRAIL receptor DcR2, whereas on activation death receptor DR5 
becomes the predominant TRAIL receptor. Despite the expression of DR5 in 
activated T cells, both resting and activated T cells are resistant to TRAIL-
mediated apoptosis. [183, 184] This is thought to be due to their expression of 
FLIP, an inhibitor of the extrinsic apoptotic pathway activated by TRAIL (see 
Figure 1.4). [183] 
The EBV-TCR T cells used in the co-culture experiment were activated, and 
hence should express both DR5 and membrane-bound TRAIL. In keeping with 
the work of Mirandola et al. regarding T cell resistance to TRAIL, exposure to 
external TRAIL (from the TRAIL-expressing MSCs), did not result in any 
significant T cell toxicity. 
	   103	  
An interesting but perhaps not surprising finding is that EBV-TCR T cells 
provide more efficient tumour cell lysis at equivalent cell ratios than MSC 
TRAIL. To my knowledge there are no papers examining the difference in 
efficiency between TRAIL-mediated and TCR antigen-specific cytotoxicity, 
however, cytotoxic T cells are known to be serial killers that are capable of 
initiating apoptosis within 5 minutes of antigen-TCR binding. Cytotoxic T cells 
most often use the granule exocytosis pathway to kill target cells, although they 
can also affect target cell death using FAS or TRAIL to activate the caspase 
cascade. [185] The granules are prepackaged within the cytoplasm of the T cell 
and hence can cause more rapid target cell apoptosis than through the binding of 
death ligands. Therefore, it is possible that the mechanism of death significantly 
impacts the overall efficiency of target cell killing in co-culture experiments. 
When MSC TRAIL were used in combination with EBV-TCR T cells, up to 95% 
of tumour cells were dead or apoptotic. However, tumour cell death was not 
increased by the dual EBV-TCR T cell and MSC TRAIL, compared with EBV-
TCR T cells alone. This could be a result of the extremely high rate of apoptosis 
and death seen within the samples in both experiments, with 95% target cells 
apoptotic or dead with either the EBV-TCR cells alone or with dual therapy at 
1:1 cell ratios.  
The advantage of co-culture experiments is that they offer quantification of 
cytotoxic activity that would be impossible in an in vivo model. However, in 
vitro co-culture tumour cell killing assays do not accurately represent the true 
tumour microenvironment in vivo, and may underestimate or overestimate the 
killing effect of a dual cell therapy. Of particular relevance is the 2-dimensional 
nature of co-culture experiments, which differs significantly from the in vivo 
scenario.  
These cells will be used in an in vivo model of LMP2 expressing MDA-MB-231 
lung metastases, to test their therapeutic activity. Although no benefit with 
combined cell therapy was seen in vitro, the in vivo treatment of established lung 
metastases could present a different scenario. 
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4. Cell labeling and tracking using conventional methods 
for Nuclear Medicine 
 
There is a pressing need to track and quantify the transfused cells during 
adoptive immunotherapy, in order to evaluate homing efficiency, biodistribution 
and the functionality of a cell therapy after administration. The next aim of my 
project was to explore conventional nuclear medicine cell tracking techniques 
used for labeling and imaging leucocytes. These radiotracers are in routine 
clinical use; hence using them to track a cell therapy poses no regulatory hurdles. 
Furthermore, nuclear imaging is more sensitive than MRI for cell tracking, and 
allows quantification of the accumulation of radiolabeled cells (although SPECT 
imaging is semi-quantitative compared with PET imaging which is fully 
quantitative). 
This chapter presents cell labeling experiments comparing the two most common 
leucocyte direct labeling agents, indium-111 tropolone and technetium-99m 
HMPAO. Direct labeling techniques are generally easier, quicker and cheaper 
than indirect methods, but their disadvantage is that they cannot be used to 
repeatedly image cells over long periods due to gradual elution of the label out of 
the cell. Any novel agent that could be used to track a cell therapy must therefore 
prove superior to the methods currently available. 
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4.1. Conventional cell labeling 
Conventional cell labeling for leucocyte tracking using nuclear imaging relies on 
the use of chelated metal ions, namely indium-111 and technetium-99m. Once 
chelated the radioactive compound is lipophilic and crosses the cell membrane. 
Inside the cell these compounds dissociate because they are inherently unstable, 
resulting in radioactive cell labeling and the diffusion of the chelating agent out 
of the cell. In the case of indium-111, cell labeling efficiency is further helped by 
the indium-111 ion binding directly to nuclear and cytoplasmic proteins, giving 
good label retention, whereas the technetium-99m ion will diffuse out of cells, 
resulting in a higher leakage of activity over time. [186] 
For cell labeling studies, I used the Jurkat T cell leukaemia line, as the cells were 
cheap to produce and less precious than transduced T cells, whilst being similar 
in size and morphology. Cell labeling with technetium-99m 
hexamethylpropyleneamine oxime (HMPAO) and indium-111 tropolone was 
achieved following a clinical protocol supplied by the Radiopharmacy of the 
Nuclear Medicine Department at University College Hospital.  
To label Jurkat cells with technetium-99m, 40 x 106 cells in a pellet were 
incubated with 123 MBq of a technetium-99m HMPAO mixture. The clinical 
guidelines for technetium-99m HMPAO cell labeling state that the expected 
labeling efficiency is between 40-80% for 200 x 106 leucocytes labeled with 750-
1,000 MBq activity (corresponding to 3.75-5 Bq/cell). [155] Jurkat cell labeling 
with technetium-99m at approximately 3 Bq/cell, resulted in a 31.88±2.1% 
labeling efficiency, but the activity diffused out of cells (loss of 25% activity 
with decay correction after 5 hours), and the short half-life of technetium-99m (6 
hours) contributed to the rapid loss of activity retained in the cells (Figure 4.1). 
To label with indium-111 tropolone, 40 x 106 cells in a pellet were incubated 
with 30 MBq of indium-111, with 150 μL tropolone added. The clinical 
guidelines for indium-111 labeling state that the expected labeling efficiency is 
between 50-80% for 200 x 106 leucocytes labeled with 20 MBq activity 
(corresponding to 0.1 Bq/cell). [178] Jurkat cell labeling with indium-111 
tropolone at 0.75 Bq/cell resulted in a labeling efficiency 60.77±1.9% (Figure 
4.2).  
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Swirski et al. have demonstrated greater than 90% viability of Indium-111 
labeled monocytes after 24 hours at activities ranging from 0.6-3.7 Bq/cell. [187] 
Hence, I increased the initial labeling activity in my experiment to maximize the 
labeling efficiency. Due to the longer half-life of 2.8 days, there was more 
activity on Indium-111 labeled cells after 24 hours, making it preferable for cell 
tracking. However, the decay corrected curves illustrate that there is actually 
more elution of label from Indium-111 labeled cells compared with Technetium-
99m labeled cells, with 46.2% elution at 5 hours versus 25% with the 
Technetium-99m label. 
Therefore, any new technique for direct cell labeling must improve on these 
currently used methods, by giving better cell labeling efficiency, improved 
retained activity over time, or reducing the administered radiation dose to the 
nucleus of the labeled cell. 
 
Figure 4.1: Representative graph showing retained activity over time in 40 x 106 Jurkat cells after 
labeling with technetium-99m HMPAO measured using a dose calibrator. Cell labeling efficiency at 
time 0 was 31.88% +/-2.1% of added activity. After 5 hours the activity remaining on the cells was 
12.48 +/-1.91 MBq and at 24 hours it was just 1.21 +/-0.31MBq. 
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Figure 4.2: Representative graph showing activity on 40 x 106 Jurkat cells over time after labeling 
with indium-111 tropolone. Cell labeling efficiency was 60.77% +/-1.9% of added activity. After 5 
hours the activity remaining on the cells was 7.60 +/-0.88 MBq and at 24 hours it was 3.55 +/-1.40 
MBq. 
 
4.2. Imaging MSCs labeled with Indium-111 Tropolone 
To assess if tracking cells labeled with indium-111 tropolone to the lungs was 
possible using our small animal SPECT/CT system, a pilot study was carried out 
using 2 mice.  
The control mouse received an i.v. injection of 5 MBq indium-111 alone in PBS 
(Figure 4.3), whereas the experimental mouse received an i.v. injection of 5 
million MSCs labeled with an activity of approximately 5 MBq indium-111 
tropolone in PBS, corresponding to 1 Bq/cell (Figure 4.4). MSCs were washed 
twice in PBS before injection to wash off excess unbound activity, and the 
labeling efficiency in this experiment was 25% (original labeling activity was 20 
MBq).  
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A previous study by Gildehaus et al. also reported a labeling efficiency of 25% 
using indium-111 oxine to label MSCs, and no effect on cell viability at a 
labeling activity of 10 Bq/cell, although their migratory capacity was reduced. 
[156] Additionally, another study by Bindslev et al. also reported a labeling 
efficiency of 25%, and no effects on MSC doubling time or intracellular markers 
after labeling with indium-111 tropolone in the activity range of 15-260 Bq/cell. 
[188] However, for the purposes of this pilot study, a total activity of 5 MBq was 
adequate for in vivo imaging. 
 Approximately 30 minutes after i.v. injection the mice were imaged in a 
NanoSPECT/CT system as described in section 2.20. 
Cell imaging using indium-111 tropolone as a labeling reagent allowed 
visualization of labeled MSCs trapped in the small capillary bed of the lungs 
after injection into the caudal vein and subsequent passage through the right side 
of the heart. Kidd et al. report that intravenous injection of luciferase transduced 
MSCs into a murine model lacking any environments of inflammation, results in 
the majority of the cells trapped in the lungs at day 1, observed using 
bioluminescence imaging. [189] At day 3 the cells still are still present 
predominantly in the lungs, with a threefold decrease in signal, followed by a 
further decrease in lung signal with small population in the liver at day 5 and 
then all of the injected cells in the liver or spleen at day 7. Therefore, this is the 
expected location of MSCs immediately after i.v. injection. However, there is a 
large activity of free indium-111 in the bladder, illustrating the significant loss of 
activity over time from labeled cells.  
There are three possibilities to explain the free indium-111 in the bladder. Firstly, 
this could be the result of a leakage of activity out of labeled cells over time. 
Secondly, this could be a result of cell death and membrane permeability, 
allowing free indium-111 to leak out into the circulation. Lastly, it is possible 
that two washes in PBS was not adequate to wash off excess unbound indium-
111 from the cells, so this free activity could have been injected alongside the 
labeled cells. 
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Figure 4.3: SPECT/CT image of the control mouse, 30 minutes after an i.v. injection of 5 MBq 111In. 
Excretion of free 111In can be seen in the kidneys and bladder. 
 
Figure 4.4: SPECT/CT image of the experimental mouse 30 minutes after i.v. injection of 5 x 106 
MSCs, labeled with 5.0 MBq 111In, 1 hour after i.v. injection. MSCs are seen primarily in the lung 
fields, with free 111In secreted by the kidneys into the bladder. 
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4.3. Imaging T cells labeled with Indium-111 Tropolone 
To assess SPECT/CT tracking of T cells using indium-111 tropolone and 
accurately measure cell survival in vivo, PBMCs were transduced with the EBV-
TCR luciferase plasmid. These were peptide stimulated three times until the 
percentage of T cells expressing EBV-TCR luciferase was approximately 65%. 
A subcutaneous tumour lung metastases model was chosen for this pilot study in 
an attempt to observe the T cells residing in the lungs after delivery and homing 
to a tumour. A murine model of T cell homing using Gaussia bioluminescence 
imaging to image T cells homing to subcutaneous A20 mouse lymphoma 
tumours showed the majority of the bioluminescence signal located in the lungs 
up to day 2, then a small proportion of T cells in the subcutaneous tumour at day 
5, with a maximum signal in the tumour at day 7, when there was negligible 
signal in the lungs. [190] Therefore, if EBV-TCR luciferase T cells could be 
visualized in the lungs at 7 days and subcutaneous tumour at 5 days, this would 
be strong evidence of tumour homing. 
Subcutaneous MDA-MB-231 LMP2 tumour bearing NSG mice (n=3) with small 
lung metastases were injected with 6 million T cells labeled with indium-111 
tropolone (average labeling efficiency 36.1%), corresponding to an average 
activity of 10.1 MBq per 6 x 106 cells, and 1.68 Bq/cell.  Mice were imaged in a 
nanoSPECT/CT scanner as described in section 2.20 (Figure 4.5), immediately 
after cell injection. To monitor cell viability in vivo, bioluminescence imaging 
was performed (Figure 4.6). At 3 hours post i.v. injection, the average 
bioluminescent signal in the lung fields was 9.79 x 103 counts per minute 
(acquisition time 5 minutes, 35 mm lens, f/1.4). 
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Figure 4.5: Representative SPECT/CT image of a mouse injected with 6 x 106 T cells labeled with 10 
MBq indium-111 tropolone. Immediately after cell injection the majority of the activity is within the 
lung fields. 
 
Figure 4.6: Bioluminescence image of the three NSG mice injected with 6 x 106 EBV-TCR luciferase 
transduced T cells. The image was taken 3 hours after i.v. injection of the cells. 
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After 24 hours, the mice were scanned in the SPECT/CT again to check the 
location of the T cells (Figure 4.7). The signal was located primarily in the liver 
and spleen, with a small amount of signal in the kidneys. Bioluminescence 
imaging was repeated to check the viability of the T cells (acquisition time 5 
minutes, 35 mm lens, f/1.4). No bioluminescence signal was seen in vivo at 24 
hours (Figure 4.8). This indicates that the injected cells died; probably due to the 
radiation dose they received. Further evidence of T cell death is provided in the 
location of the indium-111 signal in the liver and spleen. Free indium-111 would 
be excreted, hence localized in the kidneys and bladder as seen in Figure 4.3. 
Therefore, the signal in the liver and spleen is likely to be damaged cells that 
have been phagocytosed by specialized macrophages responsible for clearing cell 
debris, such as Kupffer cells in the liver, which represent 80-90% of the total 
tissue associated macrophages in the body. [191] 
In vitro data of T cells labeled with 1.68 Bq/cell of 111In tropolone shows 
approximately 80% cell death after 24 hours, and 100% cell death after 48 hours 
(Figure 4.9). In an early paper investigating indium-111 labeling of human 
lymphocytes, Wagstaff et al. recommend a maximum activity of 0.015 Bq/cell. 
[192] Botti et al. reported 90% viability at 4 hours but close to 100% cell death 
of T cells at 6 days after labeling with 0.28 Bq/cell. [193] Therefore, it seems 
that compared with MSCs, T cells are extremely sensitive to radiation dose. In 
the previous study, lowering the initial activity on the cells from approximately 
0.28 Bq/cell to 0.007 Bq/cell improved T cell viability and proliferation; 
however, this was at the expense of labeling efficiency, and the authors did not 
attempt to image radiolabeled cells in vivo. Such low activity per cell is likely to 
make SPECT/CT tracking of the transferred cells impossible in an in vivo mouse 
model.  
Contradicting these studies, van Monfrans et al. reported that 111In oxine labeling 
of T cells at approximately 1 Bq/cell resulted in no loss of T cell function in vivo 
since they homed to a murine model of experimental colitis after 48 hours. [194] 
However, the authors did not specifically monitor T cell viability. 
These pilot studies demonstrate that indium-111 is a good choice of labeling 
agent for MSC tracking, since MSCs seem fairly resistant to radiation injury. 
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However, indium-111 is not a good label for T cell tracking unless the activity on 
cells is very small. At a labeling dose sufficient for in vivo longitudinal tracking 
using SPECT/CT, it is likely that all the transferred cells will die after 48 hours. 
However, there are studies with contradicting data regarding 111In T cell labeling, 
and its effect on homing and viability.  
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Figure 4.7: SPECT/CT image of the same mouse, 24 hours after i.v. injection of 6 x106 EBV-TCR 
luciferase T cells labeled with 111In-tropolone. Signal is now located in the liver, kidneys and spleen. 
 
Figure 4.8: Bioluminescence image of the three NSG mice injected with 6 x 106 EBV-TCR luciferse 
transduced T cells. The image was taken 24 hours after i.v. injection of the cells. There is no 
measurable bioluminescence signal, indicating death of all the injected cells. 
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Figure 4.9: Cell death rates using trypan blue staining after labeling with indium-111 tropolone or 
tropolone only (n=3). 
 
4.4. Summary 
This chapter demonstrates that: 
• Conventional cell radiolabeling strategies result in leakage of activity 
from the cells over time; however, indium-111 tropolone is superior to 
technetium-99m HMPAO in terms of retained activity on the cells after 
24 hours. 
• Indium-111 can be used to track injected MSCs and T cells in murine 
models, however, bioluminescent imaging of injected T cells indicates a 
large percentage of cell death after 24 hours. 
• Indium-111 toxicity resulting in T cell death was confirmed with in vitro 
viability assessments of the labeled cells, which showed approximately 
80% cell death at 24 hours after labeling. 
• Hence, despite having a half-life of 2.8 days, indium-111 is not a suitable 
agent for longitudinal T cell tracking in a small animal SPECT/CT 
system. Various studies have reported that very low doses of 111In activity 
per cell are required to avoid detrimental effects on T cell function, 
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homing and viability. Taking into account the elution of activity from the 
cells over time, it is likely that this would preclude longitudinal T cell 
tracking using 111In. 
 
4.5. Discussion 
In order to modify and optimize a cell therapy, it is useful to assess the location, 
numbers and viability of the transferred cells. Many clinical protocols for 
adoptive immunotherapy favour several divided doses of cells, [195-197] 
therefore, a measure of the transferred cells proximity to the tumour and their 
numbers would be useful to tailor the next treatment. 
While conventional cell radiolabels have previously been used to image cell 
therapies, these have many disadvantages, such as a high radiation dose to the 
sensitive cell nucleus and detrimental effects to cell proliferation and function. In 
addition, as shown in this work, there is elution of the label out of the cells over 
time and significant cell toxicity associated with radiolabeling. The short half-life 
of 99mTc and 111In also precludes longitudinal cell tracking studies. 
For adoptive immunotherapy studies, the viability and function of the transferred 
cells are of paramount importance. An estimate of the internal dose from 111In 
cell labeling is 14.8 Gy, derived from low energy Auger electrons during the 
radioactive decay process, and which the cell absorbs. In contrast, the external 
radiation dose from characteristic x-rays and γ-radiation is estimated at 1 Gy. 
[149] Lymphocytes are known to be radiosensitive and many groups have 
demonstrated reduced viability, chemotaxis, cytotoxic function and proliferation 
after cell radiolabeling with 99mTc [198] and 111In. [199] 
As a result, these cell labeling techniques have not been widely adopted for 
adoptive immunotherapy trials, with some groups preferring to use flow 
cytometry analysis of blood samples instead to estimate the numbers of 
persisting cells. [197] A direct cell label that is not carried intracellularly could 
minimize the damage to the cells by limiting radiation dose to the cell nucleus. 
This will be discussed in the next chapter. 
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5. A novel tri-functional radiolabel for cell tracking 
 
The third aim of the project was to test a novel tri-functional probe, developed by 
UCL’s Radiochemistry department, and to compare the results to conventional 
labeling techniques. This chapter presents data exploring the use of this probe for 
T cell tracking. 
To improve on conventional cell labeling strategies, I tested a probe for direct 
cell labeling that would bind to thiols on the cell surface membrane, keeping 
activity on the outside of the cell and limiting the dose to the radiosensitive 
nucleus. The probes were synthesized by Dr Ran Yan (UCL Department of 
Chemistry and Radiochemistry) and consisted of a maleimide group for cell 
membrane thiol conjugation, iodide-125 and a fluorescent reporter (Figure 5.1). 
Two fluorescent reporters were tested, rhodamine and dansyl. The purpose of the 
fluorescent reporter is to allow measurement of cell labeling and survival in vitro 
using flow cytometry, and ex-vivo cell localisation within tumours using 
fluorescent microscopy after histological processing. The iodine-125 reporter is 
useful for in vivo cell imaging using SPECT/CT and its long half-life of 59.4 
days could allow long-term tracking. 
The method describing one-pot synthesis of a probe that can be used for both 
nuclear and optical imaging has already been published by Yan et al. and will not 
be discussed here. [174] This had previously been tested as a tri-functional 125I 
and rhodamine labeled A5B7 antibody, targeting carcinoembryonic antigen in a 
mouse xenograft model with subcutaneous colorectal tumours. The probe used in 
this work was modified version, with a maleimide group replacing the A5B7 
antibody fragment, and was also synthesized using the one-pot method (see 
Figure 1.6 for a chemical diagram). 
For cell labeling studies, I used the Jurkat T cell leukaemia line, because the cells 
were cheap to produce and less precious than transduced T cells, whilst being 
similar in size and morphology. They also express 4 nmol of cell surface thiol 
groups per 1 x 106 cells [200], equivalent to the expression of thiols by 
lymphocytes. [167] 
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Figure 5.1: Schematic diagram of the 125I-DM tri-functional probe. 
5.1. Expression of thiols on Jurkat cells is dependent on cell density 
A 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) assay is used to quantify the 
number of thiol groups in a sample. The chemical DTNB reacts with thiols 
leading to the formation of yellow 2-nitro-5-thiobenzoate (NTB), the absorbance 
of which can be measured in a microplate reader at 412 nm. The absorbance is 
used to calculate the mols of thiol in the sample, with reference to the extinction 
coefficient of NTB.  
This assay was performed on samples of Jurkat cells to measure the quantity of 
thiols available for labeling. Firstly, it was important to measure how many thiol 
groups were present on Jurkat cells to judge if thiol labeling would result in 
detectable fluorescence signal using flow cytometry. Secondly, research by Sahaf 
et al. suggests that the extracellular environment is more important than the 
redox status of the cell in determining cell surface thiol expression. [167] 
Therefore, I hypothesized that cell culture density would effect cell surface thiol 
expression, hence the cell culture protocol would almost certainly effect the 
expression of thiols and might need to be adjusted for optimal labeling. Since 
Jurkat cells are grown in suspension the effect of trypsinization, used to lift off 
!"#$%&'(&)*+
%&,$%*&%+
-.)'/"+
0$)1#2.3$)+
2%$#,+
4."&5657&+
8#("&.%+
%&,$%*&%+
9:;<+
=.>&""5)2+
%&.2&)*+
	   119	  
adherent cells, could be ignored. However, trypsinization has been shown to 
reduce cellular glutathione, [201] which may alter cell surface thiol expression, 
as the expression of cell surface thiols is linked to redox status. [202] 
A DTNB assay was performed on samples of Jurkat cells grown at increasing 
cell densities for 24 hours (Figure 5.2). These cell densities were chosen since 
they are typical densities of Jurkat cells in culture. In fact the American Type 
Culture Collection recommends that Jurkat cells should be cultured at cell 
densities between 100,000-1,000,000 cells per mL.  
The results of the DTNB assay show that increasing cell densities per millilitre of 
cell culture medium results in a significant decrease in the number of thiol 
groups expressed. Therefore, further in vitro thiol labeling experiments were 
performed with cells grown at low confluency (approximately 200,000 cells per 
mL of cell culture media). 
 
Figure 5.2: DTNB assay on Jurkat cells suspended at different confluences shows a significant 
decrease in thiol expression with increasing numbers of cells per ml of CCM. 
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5.2. Cell labeling with Iodide-Rhodamine Maleimide (I-RM) 
Jurkat cell membrane thiol labeling was first assessed using rhodamine as a 
fluorescent reporter. Rhodamine has a high quantum yield and good 
photostability, making it a good choice for flow cytometry and fluorescence 
microscopy studies.  
Flow cytometry was used to assess I-RM cell labeling as described in section 
2.14, with Annexin V and DAPI counterstaining for apoptosis and death. One 
million Jurkat cells were labeled in 1 mL PBS at room temperature for 30 
minutes with concentrations of probe in the nanomolar range (Jurkat cells 
express 4 nmol of cell surface thiol groups per 1 x 106 cells [200]), and the 
resulting toxicity was measured (Figure 5.3). The majority of labeled, rhodamine 
positive cells died within the period between cell labeling and flow cytometry 
analysis (2 hours). This toxicity was not reduced using decreasing concentrations 
of probe. A possible reason for this toxicity could be transport of the probe inside 
of the cell and interaction of the rhodamine or maleimide group with intracellular 
contents. Rhodamine is a cationic molecule and is selectively accumulated in the 
mitochondria of cells due to their trans-membrane potential. [203] A toxicity 
study by Nestmann et al. reported that a rhodamine B labeling concentration of 
960 nM for 1 hour resulted in 100% cell death of Chinese hamster ovary cells. 
[204] 
Attempting to reduce the toxicity associated with cell labeling, the cells were 
labeled with 10 nM of probe on ice to arrest active membrane transport and this 
was compared to labeling at 37°C and at room temperature (Figure 5.4). Again, 
all rhodamine stained cells were positive for Annexin V and DAPI, indicating 
cell death. No difference in cell survival was seen between the different labeling 
conditions, revealing that the cell labeling is dependent on molecular charge or 
chemical maleimide-thiol interaction, rather than an active process by the cell. 
Maleimide-thiol interaction is particularly important because many peptides, 
nanoparticles and probes modified to express thiols show enhanced cellular 
uptake. [205] Unfortunately, the mechanisms involved in the cellular uptake of 
molecules interacting with exofacial thiols have not yet been discovered, 
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although the redox status of the thiols seems to be important, with oxidization 
increasing cellular uptake. [206] 
To determine if cell labeling with I-RM was resulting in intracellular 
accumulation of the probe, confocal microscopy images were taken of I-RM 
labeled Jurkat cells counterstained with DAPI (Figure 5.5). The images reveal 
that as well as binding to the cell surface membrane, the probe has entered the 
cells and bound to intracellular organelles. This data confirms the hypothesis that 
internalization of the I-RM probe is resulting in cell death. 
In conclusion, although the I-RM probe labels cells very efficiently, the poor cell 
survival after labeling makes it undesirable for tracking a cell therapy. Its toxicity 
is due to the internalization of the probe, probably through maleimide-thiol 
interactions. Once inside the cell membrane, the toxicity could be explained by 
the reactivity of the rhodamine fluorescent group, since it is negatively charged 
and lipophilic, or the interaction of the maleimide group with intracellular 
glutathione. Therefore, to elucidate whether rhodamine was the main cause of 
toxicity, the tri-functional probe was modified with an alternative fluorophore. 
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Figure 5.3: Representative flow cytometry plots of I-RM cell labeling at different concentrations of 
probe (red), (n=3). Cell labeling increases with concentration, however the survival of the cells after 
labeling is very poor. 
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Figure 5.4: Representative flow cytometry plots of cells labeled with 10nM I-RM on ice, at room 
temperature and at 37°C (n=3). The poor survival of the cells is unchanged by the labeling conditions. 
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Figure 5.5: Confocal microscopy image of Jurkat cells labeled with 10nM I-RM (red), counterstained 
with DAPI (blue) to highlight the cell nucleus of dead cells. The left image is a maximum intensity 
projection through all imaging slices, and the right image is a single slice. All cells are dead or 
undergoing apoptosis with blebbing of the cell membrane. Rhodamine fluorescence can be seen inside 
the cell membrane, indicating internalization of the probe. 
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5.3. Cell labeling with Iodide-Dansyl Triazole Maleimide (I-DM) 
The fluorophore dansyl has a neutral charge, although it is lipophilic. Therefore, 
the tri-functional probe was modified to contain a dansyl fluorescent reporter. 
Cell labeling at nanomolar concentrations did not result in detectable 
fluorescence using flow cytometry, hence cells were labeled at micromolar 
concentrations. 
Flow cytometry was used to assess I-DM cell labeling as described in section 
2.14, with Annexin V and Propidium Iodide (PI) counterstaining for apoptosis 
and death, respectively. Due to spectral overlap with dansyl fluorescence, DAPI 
could not be used to measure cell death in these experiments. The same cell 
labeling protocol was followed, 30 minutes incubation with the probe in PBS. 
Cell labeling was observed in the micromolar concentration range and above 
(Figure 5.6). A labeling concentration of 1mM resulted in increased cell death, 
seen by a shift of the population up the y-axis (PI fluorescence). However, cell 
labeling at probe concentrations between 10-100 μM resulted in a large 
percentage of alive and labeled cells (76-85.8% survival after 2 hours). This 
positive finding enabled further evaluation of the I-DM probe and provided the 
rationale to proceed to labeling experiments using T cells. In subsequent 
experiments, 10 μM I-DM was chosen as the optimum labeling concentration, 
because it was shown to provide approximately 81% labeling and 86% survival 
at 2 hours after labeling. 
As a result of this favourable data, I-DM was used to label T cells, to assess its 
suitability for T cell tracking in vivo. 
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Figure 5.6: Representative flow cytometry plots of I-DM labeling (n=3), two hours post-labeling. Cell 
labeling increases with concentration, shown by the histogram plot moving right along the axis of 
dansyl positive signal. After gating on the dansyl positive population, apoptosis and death plots are 
shown in the right-hand column. 
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5.4. T cell survival after I-DM labeling 
In order to assess the suitability of the probe for long-term tracking of T cells, T 
cells were labeled with 10 μM I-DM, and the survival of the cells at 24 hours 
was assessed using flow cytometry. The results indicate that although T cells can 
be labeled with I-DM with approximately 65% of labeled cells alive at 2 hours, 
unfortunately no cells survive at 24 hours post-labeling (Figure 5.7). 
To assess if the probe was entering the cell cytoplasm instead of being restricted 
to the cell membrane, T cells labeled with 10 μM I-DM were imaged using 
confocal microscopy (Figure 5.8). This clearly showed I-DM inside the cells, 
bound to organelles and within cytoplasm, as well as bound to the cell 
membrane. Therefore, the toxicity of the I-DM is likely to be due to the entry of 
the probe into the cells. 
In an attempt to assess whether the dansyl group or the maleimide binding group 
was responsible for the delayed toxicity at 24 hours, T cells were labeled with 
Alexa Fluor® 488 maleimide. Unfortunately, there is a paucity of data regarding 
the toxicity of Alexa Fluor 488 itself, [207] however, the Alexa Fluor family of 
dyes are advertised as being non-toxic labeling probes. The results show 
markedly inferior cell labeling compared with the I-DM probe, with 24.2% cells 
labeled at 10μM of Alexa Fluor® 488 maleimide, and 85.6% cells labeled at 
10μM I-DM (Figure	  5.9). However, with both labels close to 100% cell labeling 
was achieved with 10mM of probe. Similar to the results achieved with I-DM 
cell labeling, the majority of cells were dead after 24 hours. This result points to 
a possible conclusion that the maleimide group is responsible for the toxicity of 
these probes, rather than any interaction of the dansyl group with the cell. The 
mechanism of death could be interaction of the maleimide group with 
intracellular redox processes, in particular, binding to intracellular glutathione. 
However, toxicity of the dansyl group alone has not be excluded and further 
testing of dansyl toxicity and maleimide toxicity is required. 
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Figure 5.7: T cell survival after labeling with 10µM I-DM, assessed using flow cytometry (n=3). 
 
 
Figure 5.8: Confocal microscopy maximum intensity projection image (x100) of I-DM labeled human 
T cells after 24 hours, showing I-DM probe (green) binding to the cell membrane, as well as to 
intracellular organelles, with probe present in the cytoplasm. 
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Figure	   5.9:	   Representative	   flow	   cytometry	   plots	   of	   cell	   labeling	   with	   Alexa	   Fluor®	   488	  
maleimide	   (n=3),	   2	   hours	   post-­labeling.	   Cell	   labeling	   increases	   with	   probe	   concentration,	  
shown	  by	  the	  movement	  of	  the	  cell	  population	  along	  the	  x-­axis	  in	  the	  left	  column.	  After	  gating	  
on	  the	  labeled	  cells,	  cell	  death	  (DAPI)	  and	  apoptosis	  (Annexin	  V)	  is	  shown	  in	  the	  right	  columns,	  
at	  2	  hours	  and	  24	  hours	  post-­labeling.	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5.5. T cells labeled with 125I-DM can be imaged using SPECT/CT 
Due to the sensitivity of SPECT/CT imaging, a much lower concentration of 
radioactive probe can be used than that required for fluorescence labeling bright 
enough to be detected by flow cytometry (10 μM). Therefore, labeling cells in 
the nanomolar range was explored for SPECT/CT imaging, and in an attempt to 
avoid cell toxicity. 
To assess if the label was retained after labeling, Jurkat cells were labeled using 
the radioactive 125I-DM probe in PBS or cell culture media, and the activities of 
the cell pellets were measured over time (section 2.17). The labeling efficiency 
with 8 MBq of probe incubated with 1 x 106 Jurkat cells was 25.6 ±0.8 % of 
added activity (specific activity of the 125I-DM sample was unknown, I received 
43.0 MBq activity in 1 mL DMSO from Radiochemistry). This is inferior to the 
labeling efficiency of 51.5 % observed using indium-111 tropolone. However, at 
24 hours after labeling with 125I-DM, 64.5 % of the original activity immediately 
after labeling was retained on the cell pellets (Figure 5.10). Leakage of the 
activity from the cells over time was small and therefore favorable for imaging. 
In contrast, only 19.5 % of the original retained activity of indium-111 was on 
the cell pellets at 24 hours, which will result in reduced sensitivity of imaging.  
In an attempt to maximize cell survival after labeling, small activities of 125I-DM 
were tested for cell labeling and imaging. Jurkat cells (1 x 106) were labeled with 
0.6 MBq 125I-DM (n=3), resulting in a labeling efficiency of 38.45 ±3.77% 
(specific activity of the 125I-DM sample was unknown, I received 24.84 MBq 
activity in 963 μL DMSO from Radiochemistry).  Control Jurkat samples were 
labeled with 0.6 MBq of 125I only (n=3), resulting in a labeling efficiency of 
39.43 ±6.77%. 
After labeling these were spun into a cell pellet and imaged using a 
nanoSPECT/CT system (Figure 5.11). Although imaging results were good, cell 
death in the samples was found to be 43.3 ±3.3 %, 5 hours post-labeling (n=3), 
with a control death rate of 5.9 ±1.6 % (n=3). In contrast the retained activity in 
the 125I labeled cells was 0.83 ±0.47% at 5 hours, with a death rate of 8.8 ±2.4% 
(n=3). 
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Figure 5.10: Activity of 125I on 1 x 106 Jurkat cells measured over time after labeling with 2 MBq/8 
MBq 125I-DM in PBS or 8 MBq 125I-DM in cell culture media (CCM), n=3. 
 
Figure 5.11: SPECT/CT image of 1 x 106 Jurkat cells (arrowed) in an eppendorf, labeled with 0.6 
MBq 125I-DM. 
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Figure 5.12: Bar graph of cell death (using trypan blue), after labeling 1 x 106 Jurkat cells with 10µM 
Dansyl chloride dye for 1 hour in PBS, n=3. 
 
Figure 5.13: HPLC analysis of the supernatant after labeling Jurkat cells with 0.6 MBq 125I-DM. 
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In order to assess the toxicity arising from the dansyl component of the I-DM 
probe, T cells were incubated with 10μM Danzyl ethyl azide dye for 30 minutes 
in PBS, as per the cell labeling protocol. In fact, labeling with Dansyl ethyl azide 
dye alone (10 μM) results in significant toxicity of approximately 20% within 2 
hours (Figure 5.12), although after 24 hours the cell death does not increase. 
Therefore, the dansyl fluorophore component is only responsible for a proportion 
of the overall toxicity. 
To further assess the consequences of maleimide binding to the cells, high 
perfomance liquid chromatography (HPLC) was performed on the cell 
supernatant 1 hour after labeling with 125I-DM, and this was compared to 
reference HPLC data of the 125I-DM probe alone, and the 125I-DM probe reacted 
with glutathione. HPLC analysis on the cell supernatant 1 hour after 125I-DM 
labeling revealed approximately 60% abundance of a 125I-DM-glutathione 
complex (Figure 5.13). This implies that once inside the cell, the probe is binding 
intracellular glutathione followed by excretion of the complex from the cell. The 
multidrug resistance-associated protein 1 (MRP1) pump is an ATP-binding 
cassette transporter, which actively translocates glutathione, glucuronate and 
sulfate conjugates across the cell membrane. [208] The MRP1 pump is widely 
expressed in human tissues and is also expressed by Jurkat cells, [209] making it 
the most likely candidate transporter responsible for the active excretion of the 
125I-DM-glutathione complex. Glutathione is the most important and prevalent 
thiol/disulfide redox buffer in the cell, and depletion of glutathione in an 
oxidizing environment leads to apoptosis. [210] Therefore, the high toxicity of 
the probe is probably multifactorial, in part due to the dansyl fluorophore and 
also due to binding of the maleimide group to intracellular glutathione and 
subsequent depletion of intracellular glutathione leading to oxidative stress. 
After much deliberation with my colleagues at UCL Radiochemistry, this probe 
was not carried forward and the project was closed. The novel tri-functional 
probe design did not achieve the objective of dual fluorescence and nuclear 
imaging, as the high concentrations of probe required for good fluorescent 
labeling resulted in cell death. Furthermore, using the probe for radiolabeling, 
even at nanomolar concentrations, still resulted in 43% cell death after 5 hours. 
Therefore, this probe is not a suitable long-term cell-tracking agent, although it 
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could be used to label a small minority of injected cells to image the delivery of 
transfused cells within the first few hours. 
 
5.6. Summary 
This chapter demonstrates: 
• Thiol targeting maleimide probes can be used for cell labeling, however 
the probe enters the cells resulting in significant toxicity. 
• Despite this, retained activity on the labeled cells is very good compared 
with conventional cell labeling techniques. 
Unfortunately, the further development of this probe was halted, as it is not a 
suitable tracking agent for a cell therapy. 
 
5.7. Discussion 
Despite promising cell labeling at nanomolar concentrations, the toxicity of the I-
RM probe was soon discovered and this limited any in vivo applications of this 
probe. One proposed advantage of our tri-functional probe design was to keep 
the iodine-125 restricted to the cell membrane, thus decreasing radiation dose to 
the radiosensitive nucleus. Therefore, internalization of the probe was an 
unwanted consequence of cell labeling. Once inside the cell, rhodamine can 
cause toxicity by interrupting mitochondrial function and binding to DNA. I 
concluded after the I-RM experiments that the toxicity of the I-RM probe could 
be due to the rhodamine reporter; hence, other fluorescent reporters were tested. 
Initial results with the cold I-DM probe looked promising, with 81% cells labeled 
at 10μM and 86% cells alive after 2 hours. However, when the probe was used to 
label T cells and their survival was traced over a prolonged period (24 hours), 
100% of the labeled cells died within that period. On confocal microscopy 
imaging of the labeled cells, intracellular dansyl staining was observed. 
However, despite this result I proceeded to experiments testing cell labeling with 
the 125I-DM probe, since lower probe concentrations could be used with 
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sufficient activity for cell imaging. Unfortunately, despite adequate labeling 
efficiency and activity on the cell pellets, toxicity was still problematic, with cell 
death in the samples found to be 43.3%, 5 hours post-labeling, with a control 
death rate of 5.9%.  
Further work was required to understand the mechanism of cell toxicity and to 
distinguish if the toxicity was primarily due to the fluorescent reporter or the 
maleimide group. Cell labeling with the dansyl ethyl azide fluorescent reporter 
alone also resulted in some cell toxicity, although this was only approximately 
20% cell death. Therefore, the fluorescent group alone cannot account for the 
high toxicity of the I-DM probe.  
Cell labeling with Alexa Fluor 488 maleimide resulted in close to 100% cell 
death after 24 hours. Unfortunately, it is difficult to assess whether toxicity is 
exclusively a result of maleimide labeling, since there is little evidence regarding 
the stability and toxicity of Alexa Fluor 488 itself. However, this result adds 
weight to the above evidence suggesting that binding of the maleimide probe to 
cell membrane thiols results in internalization of the probe and cell death. 
Following 125I-DM labeling, HPLC analysis performed on the cell supernatant 
showed an interesting result, a large amount of a 125I-DM-glutathione complex. 
This indicates that as well as entering the cell and binding to organelles, the 
probe is also binding to intracellular glutathione and then exiting the cell. This 
suggests that the toxicity of the probe could result from disruption of the cell’s 
delicate redox balance. 
Redox homeostasis is essential for many intracellular processes, including gene 
transcription, DNA synthesis and enzyme activation. The cell must also 
counteract the large number of reactive oxygen species that are generated during 
normal biological reactions, such as oxidative phosphorylation in mitochondria. 
As a result, the intracellular redox status is tightly regulated, and the most 
important component of this system is glutathione (existing at intracellular 
concentrations of 0.5-10mM), which can be either oxidized or reduced by 
reactions of its thiol group. [211] Therefore, a large concentration of maleimide 
probe (1μM- 1mM in these experiments) binding to intracellular glutathione 
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would result in an inability to reduce reactive oxygen species, oxidative stress 
and finally, cell death. 
The multi-drug resistance protein-1 pump (MRP1) is a member of the ATP-
binding cassette superfamily of transport proteins, and exports glutathione 
compounds formed during oxidative reactions to maintain cell redox 
homeostasis. [212] Therefore, it is likely that the MRP1 pump is responsible for 
the export of the 125I-DM-glutathione complex, in an attempt to regulate the 
redox environment in the cell after labeling. 
In conclusion, it is likely that the maleimide group of the tri-functional probes 
causes significant toxicity, as well as the fluorescent reporter, which contributes 
to a smaller extent.  Strategies to prevent the probe entering the cell could be 
employed to reduce toxicity, for example, making the probe too large to enter the 
cell easily. However, this is likely to result in a reduced labeling efficiency, so 
these avenues of research were not explored.  
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6. In vivo imaging of a combined T cell and MSC TRAIL 
therapy 
 
The final aim of my project was to combine engineered EBV-TCR T cells and 
MSC TRAIL as a dual cell therapy for lung metastases. This dual cell therapy is 
a novel contribution in the field of cell therapies for cancer. Furthermore, this is 
the first in vivo study using T cells expressing the chimeric EBV-TCR, and to my 
knowledge, the first application of tumour antigen specific T cells to target lung 
metastases. It is also the first use of bioluminescence imaging to track a T cell 
therapy homing to lung metastases. 
Due to the toxicity problems associated with direct labeling with conventional 
cell radiolabels and the tri-functional probes, bioluminescence imaging was used 
instead to track the T cells in vivo. Although this is an indirect labeling method 
that is not currently translatable into clinical imaging, bioluminescence imaging 
offers fast, sensitive, repeatable and highly specific imaging of the transfused 
cells. [213] In addition, fluorescent probes can be used alongside 
bioluminescence imaging to track multiple cell types. 
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6.1. Tumour models in NOD/SCID mice 
NOD/SCID mice have a severe combined immunodeficiency (SCID), on the 
background of a non-obese diabetic (NOD) genotype. The immunodeficiency is 
caused by a lack of functioning B cells and T cells, as well as defective 
macrophages and natural killer cells, and this allows the growth of human cancer 
cells in vivo. [214] 
6.1.1. A subcutaneous tumour model 
Subcutaneous tumours were set up in NOD/SCID mice by injecting 106 MDA-
MB-231 LMP2 cells into the right flank of 6 mice. The resulting tumours 
occurred in all mice within 2 weeks. These were measured regularly, and the 
tumour volume was calculated (Figure 6.1). After sacrifice at day 30, all mice 
had multiple, small lung metastases (Figure 6.2). However, for the purpose of 
testing cell therapies for lung metastases, a shorter, more direct method was 
needed. Accordingly, I set up a tumour model with intravenous injection of 
tumour cells that would result in immediately delivery of cancer cells into the 
lungs. 
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Figure 6.1: Subcutaenous tumour growth after injection of 106 MDA-MB-231 LMP2 cells into the 
right flank (n=6). 
 
 
Figure 6.2: Representative H&E staining of a 3 µm lung section showing multiple small lung 
metastases at day 30 (arrowed). 
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6.1.2. An intravenous delivery lung metastases model 
To set up a direct lung metastases model, I injected 106 MDA-MB-231 LMP2 
into the caudal vein. This resulted in the formation of multiple lung metastases in 
all mice by day 20 (Figure 6.3). 
 
Figure 6.3: Representative H&E staining of a 3 µm section of lung showing multiple small lung 
metastases (see arrows for examples) after tail vein injection of MDA-MB-231 LMP2 tumour cells. 
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6.1.3. DiR imaging biodistribution pilot study 
DiR is a lipophilic, near-infrared fluorescent dye that can be used to label cell 
membranes. Imaging in the near-infrared spectrum significantly reduces 
background fluorescence caused by tissue, and the resulting photons can be 
transmitted through a greater thickness of tissue. [215] DiR fluorescence imaging 
can be used to non-invasively track the fate of labeled stem cells in vivo. [216] 
However, I decided to use DiR imaging to track the fate of injected MDA-MB-
231 cancer cells, in order to simultaneously monitor the tracking ability of 
luciferase expressing EBV-TCR T cells. 
Before using DiR to label and image MDA-MB-231 LMP2 tumour cells, I 
conducted a pilot study looking at the biodistribution of free DiR after tail vein 
injection. Briefly, 1 μL of DiR was suspended in 200 μL PBS and this was 
injected into the tail vein of 3 NOD/SCID mice. These mice underwent serial 
fluorescence imaging on a Xenogen IVIS® Lumina II system with constant 
camera settings (f/stop 2, exposure time 10 s, excitation 745 nm, emission ICG). 
This data can be compared to the DiR signal from injected labeled tumour cells, 
in order to distinguish free DiR from tumour cell membrane bound DiR. This 
would help determine if the cells are intact after injection. After free DiR 
injection, the signal is diffuse throughout the mouse for up to 5 days, with areas 
of high signal located in the lungs and liver (Figure 6.4). After 25 days the signal 
localizes to the liver. It is interesting that there is still strong DiR fluorescent 
signal even after 25 days in the mouse. This suggests that DiR is either 
metabolized or excreted by the liver very slowly. 
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Figure 6.4: Pilot study of free DiR biodistribution. NOD/SCID mice (n=3) received a tail vein injection 
of 1 µL DiR in 200 µL PBS. These were then imaged repeatedly on a Xenogen IVIS® system at the 
same settings. 
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6.2. In vivo effects on lung metastases of a combined cell therapy 
with EBV-TCR T cells and MSC TRAIL 
NOD/SCID mice were first irradiated with 2.5 Gy to eliminate any residual 
immune cells. After 24 hours, all mice had 106 DiR labeled MDA-MB-231 
LMP2 cells injected into the caudal vein. After DiR fluorescence imaging of all 
mice to establish successful delivery of tumour cells, mice were randomized into 
4 groups (Figure 6.5). One week following tumour cell delivery, mice received 
either no cells, 5 x 106 EBV-TCR luciferase T cells, 106 MSC TRAIL, or 5 x 106 
EBV-TCR T cells combined with 106 MSC TRAIL. Mice were imaged 
throughout the experiment to monitor luciferase signal (EBV-TCR T cells) and 
DiR signal (MDA-MB-231 LMP2 cells). At day 14 and 21, mice in the groups 
treated with MSC TRAIL received further doses of 106 MSC TRAIL. 
At day 23 the mice were sacrificed and final Bioluminescence imaging (BLI) and 
Fluorescence imaging (FLI) was performed with the chest cavity open and the 
heart removed. Following imaging, the lungs were insufflated with 4% 
paraformaldehyde (PFA), before removal and storage in PFA for histology. All 
livers were also removed and fixed in PFA, due to the large amount of DiR 
signal present. The spleens were removed in each mouse, and put into RPMI 
media before being mashed, stained for T cell markers and run on the flow 
cytometer. 
Fluorescence imaging after DiR labelled tumour cell injection showed a large 
amount of signal in the liver and lungs, and often also at the injection site in the 
tail (Figure 6.6). There was no diffuse background signal as seen with injection 
of free DiR (Figure 6.4), indicating that these cells were successfully delivered 
intact to the lungs. This is where most of the cells are likely to be trapped, due to 
the pulmonary first pass effect. [217] The presence of signal in the liver is 
puzzling and is similar to that observed with injection of free DiR. This could be 
due to free DiR that was not successfully washed from the cell pellet during the 
preparation of cells, or fragments of dead cells within liver macrophages. 
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Figure 6.5: Experimental outline for the first in vivo experiment 
 
 
Figure 6.6: FLI imaging of group 3 mice after tumour cell injection (day 0). DiR signal can be seen in 
the liver and the lungs, as well as residual signal in the tail after injection. DiR imaging looked similar 
between groups and the signal characteristics did not change over the time-course of the experiment, 
remaining mainly in the liver (green box) and the lungs (red box). DiR signal in the liver is free DiR or 
dead cell fragments, whereas the signal in the lungs is a result of the delivered MDA-MB-231 cells. 
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Serial DiR fluorescence imaging did not reveal any significant changes in signal 
after treatment, or any difference in signal between treatment groups (Figure 
6.7). Fluorescence signal was measured using regions of interest (ROI) drawn 
around the livers and lung in each mouse. 
In contrast, bioluminescence imaging after the delivery of EBV-TCR luciferase 
T cells showed maximum signal in the lungs immediately after injection, and a 
subsequent decrease in signal. Analyzing the data using ROIs drawn over the 
lungs (Figure 6.8) shows that photon radiance (photons per square metre per 
second per steradian) is maximal at injection, followed by decreasing signal over 
time, indicating a lack of in vivo proliferation of the T cells. This trend was seen 
in the T cell only group, and the T cell plus MSC TRAIL group (Figure 6.9). 
Although two mice from the T cell only group died unexpectedly at day 11 
before the end of the experiment, this is unlikely to have effected the average 
bioluminescence signal for the group as the standard errors for each data point 
are very small. Background autoluminescence is not very well understood, but 
research has suggested that it is in part due to the white fur of the mice. [128] 
Autoluminescence is known to be higher in the regions of the thoracic cage and 
liver, which may explain why the lung signal does not entirely reach background 
autoluminescent levels. 
Bioluminescent signal was seen at sacrifice in the lungs of only one mouse in the 
T cell only group. (Figure 6.10) Human T cells are not thought to survive much 
longer than 3 weeks in a NOD/SCID mouse, so this data is in keeping with the 
work of others. [55] 
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Figure 6.7: Average DiR fluorescence photon count in the liver and lungs over time, per group. There 
is no significant difference in the signal between different treatment groups. 
 
Figure 6.8: Average bioluminescence photon count in the lungs of groups 2 and 4 over time. There is a 
slow decrease in signal until 6 days post-injection after which the signal is close to background 
autoluminescence signal levels. 
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Figure 6.9: Bioluminescence images of groups 2 and 4 over time (left to right- day 7 immediately after 
injection of T cells, day 9, day 13, day 16). Signal in the lungs is lost after day 16, indicating death of 
the T cells.  
 
 
Figure 6.10: Bioluminescence images of group 2 (EBV-TCR T cells only) at sacrifice (day 23). 
Bioluminescent signal can only be seen in the lung fields of one mouse. 
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Figure 6.11: A- Example of DiR fluorescence imaging of the mice after sacrifice and removal of the 
chest wall and heart. B- This allowed accurate regions of interest (ROI) to be drawn around the lungs 
and liver for comparison of average DiR photon count between groups. 
 
Fluorescence imaging of the liver and lungs was also completed at sacrifice, after 
the removal of the chest wall and heart for better visualization of the lungs 
(Figure 6.11). After DiR imaging at sacrifice, accurate ROIs were drawn around 
the lungs and liver, allowing comparison of DiR fluorescence signal between 
groups (Figure 6.11-B). This analysis revealed no significant difference in 
average DiR photon count in the liver or lungs between the groups (Figure 6.12). 
However, this may be due to the long half-life of DiR within biological tissue, 
rather than a failure of treatment. 
Lung and liver weights were taken at sacrifice and showed no significant 
difference between the control group and any treatment group (Figure 6.13). 
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Figure 6.12: Average DiR photon count in the livers and lungs of each group after sacrifice and ROI 
analysis. There is no significant difference in photon counts between groups. 
 
Figure 6.13: Average lung and liver weights in each group at sacrifice. There is no significant 
difference in lung or liver weight between the control group and any treatment group. 
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At sacrifice the spleens of all the mice were taken out, put into RPMI media, 
mashed and then stained with the appropriate antibodies for human T cells. The 
samples were run on a BD™ LSR II flow cytometer, using FACSDiva™ 
software, followed by analysis using FlowJo software. T cells and MSCs could 
be gated out separately on forward scatter and side scatter plots using their 
relative difference in sizes. Cells in the T cell size range were examined for 
human CD4 and CD8 (Figure 6.14), as well as for the murine cβ chain (data not 
shown). In all cases, there was no positive staining for these markers, 
demonstrating that there were no human EBV-TCR T cells in the spleen of any 
of the treatment groups. This result corresponds to the findings on 
bioluminescence imaging, where no signal was seen in the spleens, and signal 
was seen only in the lungs of one mouse in the T cell only treatment group. 
Cells in the MSC size range were examined for DiI fluorescence. This was 
negative in all cases (Figure 6.15), indicating that there were no MSC TRAIL in 
the spleens of any treated mouse. This result was expected, as work done by 
others suggests that MSC injected intravenously typically become trapped in the 
capillary bed of the lungs. [218, 219] Indeed, it was this effect that I hoped to 
exploit to treat lung metastases in this tumour model. 
Unfortunately, in this experiment 2 mice died in groups A, B and C, while all 5 
mice in group D survived to the end of the experiment. This could be a result of 
the irradiation performed at the beginning of the experiment, uncontrolled 
tumour growth, or cell therapy delivery. However, two mice in the control group 
(group A) died, so it is unlikely that the cell therapies were a cause of death. 
Histology performed on the mice in these groups will confirm if uncontrolled 
tumour growth is a cause of death in groups A-C. 
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Figure 6.14: Representative flow cytometry plots of cells from the spleens of mice in each 
experimental group. Antibody staining to human CD4 and CD8 was negative in each case, indicating 
that there were no human EBV-TCR T cells in the spleens at the time of sacrifice. 
 
Figure 6.15: Representative flow cytometry plots of cells from the spleens of mice in each 
experimental group. All the cells were negative for DiI fluorescence in each mouse that received MSC 
TRAIL, indicating that there was also no MSC TRAIL in the spleen at the time of sacrifice. 
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The last analysis performed on this experiment used histology to look for 
differences between different treatment groups. After sacrifice the lungs and 
livers were processed and H&E staining was performed on 3 μm sections of 
tissue. Lung metastases were easily visualized by their increased haematoxylin 
staining compared to normal lung parenchyma (Figure 6.16). 
In contrast, despite the DiR signal seen in the livers of the mice, there were no 
liver metastases in any sections of any mice (Figure 6.17). Hence the DiR signal 
seen may correspond to DiR that is trapped in liver macrophages after the 
breakdown of dead tumour cells. 
In order to assess the effects of cell treatment, an analysis of the average 
diameter of lung metastases per group was performed. Using Leica SlidePath 2.0 
software, the longest diameter of each lung metastasis was measured for each 
lung lobe in every mouse (Figure 6.18). The results were collated by group and a 
student’s t test was performed to look for significant differences between groups. 
A significant difference (p<0.01) was seen between the control group and the 
EBV-TCR T cells treatment group, and the combined EBV-TCR T cell and MSC 
TRAIL group (Figure 6.19). This is an important positive result that indicates 
EBV-TCR T cells are highly active against LMP2-expressing MDA-MB-231 
tumours in vivo, and that corroborates the in vitro findings from chromium-51 
and co-culture experiments. 
This data reveals that tumour burden is unlikely to be the cause of premature 
death before day 23 in groups A-C. Therefore, it is possible that the irradiation of 
the mice with 2.5 Gy before the experiment started was the cause of death, even 
though this was delayed until day 11.  
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Figure 6.16: Representative H&E lung lobe sections from each treatment group, A- control group, B- 
EBV-TCR T cells only, C- MSC TRAIL only, D- EBV-TCR T cells and MSC TRAIL. 
 
Figure 6.17: Representative H&E section of liver, showing no metastases and a homogenous liver 
parenchyma. 
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Figure 6.18: Representative H&E section of a lung lobe showing how the diameter of a lung 
metastasis was measured using the Leica SlidePath programme. 
 
Figure 6.19: Bar chart showing the average diameter of lung metastases in each treatment group. 
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To further assess the difference in size of lung metastases between treatment 
groups I used a MATLAB® tool developed by UCL’s Centre for Medical Image 
Computing, which automatically segmented the lung metastases and counted the 
area of pixels within each metastasis and the total area of the lung lobe. The 
percentage area of lung taken up by metastases could then be calculated for each 
lobe of the lung in every mouse (Figure 6.20). This analysis revealed significant 
differences in the area of lung metastases between the control group and the 
treated groups (Student’s t test, p<0.05). This automated analysis provides more 
robust evidence of a significant reduction in tumour burden from cell therapy 
treatment with MSC TRAIL and/or EBV-TCR T cells.  
It is important to note that this analysis is more robust that the method used by 
Loebinger et al. in their paper demonstrating a significant reduction of lung 
metastases with MSC TRAIL treatment, which relied on lung weights and an 
operator dependent use of Spot Advanced Imaging Software (Diagnostic 
Instruments Inc., Sterling Heights, MI) to measure the difference lung tumour 
burden. This may explain their confusing observation of a significant decrease in 
the number of lung metastases per unit area with inactivated TRAIL MSC 
treatment, which appears to contradict their in vitro co-culture experiments 
where inactivated MSC TRAIL seems to produce close to background levels of 
cell death and apoptosis. 
Despite these experimental differences, the work in this thesis contributes to the 
growing body of evidence that MSC TRAIL treatment is effective against a 
variety of tumour lines including cervix adenocarcinoma and breast 
adenocarcinoma, [104], rhabdomysosarcoma, [220] and multiple mesothelioma 
cell lines. [221] 
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Figure 6.20: Bar chart showing the average percentage area of lung metastases in each group. There 
is a significant difference from the control group in each treatment group (p<0.05). 
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Finally, to prove that MSC TRAIL home to and incorporate within lung 
metastases, the immunostained sections were imaged using a standard upright 
Zeiss fluorescent microscope and a Leica TCS SPE confocal microscope. MSC 
TRAIL could be identified by their DiI fluorescence (excitation 555 nm), while 
EBV-TCR T cells were stained with a primary anti-Luciferase antibody and an 
Alexa Fluor® 647 secondary antibody (excitation 647 nm). Cell nuclei were 
counterstained with DAPI (excitation 350 nm) to show the underlying structure 
of the lung and the location of the cells. As expected from the previous 
bioluminescence imaging data, anti-luciferase staining was negative for EBV-
TCR T cells present in the lung metastases. However, MSC TRAIL could be 
seen in multiple lung metastases in the MSC TRAIL treatment groups (Figure 
6.21, Figure 6.22). 
 
Figure 6.21: Immunofluorescence image of DiI labelled MSC TRAIL within a small lung metastasis. 
	   158	  
 
Figure 6.22: A- H&E stained section of a lung metastasis (x20), B- confocal image of the same 
metastasis (x20) showing DiI labelled MSC TRAIL within the metastasis. 
 
 
Figure 6.23: Confocal image (x20) of DiI labelled MSC TRAIL exiting a blood vessel and homing 
towards lung metastases. 
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DiI labelled MSC TRAIL were also seen extravasating from blood vessels within 
the lungs, and homing towards lung metastases (Figure 6.23). This provides 
further strong evidence that intravenously delivered MSC TRAIL are capable of 
trafficking towards lung metastases in this in vivo model. 
 
6.3. Summary 
In this chapter I have demonstrated that: 
• Intravenously injected MDA-MB-231 LMP2 cells will form multiple 
small lung metastases within 20 days. 
• Fluorescence imaging of DiR labelled tumour cells is not an accurate 
method to track tumour distribution or size. 
• Injected EBV-TCR luciferase T cells are trapped in the lungs 
immediately after intravenous injection and still persist in the lungs 2 
days post-injection where they provide anti-tumour effects. 
• After day 6, bioluminescence signal returns close to baseline, indicating 
the T cells do not persist in vivo. This is confirmed by the absence of 
luciferase positive cells in immunostained lung sections. 
• MSC TRAIL can be seen engrafted within lung metastases in 
immunostained lung sections. 
• There is a significant difference in the diameter of lung metastases 
between the control group and both groups treated with EBV-TCR T 
cells. 
• There is a significant difference in the percentage area of lung taken up 
by metastases between the control group and each treatment group. 
• Similar to the in vitro data, there is no benefit to combining EBV-TCR T 
cells with MSC TRAIL as a dual cell therapy, thus disproving my 
hypothesis. 
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6.4. Discussion 
Lung cancer is the second most common cancer in the UK, and the majority of 
these patients present at later stages of the disease. Unfortunately these patients 
have very poor survival rates, which have not shown much improvement since 
the 1970s. This is undoubtedly due to late presentation of the disease, as well as a 
paucity of targeted chemotherapy agents. Cell therapies that can home to lung 
tumours have the potential to improve survival compared with conventional anti-
cancer treatments. 
Adoptive transfer of tumour antigen specific T cells is a promising cancer 
therapy that redirects the specificity of TCRs on cytotoxic T cells so they target 
malignant cells. This approach has never been tested in models of lung cancer. 
Separately, MSC TRAIL have been shown to eliminate metastatic lung cancer in 
human xenograft models in NOD/SCID mice. 
In this chapter I have demonstrated that both EBV-TCR T cells and MSC TRAIL 
are highly effective in a murine model of lung metastases. Significant differences 
were found between the size of lung metastases in the control group and mice 
that received either cell therapy, and the area of lung taken up by tumour 
between the control group and the groups that received a cell therapy. Tumour 
sections from the group that received MSC TRAIL show DiI labeled MSC 
TRAIL homing to and incorporating within lung metastases. For the group that 
received T cells, luciferase expressing EBV-TCR T cells could be seen in the 
lung fields using bioluminescence imaging for 6 days after injection, after which 
the signal returned close to background levels. Consequently, no anti-luciferase 
antibody staining was noted in lung sections, indicating that no luciferase 
expressing cells were present.  
This is the first time EBV-TCR T cells have been used in an in vivo cancer 
model. It is also, to my knowledge, the first time T cells with high affinity TCRs 
for tumour associated antigen have been used to target lung cancer. Further 
experiments could examine the protocol for adoptive transfer of T cells to 
maximize tumour destruction in vivo. Several doses of T cells may improve the 
response to treatment, and this is the protocol used in several clinical trials. [195-
197] 
	   161	  
However, when EBV-TCR T cells and MSC TRAIL are combined as a dual cell 
therapy there is no benefit compared with a single cell therapy. Although this 
was also noted in in vitro experiments, this result was unexpected for the in vivo 
model, where cytokines produced by T cells could aid the homing and 
engraftment of MSCs.  
Bartholomew et al. first described the immunomodulatory properties of MSCs in 
2002, [222] when they discovered that MSCs cultured with unstimulated 
lymphocytes resulted in a 50% reduction in lymphocyte proliferation, and 
subsequently that administration of MSCs resulted in prolonged skin graft 
survival in baboons.  
MSCs are now known to modulate the functions of cells of both the innate and 
adaptive immune system in vitro. However, the exact nature and mechanisms of 
this modulation still remain unclear with some in vitro studies claiming that 
MSC-T cell interaction is required, [108] and others pointing to soluble factors 
such as TGF-β and hepatocyte growth factor, [107] metabolites of tryptophan, 
[110] or IL-2 and IL-10, [223] all of which are now thought to suppress T cells.  
Another avenue of research is the action of MSCs on regulatory T cells (Treg) as 
a mechanism of immunosuppression, particularly since MSCs have been shown 
to recruit, modulate and maintain Treg function in vitro. Naturally occurring 
Treg cells are characterized by their expression of CD4, CD25 and Foxp3, and 
inducible Treg cells can be generated from CD4+ T cells in co-cultures of MSCs 
and PBMCs with allogeneic stimulus. [224] 
Interestingly, Prevosto et al. have hypothesized that two different mechanisms 
could be responsible for MSC-induced immunomodulation, dependant on the 
cell ratio. They propose that at high ratios, soluble factors secreted by MSCs are 
predominantly responsible, whereas at low cell ratios this is dependent on the 
generation of Treg cells by interaction with MSCs. [225] This hypothesis leads 
from their observation that in co-culture experiments, very low ratios of FACS 
sorted Treg cells (1:2,000) are able to suppress lymphocyte proliferation. 
Furthermore, the generation and action of these cells was not inhibited by the 
addition of soluble factor blocking antibodies to IL-10, TGF-β or prostaglandin 
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E2 into the culture media, suggesting an independent mechanism of action from 
soluble factors secreted by MSCs. 
In co-culture experiments with MSCs and different T cell populations, Di Ianni 
et al. show that inducible Tregs are mainly recruited and upregulated from 
peripheral naïve Treg cells. [226] This group has also recently confirmed that 
Notch1 signaling is essential for MSC-induction of Tregs, by showing that MSCs 
predominantly express the Notch1 ligand Jagged1, and after co-culture with 
CD4+ T cells there was significant over-expression of Notch1 intracellular 
domain and its transmembrane/cytoplasmic portion in inducible Treg cells. [227] 
This effect was specific to Treg cells and not observed in other subtypes of T 
cells. 
In addition to their other immunomodulatory effects, MSCs are now also known 
to suppress T helper 17 (Th17) cells, which are characterized by their secretion 
of IL-17A, and are highly immunogenic, linked to autoimmune and 
inflammatory diseases. This suppression appears to be mediated by prostaglandin 
E2 [228] and results in the inhibition of cytokine secretion by fully differentiated 
Th17 cells, and inhibition of differentiation of naïve T cells into Th17 cells. 
[229]  
However, there is also evidence to suggest MSC-mediated immunomodulation is 
ineffective for activated cytotoxic T cells. Karlsson et al. have shown that MSCs 
are unable to affect the proliferation or function of activated established 
cytotoxic EBV T cells in vitro, [230] although they did suppress proliferation of 
naïve and memory T cells. Rasmusson et al. also showed MSC were unable to 
affect the cytotoxic function of activated CD8+ T cells. [231] This topic remains 
controversial, but it is possible that using activated T cells in my cell therapy 
model avoids MSC immunomodulation, particularly since EBV-TCR T cells 
were used after 3 rounds of restimulation, when cytotoxic CD8+ T cells were 
predominant. 
It is important to note that the immunosuppressive role of MSCs is still unproven 
in large, randomized, controlled clinical trails. Despite some early success in a 
phase II clinical trial involving 55 patients with steroid-resistant, acute GVHD, 
where 30 patients had a complete response, and 9 showed improvement, [105] in 
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two large, multi-centre, phase III clinical trials there was no significant 
difference between MSC therapy and placebo. [106] Furthermore, donor MSCs 
have not been identified in the bone marrow aspirates of any patients weeks after 
MSC transfusion, although they have been identified in other areas of 
inflammation days after transfusion, suggesting successful cell delivery and 
homing, but no long-term MSC engraftment. Therefore, current evidence 
suggests that MSCs do not cause significant immunosuppressive effects in vivo. 
In a recent attempt to overcome these problems, Kimbrel et al. have isolated a 
precursor MSC cell-type from human embryonic stem cells. [232]These cells 
were immunosuppressive in two mouse models of immune disease, lupus and 
autoimmune uveitis, as well as suppressing T cell proliferation in vitro and 
stimulating regulatory T cells. It is possible that these precursor cells may 
eventually prove more potent than mesenchymal stem cells, and their further 
work will assess the mechanism of immunosuppression and the use of these cells 
in other autoimmune disease models. 
In the context of this work, MSC TRAIL could possibly cause 
immunosuppression due to the secretion of soluble factors such as TGF-β or IL-
2. Cell ratios of MSC:T cell of between 1:1 to 1:10 have been found to produce 
this effect in vitro [225] and this ratio is probably achieved in vivo with the initial 
injection of 6x106 EBV TCR T cells and 1x106 MSC TRAIL. This may explain 
the lack of a significant benefit to combined cell therapy, since although the 
MSC TRAIL would suppress T cell function they would still be capable of 
triggering TRAIL-mediated tumour cell apoptosis, leading to no overall benefit 
to a dual-cell therapy, but a similar benefit to MSC TRAIL alone. 
It is also possible that the lack of benefit to a combined therapy could be due to 
the generation of inducible Treg cells by cell contact-dependent action of MSC 
TRAIL on the EBV-TCR T cells. There is strong evidence to suggest that this 
effect occurs in vitro, and in this cancer model with tail vein delivery of the 
mixed EBV-TCR T cell and MSC TRAIL it is likely that the cells have come 
into close contact during the experiment, either in the eppendorf prior to cell 
injection, or in vivo in the lung parenchyma where they are delivered due to the 
first pass effect. This effect could also explain the lack of benefit of a dual cell 
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therapy as again the MSC TRAIL can continue to cause TRAIL-mediated 
tumour apoptosis, whilst the EBV-TCR T cells would have been rendered 
anergic. 
Lastly it is important to note that the experiment was carried out with only a 
small number of mice per group (n=5). Perhaps with a larger cohort of animals, a 
significant difference could be demonstrated between the single cell and dual cell 
therapies. 
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7. Discussion 
 
7.1. Overview 
Lung cancer is the second most common cancer in the UK, and the majority of 
patients present at advanced stages of the disease. This late diagnosis has lead to 
very low 5-year survival rates of 7.8% for males and 9.3% for females. [1] 
Chemotherapy, radiotherapy and surgery are currently the most effective and 
widely used treatments for lung cancer, and are usually combined for maximum 
anti-tumour effect. However, chemotherapy and radiotherapy both result in 
unpleasant side effects such as tiredness, nausea and vomiting, hair loss, 
immunosuppression and in some cases severe infections leading to death. This is 
a result of the poor selectivity of radiotherapy and chemotherapy, which often 
results in the death of rapidly dividing healthy cells as well as cancerous cells, 
and causes bone marrow suppression. 
The use of a cell therapy to specifically target cancer cells would revolutionize 
cancer treatment, as well as dramatically reducing the side effects associated 
with cancer treatment. Both adoptive T cell immunotherapy, which harnesses the 
potential of T cells to specifically kill cancer cells, and MSC TRAIL, which uses 
a death ligand to target TRAIL receptors expressed by cancer cells, have resulted 
in promising anti-cancer effects in vitro and in vivo. Both cell types have been 
shown to home to tumour sites within the body, and specifically kill cancer cells. 
This thesis has combined these two separate fields of research into a dual 
pronged anti-cancer therapy, using both adoptive T cell immunotherapy and 
MSC TRAIL. 
In addition to this dual cell therapy approach, my project has explored 
conventional and novel cell radiolabeling probes for imaging the cell therapies, 
eventually selecting bioluminescence imaging to track the engineered T cells 
homing to tumours. This part of the project aimed to answer questions about the 
location and persistence of transferred cells in vivo. 
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7.2. Engineering EBV-TCR T cells and their use in vitro 
Adoptive transfer of tumour antigen specific cytotoxic T cells is a promising 
anti-cancer therapy that redirects the host’s immune system against cancer cells. 
Modified TCRs with a high specificity for a tumour antigen of interest can be 
inserted into T cells using a retrovirus. These genetically engineered T cells can 
then be transfused into the patient. 
The Epstein-Barr virus is ubiquitous, with established latency in 90% of adults, 
and is associated with certain malignancies, such as Hodgkin’s lymphoma. The 
latent membrane protein 2 is expressed by some EBV infected cells and 
promotes a malignant phenotype, with many EBV-related cancers, for example 
nasopharyngeal carcinoma, expressing the LMP2 antigen. LMP2 is poorly 
immunogenic, eliciting only weak T cell responses, so a molecular biology 
approach has been used to generate TCRs with high specificity for adoptive 
immunotherapy. 
In this thesis, I have used an engineered chimeric TCR that targets the EBV-
associated LMP2 antigen in tumour cells. A retroviral vector was used to 
incorporate the EBV-TCR and luciferase into human donor PBMCs. T cells 
could be successfully and reproducibly transduced, as shown by the expression 
of a murine cβ chain and binding of the EBV-TCR to CLG peptide, as well as 
the production of light after administering D-luciferin, which could be imaged in 
an IVIS Lumina system. Transduced EBV-TCR T cells could produce cytokines 
and specifically lyse tumour cells expressing the LMP2 antigen after peptide 
activation.  
Previously, LMP2 antigen specific T cells have failed to produce reliable 
clearance of tumour burden in clinical trials, [233, 234] possibly due to the 
immunosuppressive tumour environment, poor T cell survival in vivo, or the 
weak specificity of endogenous LMP2 targeting cytotoxic T cells. Therefore, a 
new approach was required, using an engineered TCR with a high affinity for 
LMP2. Using the chimeric EBV-TCR I have shown 60-100% death of peptide-
coated target cells at T cell to target cell ratios of 0.75:1 and above. This is 
similar to the target cell cytotoxicity demonstrated in the original paper by Hart 
et al. describing the chimeric EBV-TCR, which shows target cell lysis of 
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between 30-90% at similar ratios. [64] A minor difference in my results is that 
the EBV-TCR T cells in my experiment are more functionally active at lower T 
cell to target cell ratios, for example at a ratio of 0.75:1 my results show 60% cell 
lysis, whereas at a ratio of 0.625:1 Hart et al. show target cell lysis of just 30%. 
This discrepancy can be accounted for by the observation that Hart et al. did not 
use peptide stimulation to increase the percentage of EBV-TCR positive cells 
prior to the chromium-51 cytotoxicity assay, they performed assays using 39% 
EBV-TCR positive T cells, whereas I used peptide stimulation to increase the 
population of EBV-TCR positive cells to 50% or greater before performing in 
vitro assays. 
It may also be possible to increase the therapeutic effect of EBV-TCR T cells by 
combining them with another targeted anti-cancer therapy. This hypothesis was 
tested in this work by using a dual cell therapy of EBV-TCR T cells and MSC 
TRAIL in a murine lung metastasis model. 
Mesenchymal stem cells are characterized by their ability to self-renew and to 
differentiate into osteoblasts, chondrocytes and adipocytes. [235] They can be 
easily acquired with a bone marrow biopsy and can be isolated from other cells 
by their ability to adhere onto tissue culture plastic. MSCs are immunoprivileged 
and exhibit a natural tropism towards tumours and metastases, which can be 
exploited to deliver anti-cancer therapies. MSCs expressing TRAIL can kill a 
variety of tumour cells, both in vitro and in vivo. [104] 
Co-culture cytotoxicity assays using MSC TRAIL show apoptosis of 50% and 
death of 12% at a 1:1 MSC TRAIL to tumour cell ratio. This is superior to the 
death rate seen by Loebinger et al. in MDA-MB-231 cells, of 15.4% death after 
co-culture with MSC TRAIL. [104] However, in this study TRAIL expression by 
MSCs was inducible with doxycycline treatment, and 82% of MSCs were 
successfully transduced. The MSC TRAIL used in these experiments 
constitutively expressed TRAIL and were FACS sorted for 100% TRAIL 
expression. This may account for the differences in tumour cell death. 
When MSC TRAIL were used in combination with EBV-TCR T cells, up to 95% 
of tumour cells were dead or apoptotic. However, tumour cell death was not 
increased by the dual EBV-TCR T cell and MSC TRAIL treatment, compared 
	   168	  
with EBV-TCR T cells alone. This could be a failure of the in vitro assay to 
accurately stimulate the in vivo environment, or a direct result of competition 
between the two cell types to come into contact with tumour cells, although cell 
densities were kept deliberately low in an attempt to avoid physical competition. 
In combined co-culture experiments, at the maximum ratio (1:1) of effector cells 
to cancer cells, there was a total of 1.5 x 105 cells per well in a 6-well plate, well 
below the recommended seeding density of 3 x 105 cells per well. 
Another possibility is that the MSC TRAIL cause immunosuppressive effects 
that reduce the function of EBV-TCR T cells. Prevosto et al. hypothesize that 
MSCs can cause immunosuppression by two mechanisms dependent on MSC, T 
cell ratios. They propose that at low MSC to T cell ratios, immunosuppression is 
mediated by the generation of inducible Treg cells, and at high ratios of 1:10 and 
above, it is a result of the secretion of soluble factors known to suppress T cells, 
such as hepatocyte growth factor. [225] This theory is attractive since it neatly 
ties together observations by many different labs that propose various soluble 
factors, enzymes or the induction of regulatory T cells to explain the inhibition of 
T cell function. 
Di Nicola et al. show that transforming growth factor β1 and hepatocyte growth 
factor mediate the suppression of T cell proliferation by using neutralizing 
monoclonal antibodies to block their suppressive effect. [107] Transwell 
experiments were used to prove that this effect was not dependant on cell 
contact, but on soluble factors. Following this work, Meisel et al. published data 
showing that IFN-γ mediated IDO production in MSCs reduced tryptophan 
concentration in culture media and suppressed T cell allogeneic responses, as 
well as proliferation. [110] Either of these pathways could be responsible for the 
lack of a significant benefit to combined MSC TRAIL and EBV-TCR T cells in 
co-culture experiments.  
Cell-contact dependent inhibition may also be responsible for a lack of benefit in 
combined cell therapy. MSC TRAIL and EBV-TCR T cells were mixed in an 
eppendorf and kept on ice for storage down to the Biological Sciences Unit, 
where they were then injected. It is also likely that these cells came into contact 
in vivo after injection, as they would have been trapped in the lung capillary bed 
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through the first pass effect. Soon after the work on soluble factors from MSCs 
inhibiting T cell proliferation and activation, Krampera et al. demonstrated that 
MSCs reduce the response of naïve and memory T cells to their cognate antigen 
by a cell contact dependent effect. [108] Other papers followed that also showed 
a cell contact dependent inhibition. [236] 
Either the cell-contact dependent mechanism of inhibition, the secretion of 
soluble factors or perhaps both of these mechanisms may be responsible for the 
failure of a dual cell therapy to provide a significant increase in tumour cell 
death. These results are therefore in keeping with the work of others, which in 
general shows loss of T cell activity against their cognate antigen after exposure 
to MSCs or their supernatant. 
Recent evidence suggests that MSCs can either suppress or promote immune 
responses depending on their environment. [237] It is likely that the in vivo 
environment differs in many significant respects to the in vitro testing of a dual 
cell therapy using co-cultures and flow cytometry analysis. Cancer cells adherent 
to tissue culture plastic represent a very different environment to a 3-dimensional 
lung tumour, with cancer cells packed tightly together and consequently difficult 
to access. Secondly, in the lung metastases model, cells must first home to the 
metastases before they can exert their effects, hence, cells are likely to arrive in 
significantly less numbers relative to cancer cells than the ratios used for co-
culture experiments. It is possible that in vitro co-culture experiments 
significantly overestimate the true in vivo cancer cell death with these cell 
therapies. In this case, it may be easier to elucidate differences in cancer cell 
death in vivo between a single cell therapy with EBV-TCR T cells and a dual cell 
therapy combining them with MSC TRAIL. 
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7.3. Conventional cell radiolabeling methods  
Indium-111 has been used since 1976 [148] to radiolabel leucocytes for clinical 
applications, such as imaging infection, fever of unknown origin and 
osteomyelitis. In the past 10 years indium-111 labeling has also been applied to 
tracking mesenchymal stem cells, with in vitro testing of cell viability revealing 
no effect on proliferation or differentiation at 30 Bq/cell [188], and in vivo 
imaging after intra-osseous delivery of labeled MSCs in a rat model showing 
detection of 3 x 105 cells. [156] In my pilot study I labeled 5 x 106 MSCs at 1 
Bq/cell, and was able to confirm MSC retention in the lungs shortly after 
intravenous delivery using a nanoSPECT/CT system. 
However, despite the availability and ease of use of indium-111, its main 
disadvantage is the high radiation dose of 3.5 mGy/decay, given to cells over its 
67-hour half-life. [151] This is especially problematic for imaging T cells, which 
are more radiosensitive, with several studies recommending extremely low 
radiolabeling activities to conserve cell viability and homing. For example, Botti 
et al. recommend 0.04 Bq/cell, [193] and Kelson et al. use 0.15 Bq/cell and show 
97-100% viability. [238] In a clinical protocol published by the European Journal 
of Nuclear Medicine & Molecular Imaging, 0.1 Bq/cell is recommended for 
leucocyte labeling, however no mention of viability is made. [178] 
In my pilot study using Indium-111 to label EBV-TCR T cells at an activity of 
1.67 Bq/cell, almost 100% of the administered T cells were dead after 24 hours. 
While decreasing the activity to 0.04 Bq/cell would have conserved lymphocyte 
viability, this very low total activity would have necessitated extremely long scan 
times to acquire a decent image using the SPECT/CT system. This would have 
been time-consuming and impractical for cell tracking, which is a dynamic 
process. Scan times also had to be kept less than three hours to conform to the 
project license. With such low initial activity, long-term tracking would be 
virtually impossible. Therefore, I searched for another method of direct 
radiolabeling that could minimize toxicity to the cell, allowing higher activities 
to be used in cell tracking experiments. 
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7.4. A novel tri-functional probe for T cell radiolabeling 
In chapter 5, I explored the use of a tri-functional probe targeting cell membrane 
thiols. This probe had a fluorescent reporter, an iodine-125 reporter and a 
maleimide group for cell membrane thiol conjugation. Lymphocytes have been 
shown to express a large number of cell surface thiols, with thiol binding 
saturation occurring at 5 μM of maleimide probe concentration, [167] hence thiol 
labeling seemed like a good strategy. The purpose of using thiol labeling was to 
keep the iodine-125 reporter away from the radiosensitive cell nucleus by 
binding it to the cell surface membrane instead, unlike conventional cell 
radiolabeling techniques where the radiolabel diffuses inside the cell cytoplasm.  
Two probes with different fluorescent reporters were tested, but both were 
extremely cytotoxic and were found to bind intracellular structures, as well as the 
cell surface membrane, using confocal microscopy. However, the radiolabeling 
characteristics were extremely good, with approximately 65% of the labeled 
activity on the cells after 24 hours. This is dramatically improved compared to 
the retention of conventional radiolabels. 
Cell labeling experiments performed with an Alexa Fluor maleimide probe also 
showed close to 100% cell death after 24 hours. This experiment demonstrated 
that the maleimide group was implicated in the toxicity of the tri-functional 
probe. To assess this further, HPLC analysis was performed on the cell 
supernatant after labeling and this showed an interesting result, a large amount of 
a 125I-DM-glutathione complex. This indicates that as well as entering the cell 
and binding to organelles, the probe is also binding to intracellular glutathione 
and then exiting the cell.  
Glutathione plays a central role in cell redox homeostasis by acting as a thiol-
disulphide redox buffer. [210] Redox homeostasis is essential for many 
intracellular processes, including gene transcription, DNA synthesis and enzyme 
activation. The cell must also counteract the large number of reactive oxygen 
species that are generated during normal biological reactions, such as oxidative 
phosphorylation in mitochondria. As a result, the intracellular redox status is 
tightly regulated, and the most important component of this system is glutathione 
which can be either oxidized or reduced by reactions of its thiol group. [211] The 
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average concentration of glutathione in the cytosol is 1-11 mM, and glutathione-
disulphide, its oxidized form, is excreted from cells as a mechanism of protection 
from oxidative stress. [239] Therefore, binding of the maleimide probe to 
glutathione and a large efflux of 125I-DM-glutathione from the cell could rapidly 
produce cell apoptosis and death by interfering with the cell’s redox control. 
The multi-drug resistance protein-1 pump (MRP1) is a member of the ATP-
binding cassette superfamily of transport proteins, and exports glutathione 
compounds formed during oxidative reactions to maintain cell redox 
homeostasis. [212] Therefore, it is likely that the MRP1 pump is responsible for 
the export of the 125I-DM-glutathione complex, in an attempt to regulate the 
redox environment in the cell after labeling. This hypothesis could be tested by 
inhibiting MRP1 function using verapamil added to cell culture media and 
repeating the HPLC analysis on the supernatant of 125I-DM labeled cells. 
Redox homeostasis is especially important for T cells, because their function can 
be influenced by changes in their redox status. [240] The reverse is also true, 
since during T cell activation there is an increase in intracellular reactive oxygen 
species, with a corresponding increase in the transcription of anti-oxidant 
molecules and enzymes. [241] Gringhuis et al. demonstrated that reduced 
intracellular glutathione in T cells resulted in impairment of TCR function and T 
cell hyporesponsiveness. [242] Hence, labeling T cells with this probe would 
impair their effector function, as well as their viability. Therefore, the tri-
functional probe is not a good choice for direct labeling of a T cell therapy.  
It is interesting to note that the paper by Digilio et al. describing labeling of cell 
surface thiols by gadolinium complexes, shows 90% viability immediately after 
labeling, however, longer-term viability measurements were not reported. [169] 
The authors also describe internalization of their probe resulting in good 
labeling. This work has not been translated into preclinical models, so it is 
possible that these complexes also caused significant cell toxicity that was not 
reported in the paper. 
Another paper by Amartey et al. investigating radiolabeled maleimide 
derivatives for cell labeling also demonstrated good in vitro labeling but failed to 
assess cell viability after a final time-point of 180 minutes, when cell viability 
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was 95% or greater. [171] These cells were injected into a nude mouse to assess 
the initial biodistribution of labeled cells. Similar to my data showing cells 
trapped in the lungs after 1 hour and then predominantly in the liver at 24 hours 
indicating cell death, the authors state that at 1 hour the labeled cells were 
predominantly in the lungs and then in the liver after 24 hours. They argue that 
this distribution could indicate that the labeled cells were still viable. However, 
this may not be accurate since my data showed that luciferase expressing T cells 
trapped in the liver at 24 hours post-injection were not viable on 
bioluminescence imaging. The authors conclude that further viability testing is 
needed to assess this labeling strategy for in vivo applications. There have been 
no further publications from this group applying these iodinated maleimide 
derivatives in preclinical models, suggesting that after further evaluation of cell 
viability these probes were discovered to be unsuitable for cell tracking. 
Therefore, the work presented in chapter 5 complements the work of others since 
I show good cell labeling of cell surface thiol groups at similar or lower 
concentrations of tri-functional probe to the agents they developed. The high 
toxicity I observe at 24 hours is not seen in other authors’s work because they do 
not track cell survival beyond 3 hours. However, the biodistribution data from 
Amartey et al. suggests that cell viability is problematic with the radiolabeled 
maleimide derivatives because at 24 hours a high proportion of radiolabel resides 
in the liver. 
Following these results, the development of the tri-functional probe was halted 
because modifications proposed to reduce to cell toxicity would also reduce the 
labeling efficiency, as a smaller proportion of the probe would enter the 
cytoplasm. Fortunately, the EBV-TCR plasmid used in these experiments also 
contained the luciferase gene; hence long-term T cell monitoring in vivo could 
still be achieved using bioluminescence imaging, despite the negative results 
from direct cell radiolabeling. 
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7.5. A combined MSC TRAIL and EBV-TCR T cell cancer therapy  
Chapter 6 explored the use of MSC TRAIL and EBV-TCR T cells as a dual cell 
therapy against lung cancer. In order to test this therapy, a lung metastases model 
using intravenously injected MDA-MB-231 human breast cancer cells in a 
NOD/SCID mouse was developed. MSC TRAIL and EBV-TCR T cells were 
both shown to kill cancer cells in vivo, resulting in a significantly reduced 
tumour burden compared with controls. Using MSC TRAIL and EBV-TCR T 
cells as a dual cell therapy also resulted in cancer cell death, however, there was 
no significant improvement compared with using a single cell therapy. 
To confirm delivery of the T cells, bioluminescence imaging was used to track 
EBV-TCR T cells homing to lung metastases. In fact, due to the first-pass effect 
the majority of injected T cells were delivered first to the lung capillary bed. 
Encouragingly, the EBV-TCR T cells then resided in the lungs until they died 6 
days later, without moving to the spleen or other organs. This is an encouraging 
demonstration of tumour site specificity since a biodistribution study by Pittet et 
al. reports that 24 hours after systemic injection of adoptively transferred T cells, 
there are few cells remaining in the lungs and the majority reside in the liver and 
spleen. [243] Following sacrifice, anti-luciferase immunostaining was negative 
in lung sections, confirming that all the luciferase-expressing EBV-TCR T cells 
had died. Flow cytometry on cells derived from the spleens of each mouse also 
confirmed that no EBV-TCR T cells persisted in vivo at sacrifice. 
Despite the death of the transfused cells after 6 days and the presumed 
exponential growth of any remaining cancer cells, at sacrifice on day 23 there 
was still a significant decrease in lung metastases diameter and percentage area 
of metastases, compared with control mice. This difference was very similar to 
that observed using MSC TRAIL, which did not die in vivo and could be seen 
within lung metastases using confocal imaging. This is the first in vivo 
demonstration of the efficacy of the engineered chimeric EBV TCR, since the 
previously published data only reported cytotoxicity assays using T2 target cells 
coated with LMP2 peptide. Furthermore, these T cells were shown to be as 
effective as divided doses of MSC TRAIL, which has a proven track record of 
activity against MDA-MB-231 lung metastases. [104] Due to the different MSC 
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TRAIL used (doxycycline induced TRAIL expression versus constitutive 
expression in my model) and methodology for assessing tumour burden, it is 
difficult to make a direct comparison between my MSC TRAIL only cell therapy 
results and the results from Loebinger et al using MSC TRAIL in a similar 
model. However, both data sets show a significant decrease in lung metastases. 
It is possible that repeated doses of EBV-TCR T cells spaced 7 days apart could 
provide further benefit in this lung metastases model. A preclinical study by 
Kircher et al. suggests that multiple doses of adoptively transferred T cells result 
in better intra-tumoral distribution and engraftment, corresponding to a more 
effective treatment compared with a single dose. [244] In fact, several clinical 
trials have favoured this approach, administering T cells in divided doses spaced 
2 days [196] or 2-4 weeks apart [197]. Future mouse studies could assess the 
optimum dose of EBV-TCR T cells and dosing schedule. Repeated doses of 
EBV-TCR T cells similar to the protocol used for MSC TRAIL therapy, would 
overcome the poor in vivo persistence of transferred T cells and potentially 
provide greater anti-tumour efficacy.   
It is interesting that the dual cell therapy resulted in no additional benefit 
compared with a single cell therapy. The initial hypothesis was that cytokines 
released by activated cytotoxic T cells would aid the homing and engraftment of 
MSC TRAIL to tumour sites. Inflammatory mediators secreted by tumours are 
known to recruit macrophages and lymphocytes, as well as MSCs. The receptors 
involved in homing of MSCs to tumours are numerous, with ligands including 
growth hormones, cytokines, adhesion molecules and immune surveillance 
molecules, and there is also some overlap with T cell homing in cytokine 
receptors CCR1-CCR10 and CXCR3-CXCR6. [175] In addition, Hemeda et al. 
have shown that MSCs are highly responsive to TNF-α and IFN-γ, both of 
which are secreted by activated cytotoxic T cells. In particular, they showed that 
TNF-α increased the cytokine response of MSCs and induced migration. [245] 
Data by Croitoru-Lamoury et al. suggests that both TNF-α and IFN-γ are major 
regulators of the expression of chemokines and their receptors in MSCs. [246] 
However, to my knowledge there have been no studies specifically examining 
the role of activated T cells in MSC migration, and the literature is primarily 
concerned with examining the effect of MSCs on T cell function. 
	   176	  
Unfortunately, confocal microscopy imaging of DiI fluorescent MSC TRAIL in 
lung metastases could not be used as accurate measure of MSC cell numbers in 
order to compare homing efficiency between the MSC TRAIL only group and 
the MSC TRAIL combined with EBV-TCR T cells group. This would have 
required imaging of serial sections throughout the entire lung volume to get an 
accurate picture of MSC distribution, since overall MSC numbers were 
extremely low. It would also not examine the distribution and number of MSC 
TRAIL throughout the time-course of the experiment. Further experiments using 
MSC TRAIL transduced with another, complementary bioluminescent reporter 
gene could allow more accurate quantification of cell numbers and behaviour. 
Differences could then be sought in MSC migration with or without the presence 
of EBV-TCR T cells. 
It is possible that the lack of benefit of a combined cell therapy can be explained 
by the immunosuppressive effect of MSCs on T cells. However, there are 
conflicting studies about the effect of MSCs on T cells. Krampera et al. showed 
MSC inhibition of cytotoxicity, proliferation and IFN-γ production in naïve, 
memory and antigen-reactive T cells. [108] Others have reported that the 
immunosuppressive effects of MSCs on T cells could be discounted if the T cells 
had been previously activated, [230, 231] as was the case in this work, during 
peptide stimulation and expansion. Furthermore, data from Polchert et al. 
suggests that MSCs of a low passage are required for the suppression of T cells 
in acute GVHD. [247] Clinically, low passage MSCs (passage 1-3) are 
commonly used to treat acute GVHD after allogeneic hematopoietic stem cell 
transplantation. [248] The MSC TRAIL used in this thesis were all passage 9 or 
10, therefore, according to these studies they are unlikely to have strong 
immunosuppressive effects, especially since the EBV-TCR T cells had been 
previously expanded and activated in vitro.  
Co-culture experiments in chapter 3 revealed MSC TRAIL had no effect on T 
cell survival. In fact, activated cytotoxic T cells also express TRAIL, hence it 
seems unlikely that TRAIL expression by the MSCs could have deleterious 
effects on the EBV-TCR T cells.  
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During the in vivo experiment using bioluminescent imaging, EBV-TCR T cells 
that were co-injected with MSC TRAIL behaved similarly in their location and 
persistence to EBV-TCR T cells alone, lending further weight to the argument 
that the immunosuppressive effects of MSC TRAIL on EBV-TCR T cells can be 
discounted. To determine if this is the case, co-culture experiments with tumour 
cells, MSC TRAIL and EBV-TCR T cells could be repeated and the supernatant 
could be taken for IL-2 and IFN-γ ELISA, to measure if co-culture with MSC 
TRAIL reduces cytokine secretion by EBV-TCR T cells. However, although 
these factors are not secreted by MSCs in culture, Schinköthe et al. found that 
they were consumed by MSCs, making interpretation of the results from this 
assay difficult. [249] Real-time confocal imaging of the interaction between 
fluorescently labeled tumour cells, MSC TRAIL and EBV-TCR T cells may shed 
light on the interaction between these cells. The data from these experiments 
cannot elucidate if the killing effect of MSC TRAIL or EBV-TCR T cells 
predominates in vitro or in vivo. 
The work presented in this thesis advances the field of cell therapies for cancer 
by demonstrating two important findings. The first is that MSC TRAIL treatment 
in vivo is similar to the EBV-TCR T cell anti-tumour effect. In fact, there was no 
significant difference between these groups in the average diameter of lung 
metastases after treatment, or the percentage area of metastases in total lung area, 
however both showed a significant difference compared to the control group.  
There have been no previous reports in the literature comparing the efficacy of 
adoptive T cell therapy versus MSC TRAIL, hence these results are interesting to 
those who are developing clinical cell therapy treatments. Cost-benefit analysis 
may favour the development of MSC TRAIL therapy since their 
immunoprivileged status allows them to be an ‘off-the-shelf’ treatment, without 
the need to isolate and expand cells on an individual patient basis, and the 
consequent costs involved in such an individually tailored approach. 
The second important finding is that the use of a combined MSC TRAIL and 
EBV-TCR T cell therapy does not result in a significant treatment benefit in this 
model. This finding must be put into context with the emerging body of evidence 
suggesting that in certain environments MSCs can modulate the immune 
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response. As described above, they have been shown by many groups to reduce 
the activation and effector function of cytotoxic T cells. The soluble factors 
implicated in this immunomodulation are inducible by inflammatory cytokines 
involved in the immune response, and are minimally expressed in inactivated 
MSCs. This immunomodulation effect of MSCs may explain the lack of benefit 
to combined cell therapy. Antibody blockage of the inflammatory cytokines 
involved, such as TNF-α and IFN-γ, might reduce the immunosuppressive effect 
of MSCs, but this would be at the expense of the T cell therapy and is unlikely to 
result in better tumour cell death. Therefore, further work in developing this 
combined cell therapy is unlikely to yield promising results.  
As demonstrated in this thesis, individually, both cell therapies show promise for 
the treatment of lung cancer and should be developed further. Many questions 
still remain about adoptive T cell therapy, in particular, the dose and timing of T 
cell delivery, and the need to establish T cell persistence and memory. Along 
with these scientific challenges there are also commercial problems that need 
solving, such as cell expansion protocols, GMP cell culture facilities, product 
quality and safety. These concerns also apply to the development of MSC 
TRAIL as a cell therapy for lung cancer. 
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8. Summary and Future Directions 
 
This thesis has demonstrated that both LMP2-specific EBV-TCR T cells and 
MSC TRAIL are highly effective cell therapies for lung cancer in a NOD/SCID 
mouse model. However, as a combination therapy, there is no additional benefit 
in reduction of lung metastases diameter or the total percentage area of 
metastases in the lung. Many basic science questions about the interaction 
between MSC TRAIL and EBV-TCR T cells in vivo remain unanswered. Whilst 
the cells did not appear to hinder one another in cancer cell killing, the lack of 
any benefit to combined treatment is surprising.  
Future in vitro studies could look at the effect of cytokines secreted by activated 
T cells on MSC TRAIL homing. Quantification of MSC TRAIL in lung 
metastases using histology sections is unreliable and difficult, so I could not 
draw any conclusions about differences in MSC TRAIL numbers between the 
MSC TRAIL only group and the dual cell therapy group. Further in vivo 
experiments could use Renilla luciferase-expressing MSC TRAIL and 
bioluminescence imaging to quantify photon flux as a surrogate marker for cell 
numbers. The use of Renilla luciferase in MSC TRAIL would provide a dual-
reporter system with Firefly luciferase in EBV-TCR T cells, allowing imaging of 
both cell therapies. [250] 
The timing and dose of EBV-TCR T cells also needs study. It is possible that 
divided doses could result in improved metastases clearance, thus negating the 
need for another cell therapy.  
The data presented in this thesis has shown that tumour antigen specific T cells 
can provide significant benefit in treating lung metastases. Consequently, it will 
be important to identify common tumour associated antigens expressed by non-
small cell lung carcinoma, and engineer corresponding TCR candidates that are 
highly active against these antigens. These tumour assocated antigen targets and 
engineered TCR T cells will need to be tested first in vitro and then in mouse 
models to verify their efficacy, before they can be used in patients. Lung cancer 
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is the second most common cancer in the UK; therefore any increase in lung 
cancer survival has the potential to benefit a large number of patients. 
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